PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS

Description

TECHNICAL FIELD

[0001] This application relates to pyrrolotriazine inhibitors of TAM kinases, and in one embodiment inhibitors of AXL and MER kinases, which are useful in the treatment of disorders such as cancer, as well as pharmaceutical compositions related thereto.BACKGROUND OF INVENTION

[0002] Receptor tyrosine kinases (RTKs) are cell surface proteins that transmit signals from the extracellular environment to the cell cytoplasm and nucleus to regulate cellular events such as survival, growth, proliferation, differentiation, adhesion and migration.

[0003] The TAM subfamily consists of three RTKs including Tyro3, AXL and Mer (Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). TAM kinases are characterized by an extracellular ligand binding domain consisting of two immunoglobulin-like domains and two fibronectin type III domains. Two ligands, growth arrest specific 6 (GAS6) and protein S (PROS 1), have been identified for TAM kinases. GAS6 can bind to and activate all three TAM kinases, while PROS 1 is a ligand for Mer and Tyro3 (Graham et al., 2014, Nature Reviews Cancer 14, 769-785).

[0004] AXL (also known as UFO, ARK, JTK11 and TYRO7) was originally identified as a transforming gene from DNA of patients with chronic myelogenous leukemia (O'Bryan et al., 1991, Mol Cell Biol 11, 5016-5031; Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). GAS6 binds to AXL and induces subsequent auto-phosphorylation and activation of AXL tyrosine kinase. AXL activates several downstream signaling pathways including PI3K-Akt, Raf-MAPK, PLC-PKC (Feneyrolles et al., 2014, Molecular Cancer Therapeutics 13, 2141-2148; Linger et al., 2008, Advances in Cancer Research 100, 35-83).

[0005] MER (also known as MERTK, EYK, RYK, RP38, NYK and TYRO12) was originally identified as a phospho-protein from a lymphoblastoid expression library (Graham et al., 1995, Oncogene 10, 2349-2359; Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). Both GAS6 and PROS 1 can bind to Mer and induce the phosphorylation and activation of Mer kinase (Lew et al., 2014). Like AXL, MER activation also conveys downstream signaling pathways including PI3K-Akt and Raf-MAPK (Linger et al., 2008, Advances in Cancer Research 100, 35-83).

[0006] TYRO3 (also known as DTK, SKY, RSE, BRT, TIF, ETK2) was originally identified through a PCR-based cloning study (Lai et al., Neuron 6, 691-70, 1991; Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). Both ligands, GAS6 and PROS 1, can bind to and activate TYRO3. Although the signaling pathways downstream of TYRO3 activation are the least studied among TAM RTKs, it appears that both PI3K-Akt and Raf-MAPK pathways are involved (Linger et al., 2008, Advances in Cancer Research 100, 35-83). AXL, MER and TYRO3 are found to be over-expressed in cancer cells.

[0007] Accordingly, there is a need for compounds and methods of use thereof for the modulation of TAM kinases in the treatment of cancer.

[0008] EP 2465505 A1 discloses an invention which relates to pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and / or treatment of hyperproliferative disorders and diseases associated with angiogenesis.

[0009] WO 2007 / 061737 A2 discloses compounds that are inhibitors of mTOR and useful in the treatment of cancer.

[0010] Baladi, T. et al. (2015). State-of-the-art of small molecule inhibitors of the TAM family: the point of view of the chemist. Eur J Med Chem, 105, pp. 220-237 discusses the role of the TAM family of tyrosine kinases receptors (Tyro3, Axl and Mer) in cancer development, autoimmune reactions and viral infection and considers how different compounds are able to act on either one, two or three TAM kinases.SUMMARY OF INVENTION

[0011] In one aspect, the present application relates to compounds having Formula (IIb1) or Formula (IIb2): or a pharmaceutically acceptable salt thereof, wherein variables R 1< , R C< and Cy B< are as described herein.

[0012] The present application further provides compositions comprising a compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

[0013] The present application also provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in inhibiting TAM kinases, and in one embodiment a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in inhibiting AXL and MER kinases.

[0014] The present application also provides a compound described herein, or a pharmaceutically acceptable salt thereof, for use in any of the methods described herein.DETAILED DESCRIPTION

[0015] The application provides, inter alia, a compound of Formula (IIb1) or Formula (IIb2): or a pharmaceutically acceptable salt thereof, wherein: R 1< is A 1< -A 2< -A 3< -R A< ; A 1< is selected from a bond, Cy A1< , -Y-, -C 1-3 alkylene-, -C 1-3 alkylene-Y-, - Y-C 1-3 alkylene-, and -C 1-2 alkylene-Y-C 1-2 alkylene-; wherein said alkylene groups are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, and di(C 1-3 alkyl)amino; A 2< is selected from a bond, Cy A2< , -Y-, -C 1-3 alkylene-, -C 1-3 alkylene-Y-, - Y-C 1-3 alkylene-, and -C 1-2 alkylene-Y-C 1-2 alkylene-; wherein said alkylene groups are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, and di(C 1-3 alkyl)amino; A 3< is selected from a bond, Cy A3< , -Y-, -C 1-3 alkylene-, -C 1-3 alkylene-Y-, - Y-C 1-3 alkylene-, and -C 1-2 alkylene-Y-C 1-2 alkylene-; wherein said alkylene groups are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, and di(C 1-3 alkyl)amino; R A< is H, C 1-6 alkyl, C 1-6 haloalkyl, halo, CN, NO 2 , OR a1< , SR a1< , C(O)R b1< , C(O)NR c1< R d1< , C(O)OR a1< , OC(O)R b1< , OC(O)NR c1< R d1< , NR c1< R d1< , NR c1< OR d1< , NR c1< C(O)R b1< , NR c1< C(O)OR a1< , NR c1< C(O)NR c1< R d1< , C(=NR e1< )R b1< , C(=NR e1< )NR c1< R d1< , NR c1< C(=NR e1< )NR c1< R d1< , NR c1< S(O)R b1< , NR c1< S(O) 2 R b1< , NR c1< S(O) 2 NR c1< R d1< , S(O)R b1< , S(O)NR c1< R d1< , S(O) 2 R b1< , or S(O) 2 NR c1< R d1< ; wherein said C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 11< ; Y is O, S, S(O), S(O) 2 , C(O), C(O)NR f< , NR f< C(O), NR f< C(O)NR f< , NR f< S(O) 2 NR f< , S(O) 2 NR f< , NR f< S(O) 2 , or NR f< ; each R f< is independently selected from H and C 1-3 alkyl; Cy A1< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A1< ; each R A1< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; Cy A2< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A2< ; each R A2< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; Cy A3< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A3< ; each R A3< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; each R C< is independently selected from OH, CN, halo, C 1-4 alkyl, C 1-3 haloalkyl, C 1-4 alkoxy, C 1-3 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 alkylsulfinyl, C 1-4 alkylsulfonyl, carbamyl, C 1-4 alkylcarbamyl, di(C 1-4 alkyl)carbamyl, carboxy, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkylcarbonylamino, C 1-4 alkylsulfonylamino, aminosulfonyl, C 1-4 alkylaminosulfonyl, and di(C 1-4 alkyl)aminosulfonyl; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently selected from halo, C 1-6 alkyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, OR a2< , C(O)R b2< , C(O)NR c2< R d2< , C(O)OR a2< , NR c2< R d2< , NR c2< C(O)R b2< , and NR c2< C(O)OR a2< ; wherein said C 1-6 alkyl, C 2-6 alkynyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R 11< is independently selected from CN, NO 2 , OR a3< , SR a3< , C(O)R b3< , C(O)NR c3< R d3< , C(O)OR a3< , OC(O)R b3< , OC(O)NR c3< R d3< , NR c3< R d3< , NR c3< OR d3< , NR c3< C(O)R b3< , NR c3< C(O)OR a3< , NR c3< C(O)NR c3< R d3< , NR c3< S(O)R b3< , NR c3< S(O) 2 R b3< , NR c3< S(O) 2 NR c3< R d3< , S(O)R b3< , S(O)NR c3< R d3< , S(O) 2 R b3< , and S(O) 2 NR c3< R d3< ; each R 12< is independently selected from halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, OR a4< , SR a4< , C(O)R b4< , C(O)NR c4< R d4< , C(O)OR a4< , OC(O)R b4< , OC(O)NR c4< R d4< , NR c4< R d4< , NR c4< OR d4< , NR c4< C(O)R b4< , NR c4< C(O) a4< , NR c4< C(O)NR c4< R d4< , NR c4< S(O)R b4< , NR c4< S(O) 2 R b4< , NR c4< S(O) 2 NR c4< R d4< , S(O)R b4< , S(O)NR c4< R d4< , S(O) 2 R b4< , and S(O) 2 NR c4< R d4< ; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; R a1< , R c1< and R d1< are each independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; or alternatively, R c1< and R d1< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg., R b1< is selected from C 1-6 alkyl and C 1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; R e1< is selected from H, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkylthio, C 1-6 alkylsulfonyl, C 1-6 alkylcarbonyl, C 1-6 alkylaminosulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, aminosulfonyl, C 1-6 alkylaminosulfonyl, and di(C 1-6 alkyl)aminosulfonyl; each R a2< , R c2< , and R d2< is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; or alternatively, any R c2< and R d2< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R 12< ; each R b2< is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R a3< , R c3< and R d3< is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; or alternatively, any R c3< and R d3< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg., each R b3< is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R a4< , R c4< and R d4< , is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; or alternatively, any R c4< and R d4< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R g< ; each R b4< is independently selected from C 1-6 alkyl and C 1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R g< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; and wherein "cycloalkyl" refers to non-aromatic cyclic hydrocarbons including cyclized alkyl and / or alkenyl groups, including moieties that have one or more aromatic rings fused to the cycloalkyl ring; provided that: 1) A 1< -A 2< -A 3< is not Y-Y when one of A 1< , A 2< or A 3< is a bond, or Y-Y-Y; and 2) when A 3< is -Y- or -C 1-3 alkylene-Y- then R A< is H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein said C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 11< .

[0016] In some embodiments, A 1< is a bond.

[0017] In some embodiments, A 2< is a bond.

[0018] In some embodiments, A 3< is a bond.

[0019] In some embodiments, R A< is H, halo, C 1-6 alkyl or C 1-6 haloalkyl.

[0020] In some embodiments, R A< is C 1-6 alkyl.

[0021] In some embodiments, R A< is methyl or ethyl.

[0022] In some embodiments, A 1< is a bond. For example, R 1< is A 2< -A 3< -R A< .

[0023] In some embodiments, A 1< is a bond, A 2< is a bond, and A 3< is Cy A3< . For example, R 1< is Cy A3< -R A< .

[0024] In some embodiments, one of A 1< , A 2< , and A 3< is not a bond.

[0025] In some embodiments, one of A 1< , A 2< , and A 3< is -C 1-3 alkylene-, -Y-, -C 1-3 alkylene-Y-, or -Y-C 1-3 alkylene-. In some embodiments, one of A 1< , A 2< , and A 3< is - C 1-6 alkylene- or -Y-. In some embodiments, one of A 1< , A 2< , and A 3< is -C 1-6 alkylene-. In some embodiments, one of A 1< , A 2< , and A 3< is methylene.

[0026] In some embodiments, R 1< is H, halo, C 1-6 alkyl or C 1-6 haloalkyl.

[0027] In some embodiments, R 1< is C 1-6 alkyl. In some embodiments, R 1< is methyl or ethyl.

[0028] In some embodiments, R 1< is A 2< -A 3< -R A< .

[0029] In some embodiments, R 1< is Cy A3< -R A< .

[0030] In some embodiments, Cy A3< is C 3-7 cycloalkyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A3< .

[0031] In some embodiments, Cy A3< is C 3-6 cycloalkyl or 4-6 membered heterocycloalkyl, each optionally substituted with 1 or 2 substituents independently selected from R A3< .

[0032] In some embodiments, Cy A3< is piperidinyl, cyclohexyl, or tetrahydropyranyl; each optionally substituted with 1 or 2 substituents independently selected from R A3< .

[0033] In some embodiments, Cy A3< is C 3-6 cycloalkyl optionally substituted with 1, 2, 3 or 4 independently selected R A3< groups. In some embodiments, Cy A3< is cyclohexyl and cyclopropyl optionally substituted with 1, 2, 3 or 4 independently selected R A3< groups.

[0034] In some embodiments, Cy A3< is 4-6 membered heterocycloalkyl optionally substituted with 1, 2, 3 or 4 independently selected R A3< groups. In some embodimets, Cy A3< is piperidinyl or morpholinyl optionally substituted with 1, 2, 3 or 4 independently selected R A3< groups. In some embodiments, Cy A3< is pyridyl optionally substituted with 1, 2, 3 or 4 independently selected R A3< groups.

[0035] In some embodiments, Cy A3< is piperidinyl, cyclohexyl, tetrahydropyranyl, pyrazolyl, pyridinyl, azetidinyl, cyclopropyl, or morpholinyl; each optionally substituted with 1 or 2 substituents independently selected from R A3< .

[0036] In some embodiments, Cy A3< is piperidinyl, pyridyl, morpholinyl, cyclohexyl, or tetrahydropyranyl; each optionally substituted with 1, 2, 3 or 4 independently selected R A3< groups.

[0037] In some embodiments, Cy A3< is piperidinyl optionally substituted with 1, 2, 3 or 4 independently selected R A3< groups.

[0038] In some embodiments, Cy A3< is cyclohexyl optionally substituted with 1, 2, 3 or 4 independently selected R A3< groups.

[0039] In some embodiments, Cy A3< is morpholinyl optionally substituted with 1, 2, 3 or 4 independently selected R A3< groups.

[0040] In some embodiments, Cy A3< is wherein Cy A3< -1, Cy A3< -2 and Cy A3< -3 are each optionally substituted with 1, 2 or 3 substituents independently selected from R A3< .

[0041] In some embodiments, A 1< is a bond, A 2< is a bond, A 3< is a bond, and R A< is methyl or ethyl; or A 1< is a bond, A 2< is a bond, and A 3< is Cy A3< -R A< selected from

[0042] In some embodiments, R A< is C 1-6 alkyl, CN, OR a1< , NR c1< R d1< , C(O)R b1< , C(O)NR c1< R d1< , C(O)OR a1< , S(O)R b1< , S(O)NR c1< R d1< , S(O) 2 R b1< or S(O) 2 NR c1< R d1< ; wherein said C 1-6 alkyl is optionally substituted with 1 or 2 substituents independently selected from R 11< , provided that if R A< is attached to a nitrogen atom, then R A< is not CN, OR a1< , or NR c1< R d1< .

[0043] In some embodiments, R A< is C 1-6 alkyl, CN, OR a1< , C(O)R b1< , C(O)NR c1< R d1< , C(O)OR a1< , and S(O) 2 R b1< ; wherein said C 1-6 alkyl is optionally substituted with 1 substituent selected from R 11< , provided that if R A< is attached to a nitrogen atom, then R A< is not CN or OR a1< . In some embodiments, R b1< is isopropyl.

[0044] In some embodiments, each R A< is independently selected from C 1-3 alkyl, CN, OH, methylcarbonyl, methoxycarbonyl, N,N-dimethylaminocarbonyl, and methylsulfonyl, wherein said C 1-3 alkyl is optionally substituted with a OH or OCH 3 group, provided that if R A< is attached to a nitrogen atom, then R A< is not CN or OH.

[0045] In some embodiments, each R A< is independently selected from CH 3 , CH 2 CH 3 , CN, OH, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , C(O)CH 3 , C(O)CH 2 OH, C(O)CH(OH)CH 3 , S(O) 2 CH 3 , C(O)OCH 3 , C(O)N(CH 3 ) 2 , C(O)NHCH 3 , C(O)N(CH 2 CH 3 ) 2 , and C(O)N(CH 3 )(CH 2 CH 3 ).

[0046] In some embodiments, each R A< is independently selected from CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CN, OH, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , C(O)CH 3 , C(O)CH 2 CH 3 , C(O)CH(CH 3 ) 2 , C(O)CH 2 OH, C(O)CH(OH)CH 3 , S(O) 2 CH 3 , C(O)OCH 3 , C(O)N(CH 3 ) 2 , C(O)N(CH 2 CH 3 ) 2 , C(O)N(CH 3 )(CH 2 CH 3 ), C(O)NHCH 3 , C(O)NH(CH 2 CH 3 ) and C(O)[morpholin-4-yl].

[0047] In some embodiments, each R 11< is independently OR a3< .

[0048] In some embodiments, each R 11< is independently OH or OCH 3 .

[0049] In some embodiments, Cy A3< is piperidinyl, cyclohexyl, tetrahydropyranyl, pyrazolyl, pyridinyl, azetidinyl, cyclopropyl, or morpholinyl; each optionally substituted with R A< independently selected from CH 3 , CN, OH, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , C(O)CH 3 , C(O)CH 2 CH 3 , C(O)CH(CH 3 ) 2 , C(O)CH 2 OH, C(O)CH(CH 3 )OH, S(O) 2 CH 3 , C(O)OCH 3 , C(O)N(CH 3 ) 2 , C(O)NH(CH 3 ), C(O)N(CH 2 CH 3 ) 2 , C(O)NH(CH 2 CH 3 ), C(O)N(CH 3 )(CH 2 CH 3 ), CH 2 C(O)N(CH 3 ) 2 , 1-methyl-2-oxopyrrolidin-3-yl, C(O)(cyclopropyl), N(CH 3 ) 2 , and C(O)(morpholin-4-yl).

[0050] In some embodiments, Cy A3< is piperidinyl, cyclohexyl, or tetrahydropyranyl; each optionally substituted with R A< independently selected from CH 3 , CN, OH, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , C(O)CH 3 , C(O)CH 2 OH, C(O)CH(CH 3 )OH, S(O) 2 CH 3 , C(O)OCH 3 , C(O)N(CH 3 ) 2 , C(O)NH(CH 3 ), C(O)N(CH 2 CH 3 ) 2 , C(O)NH(CH 2 CH 3 ) and C(O)N(CH 3 )(CH 2 CH 3 ).

[0051] In some embodiments, Cy A3< is piperidinyl, cyclohexyl, or tetrahydropyranyl; each optionally substituted with R A< independently selected from CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CN, OH, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , C(O)CH 3 , C(O)CH 2 CH 3 , C(O)CH(CH 3 ) 2 , C(O)CH 2 OH, C(O)CH(OH)CH 3 , S(O) 2 CH 3 , C(O)OCH 3 , C(O)N(CH 3 ) 2 , C(O)N(CH 2 CH 3 ) 2 , C(O)N(CH 3 )(CH 2 CH 3 ), C(O)NHCH 3 , C(O)NH(CH 2 CH 3 ) and C(O)(morpholin-4-yl)

[0052] In some embodiments, Cy A3< is piperidinyl, pyridyl, morpholinyl, cyclohexyl, or tetrahydropyranyl; each optionally substituted with 1, 2, 3 or 4 groups independently selected from CH 3 , CH 2 CH 3 , CN, OH, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , C(O)CH 3 , C(O)CH 2 OH, C(O)CH(OH)CH 3 , S(O) 2 CH 3 , C(O)OCH 3 , C(O)N(CH 3 ) 2 , C(O)NHCH 3 , C(O)N(CH 2 CH 3 ) 2 , and C(O)N(CH 3 )(CH 2 CH 3 ).

[0053] In some embodiments, A 1< is a bond, A 2< is Cy A2< , A 3< is -Y-, R A< is C 3-6 cycloalkyl (e.g., cyclopropyl), -Y- is C(O), and Cy A2< is 4-7 membered heterocycloalkyl (e.g., piperidinyl).

[0054] In some embodiments, R 1< is In some embodimebts, R 1< is In some embodiments, R 1< is In some embodiments, R 1< is In some embodiments, R 1< is

[0055] In preferred embodiments, Cy B< forms a hydrogen bond with the NH of the amide group. For example, if the Cy B< group has an oxo group, the Cy B< can form a hydrogen bond through the carbonyl group with the NH of the amide group. Similarly, Cy B< can be substituted with an electron donating substituent capable of forming a hydrogen bond with the NH of the amide group. Below are illustrative examples wherein W is an electron donating group such as halo, CN, NO 2 , OR a2< , SR a2< , C(O)R b2< , C(O)NR c2< R d2< , C(O)OR a2< , OC(O)R b2< , OC(O)NR c2< R d2< , NR c2< R d2< , NR c2< OR d2< , NR c2< C(O)R b2< , NR c2< C(O)OR a2< , NR c2< C(O)NR c2< R d2< , NR c2< S(O)R b2< , NR c2< S(O) 2 R b2< , NR c2< S(O) 2 NR c2< R d2< , S(O)R b2< , S(O)NR c2< R d2< , S(O) 2 R b2< , and S(O) 2 NR c2< R d2< :

[0056] In some embodiments, Cy B< is Cy B< -1 optionally substituted with 1, 2 or 3 independently selected R B< groups. In some embodiments, Cy B< is Cy B< -2 optionally substituted with 1, 2 or 3 independently selected R B< groups. In some embodiments, Cy B< is Cy B< -3 optionally substituted with 1, 2 or 3 independently selected R B< groups.

[0057] In some embodiments, Cy B< is In some embodiments, Cy B< is Cy B< -1a. In some embodiments, Cy B< is Cy B< -2a. In some embodiments, Cy B< is Cy B< -3a.

[0058] In embodiments of the invention, Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< .

[0059] In some embodiments, Cy B< is wherein Cy B< -1 and Cy B< -2 are each optionally substituted with 1, 2 or 3 independently selected R B< groups.

[0060] In some embodiments, Cy B< is wherein Cy B< -1 and Cy B< -2 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< .

[0061] In some embodiments, Cy B< is wherein Cy B< -1, Cy B< -2 and Cy B< -3 are each optionally substituted with 1, 2 or 3 independently selected R B< groups.

[0062] In some embodiments, Cy B< is wherein Cy B< -1 is optionally substituted with 1, 2 or 3 independently selected R B< groups.

[0063] In some embodiments, Cy B< is wherein Cy B< -2 is optionally substituted with 1, 2 or 3 independently selected R B< groups.

[0064] In some embodiments, Cy B< is wherein Cy B< -3 is optionally substituted with 1, 2 or 3 independently selected R B< groups.

[0065] In some embodiments, Cy B< is wherein Cy B< -1 and Cy B< -2 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently methyl, ethyl, isopropyl, sec-butyl, or phenyl, each of which is optionally substituted by 1 or 2 substituents independently selected from R 12< ; each R 12< is independently selected from halo, phenyl, and OR a4< ; wherein said phenyl is optionally substituted by 1 or 2 substituents independently selected from R g< group; each R a4< is H or C 1-3 alkyl; and each R g< is independently selected from halo.

[0066] In some embodiments, Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently methyl, ethyl, isopropyl, sec-butyl, 2-pyridinyl, or phenyl, each of which is optionally substituted by 1 or 2 substituents independently selected from R 12< ; each R 12< is independently selected from C 1-6 alkyl, halo, phenyl, and OR a4< ; wherein said C 1-6 alkyl and phenyl are each optionally substituted by 1 or 2 substituents independently selected from R g< group; each R a4< is H or C 1-3 alkyl; and each R g< is independently selected from halo.

[0067] In some embodiments, Cy B< is wherein Cy B< -1, Cy B< -2 and Cy B< -3 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently methyl, ethyl, isopropyl, sec-butyl, or phenyl, each of which is optionally substituted by 1 or 2 substituents independently selected from R 12< ; each R 12< is independently selected from halo, phenyl, and OR a4< ; wherein said phenyl is optionally substituted by 1 or 2 substituents independently selected from R g< group; each R a4< is H or C 1-3 alkyl; and each R g< is independently selected from halo.

[0068] In some embodiments, Cy B< is wherein Cy B< -1 and Cy B< -2 are each optionally substituted with 1, 2 or 3 groups independently selected from unsubstituted phenyl, 4-fluoro-phenyl, CH 2 (phenyl), CH(CH 2 OH)phenyl, CH 3 , CH 2 CH 3 , CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH, OCH 2 CH 3 and OCH 3 .

[0069] In some embodiments, Cy B< is wherein Cy B< -1, Cy B< -2, and Cy B< -3 are each optionally substituted with 1, 2 or 3 groups independently selected from unsubstituted phenyl, 4-fluoro-phenyl, 3-fluorophenyl, 2-fluorophenyl, 2-pyridinyl, CH 2 (phenyl), CH(CH 2 OH)phenyl, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH, OCH 2 CH 3 and OCH 3

[0070] In some embodiments, Cy B< is wherein Cy B< -1, Cy B< -2 and Cy B< -3 are each optionally substituted with 1, 2 or 3 substituents independently selected from unsubstituted phenyl, 4-fluoro-phenyl, 3-fluoro-phenyl, 2-fluoro-phenyl, CH 2 (phenyl), CH(CH 2 OH)phenyl, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH, OCH 2 CH 3 and OCH 3 .

[0071] In some embodiments, Cy B< is wherein Cy B< -2 and Cy B< -3 are each optionally substituted 1, 2 or 3 groups independently selected from unsubstituted phenyl, CH(CH 3 ) 2 , and 2-pyridinyl.

[0072] In some embodiments, Cy B< is wherein Cy B< -2 is optionally substituted 1, 2 or 3 groups independently selected from unsubstituted phenyl, CH(CH 3 ) 2 , and 2-pyridinyl.

[0073] In some embodiments, Cy B< is wherein Cy B< -3 is optionally substituted 1, 2 or 3 groups independently selected from unsubstituted phenyl, CH(CH 3 ) 2 , and 2-pyridinyl.

[0074] In some embodiments, Cy B< is wherein Cy B< -3 is substituted with unsubstituted phenyl and CH(CH 3 ) 2 . In some embodiments, Cy B< is wherein Cy B< -3 is substituted with pyridinyl (e.g., 2-pyridinyl, 3-pyridinyl, and 4-pyridinyl) and CH(CH 3 ) 2 .

[0075] In some embodiments, each R B< is independently selected from halo, C 1-6 alkyl, C 2-6 alkynyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, OR a2< , C(O)R b2< , C(O)NR c2< R d2< , C(O)OR a2< , NR c2< R d2< , NR c2< C(O)R b2< , and NR c2< C(O)OR a2< ; wherein said C 1-6 alkyl, C 2-6 alkynyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< .

[0076] In some embodiments, each R B< is independently unsubstituted phenyl, 4-fluoro-phenyl, 3-fluorophenyl, 2-fluorophenyl, CH 2 (phenyl), CH(CH 2 OH)phenyl, Br, Cl, CN, CH 3 , CHF 2 , CH 2 CH 3 , CH 2 OCH 3 , CH 2 OCH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH, CH 2 CH(OH)(CH 3 ), OCH 3 , OCH 2 CH 3 , C(O)NH 2 , C(O)CH 3 , 2,5-difluorophenyl, 3-pyridinyl, 2-pyridinyl, 1-methyl-1H-pyrazol-4-yl, 1-methyl-17f-pyrazol-3-yl, 1-methyl-1H-pyrazol-5-yl, 1,4-dimethyl-1H-pyrazol-3-yl, 1,5-dimethyl-1H-pyrazol-3-yl, 2-methylthiazol-5-yl, cyclohexyl, 3-cyanophenyl, 5-methylisoxazol-3-yl, 5-fluoropyridin-3-yl, 5-fluoropyridin-2-yl, 3-cyanophenyl, CH 2 CN, thiazol-4-yl, 6-methylpyridin-3-yl, 2-methylpyridin-3-yl, 6-methylpyridin-2-yl, pyrimidin-2-yl, morpholin-4-yl, cyclopropyl, oxazol-2-yl, CCCH(OH)(CH 3 ), or C(O)NH(4-fluoro-phenyl).

[0077] In some embodiments, each R B< is independently unsubstituted phenyl, 4-fluoro-phenyl, 3-fluorophenyl, 2-fluorophenyl, CH 2 (phenyl), CH(CH 2 OH)phenyl, Br, CN, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH, CH 2 CH(OH)(CH 3 ), OCH 3 , OCH 2 CH 3 , C(O)NH 2 , C(O)CH 3 , 2,5-difluorophenyl, 3-pyridinyl, 2-pyridinyl, 1-methyl-1H-pyrazol-4-yl, 1-methyl-1H-pyrazol-3-yl, 1-methyl-1H-pyrazol-5-yl, 2-methylthiazol-5-yl, cyclohexyl, 3-cyanophenyl, 5-methylisoxazol-3-yl, 5-fluoropyridin-3-yl, 3-cyanophenyl, CH 2 CN, thiazol-4-yl, 6-methylpyridin-3-yl, pyrimidin-2-yl, morpholin-4-yl, cyclopropyl, oxazol-2-yl, CCCH(OH)(CH 3 ), or C(O)NH(4-fluoro-phenyl).

[0078] In some embodiments, each R B< is independently unsubstituted phenyl, 4-fluoro-phenyl, 3-fluorophenyl, 2-fluorophenyl, 2-pyridinyl, CH 2 (phenyl), CH(CH 2 OH)phenyl, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH, OCH 3 , OCH 2 CH 3 , or C(O)NH(4-fluoro-phenyl).

[0079] In some embodiments, each R B< is independently unsubstituted phenyl, 4-fluoro-phenyl, CH 2 (phenyl), CH(CH 2 OH)phenyl, CH 3 , CH 2 CH 3 , CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH, OCH 3 , OCH 2 CH 3 , or C(O)NH(4-fluoro-phenyl).

[0080] In some embodiments, each R B< is independently unsubstituted phenyl, 4-fluoro-phenyl, 3-fluoro-phenyl, 2-fluoro-phenyl, CH 2 (phenyl), CH(CH 2 OH)phenyl, CH 3 , CH 2 CH 3 , CH(CH 3 ) 2 , CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH, OCH 3 , OCH 2 CH 3 , or C(O)NH(4-fluoro-phenyl).

[0081] In some embodiments, each R B< is independently unsubstituted phenyl or 4-fluoro-phenyl, 3-fluoro-phenyl, 2-fluoro-phenyl, 2-pyridinyl, CH 3 , CH 2 CH 3 or CH(CH 3 ) 2 . In some embodiments, each R B< is independently unsubstituted phenyl or 4-fluoro-phenyl, 3-fluoro-phenyl, 2-fluoro-phenyl, CH 3 , CH 2 CH 3 or CH(CH 3 ) 2 . In some embodiments, each R B< is unsubstituted phenyl, CH(CH 3 ) 2 , or 2-pyridinyl. In some embodiments, each R B< is independently unsubstituted phenyl or 4-fluoro-phenyl. In some embodiments, each R B< is unsubstituted phenyl. In some embodiments, each R B< is 4-fluoro-phenyl. In some embodiments, each R B< is pyridinyl (e.g., 2-pyridinyl). In some embodiments, each R B< is independently unsubstituted phenyl or CH(CH 3 ) 2 . In some embodiments, each R B< is independently unsubstituted phenyl or CH 2 CH 3 . In some embodiments, each R B< is independently 4-fluoro-phenyl or CH(CH 3 ) 2 . In some embodiments, each R B< is independently 4-fluoro-phenyl or CH 2 CH 3 . In some embodiments, each R B< is independently 3-fluoro-phenyl or CH(CH 3 ) 2 . In some embodiments, each R B< is independently 3-fluoro-phenyl or CH 2 CH 3 . In some embodiments, each R B< is independently 2-fluoro-phenyl or CH(CH 3 ) 2 . In some embodiments, each R B< is independently 2-fluoro-phenyl or CH 2 CH 3 .

[0082] In some embodiments, each R C< is independently selected from OH, halo, C 1-4 alkyl, and C 1-3 haloalkyl. In some embodiments, each R C< is independently halo or C 1-4 alkyl. In some embodiments, each R C< is independently F, Cl, or methyl. In some embodiments, each R C< is F.

[0083] In some embodiments, R 1< is R A< is CH 3 , CH 2 CH 3 , CN, OH, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , C(O)CH 3 , C(O)CH(CH 3 ) 2 , C(O)(cyclopropyl), C(O)CH 2 CH 3 , C(O)CH 2 OH, C(O)CH(OH)CH 3 , SO 2 CH 3 , C(O)OCH 3 , C(O)N(CH 3 ) 2 , C(O)NHCH 3 , C(O)N(CH 2 CH 3 ) 2 , C(O)N(CH 3 )(CH 2 CH 3 ), or C(O)(morpholin-4-yl); Cy B< is wherein Cy B< -1, Cy B< -2, and Cy B< -3 are each optionally substituted with 1 or 2 substituents independently selected from R B< ; each R B< is independently unsubstituted phenyl, 4-F-phenyl, 3-F-phenyl, 2-F-phenyl, 2-pyridinyl, CH 2 (phenyl), CH(phenyl)CH 2 OH, methyl, ethyl, isopropyl, CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH or OCH 2 CH 3 ; and R C< is F, Cl or Br.

[0084] In some embodiments, R 1< is R A< is CH 3 , CH 2 CH 3 , CN, OH, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , C(O)CH 3 , C(O)CH 2 OH, C(O)CH(OH)CH 3 , SO 2 CH 3 , C(O)OCH 3 , C(O)N(CH 3 ) 2 , C(O)NHCH 3 , C(O)N(CH 2 CH 3 ) 2 or C(O)N(CH 3 )(CH 2 CH 3 ); Cy B< is wherein Cy B< -1 and Cy B< -2 are each optionally substituted with 1 or 2 substituents independently selected from R B< ; each R B< is independently unsubstituted phenyl, 4-F-phenyl, CH 2 (phenyl), CH(phenyl)CH 2 OH, methyl, ethyl, CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH or OCH 2 CH 3 ; and R C< is F, Cl or Br.

[0085] In some embodiments, R 1< is R A< is CH 3 , CH 2 CH 3 , CN, OH, CH 2 CH 2 OH, CH 2 CH 2 OCH 3 , C(O)CH 3 , C(O)CH(CH 3 ) 2 , C(O)CH 2 CH 3 , C(O)CH 2 OH, C(O)CH(OH)CH 3 , SO 2 CH 3 , C(O)OCH 3 , C(O)N(CH 3 ) 2 , C(O)NHCH 3 , C(O)N(CH 2 CH 3 ) 2 , C(O)N(CH 3 )(CH 2 CH 3 ), or C(O)(morpholin-4-yl); Cy B< is wherein Cy B< -1, Cy B< -2, and Cy B< -3 are each optionally substituted with 1 or 2 substituents independently selected from R B< ; each R B< is independently unsubstituted phenyl, 4-F-phenyl, 3-F-phenyl, 2-F-phenyl, CH 2 (phenyl), CH(phenyl)CH 2 OH, methyl, ethyl, isopropyl, CH(CH 2 OH)CH 2 CH 3 , CH(CH 2 OH)CH 3 , CH 2 CH 2 OH or OCH 2 CH 3 ; and R C< is F, Cl or Br.

[0086] In some embodiments: (1) A 1< , A 2< , and A 3< are each a bond and R A< is C 1-6 alkyl or (2) A 1< and A 2< are each a bond, A 3< is Cy A3< , and each R A< is independently selected from C 1-6 alkyl, CN, OR a1< , C(O)R b1< , C(O)NR c1< R d1< , C(O)OR a1< , and S(O) 2 R b1< ; wherein said C 1-6 alkyl is optionally substituted with a R 11< group, provided that if R A< is attached to a nitrogen atom, then R A< is not CN or OR a1< ; each R a1< , R c1< , and R d1< are independently H or C 1-4 alkyl; each R b1< is independently C 1-4 alkyl; each R 11< is independently OR a3< ; Cy B< is a 7,8-dihydroquinoline-2,5(1H,6H)-dione or 2-pyridone ring, which is optionally substituted with 1 or 2 independently selected R B< groups; each R B< is independently methyl, ethyl, isopropyl, sec-butyl, or phenyl, each of which is optionally substituted by 1 or 2 independently selected R 12< groups; each R 12< is independently selected from halo, phenyl, and OR a4< ; wherein said phenyl is optionally substituted by 1 or 2 independently selected R 8< group; and each R g< is independently halo; each R a4< is independently H or C 1-4 alkyl; and each R C< is independently halo or C 1-4 alkyl.

[0087] In some embodiments: (1) A 1< , A 2< , and A 3< are each a bond and R A< is methyl or ethyl; or (2) A 1< and A 2< are each a bond, A 3< -R A< is selected from and each R A< is independently selected from C 1-3 alkyl, CN, OH, methylcarbonyl, methoxycarbonyl, N,N-dimethylaminocarbonyl, and methylsulfonyl, wherein said C 1-3 alkyl is optionally substituted with a OH or OCH 3 group, provided that if R A< is attached to a nitrogen atom, then R A< is not CN or OH; Cy B< is a 7,8-dihydroquinoline-2,5(1H,6H)-dione or 2-pyridone ring, which is optionally substituted with a R B< group; each R B< is independently methyl, ethyl, isopropyl, sec-butyl, or phenyl, each of which is optionally substituted by 1 or 2 independently selected R 12< groups; each R 12< is independently selected from halo, phenyl, and OH; wherein said phenyl is optionally substituted by 1 or 2 independently selected R g< group; and each R g< is F.

[0088] In some embodiments: A 1< and A 2< are each a bond, A 3< -R A< is, each R A< is independently selected from C 1-3 alkyl, methylcarbonyl, ethylcarbonyl, iso-propylcarbonyl, N,N-dimethylaminocarbonyl, N,N-diethylaminocarbonyl, N,N-(methyl)(ethyl)aminocarbonyl and C(O)[morpholin-4-yl].; Cy B< is a 7,8-dihydroquinoline-2,5(1H,6H)-dione or 2,4-dioxo-1,2,3,4-tetrahydropyrimidine ring, which is optionally substituted by 1 or 2 independently selected R B< groups; each R B< is independently methyl, ethyl, isopropyl, sec-butyl, or phenyl, each of which is optionally substituted by 1 or 2 independently selected R 12< groups; and each R 12< is independently selected from halo.

[0089] In some embodiments, the present disclosure provides compounds having Formula (IIc1) or Formula (IIc2): or a pharmaceutically acceptable salt thereof, wherein the variables of Formula (IIc1) and Formula (IIc2) are as defined in Formula (IIb1 ) or Formula (IIb2) or any embodiments of compounds of Formula (IIb1) or Formula (IIb2) as described herein

[0090] In some embodiments, the present disclosure provides compounds having Formula (IId1) or Formula (IId2): or a pharmaceutically acceptable salt thereof, wherein the variables of Formula (IId1) and Formula (IId2) are as defined in Formula (IIb1) or Formula (IIb2) or any embodiments of compounds of Formula (IIb1) or Formula (IIb2) as described herein.

[0091] In some embodiments, the present disclosure provides compounds having Formula (IIg1) or Formula (IIg2): or a pharmaceutically acceptable salt thereof, wherein the variables of Formula (IIg1) and Formula (IIg2) are as defined in Formula (IIb1 ) or Formula (IIb2) or any embodiments of compounds of Formula (IIb1) or Formula (IIb2) as described herein.

[0092] In some embodiments, the present disclosure provides compounds having Formula (IIg3), Formula (IIg4), Formula (IIg5): or a pharmaceutically acceptable salt thereof, wherein the variables of Formula (IIg3), Formula (IIg4), and Formula (IIg5) are as defined in Formula (IIb1) or Formula (IIb2) or any embodiments of compounds of Formula (IIb1) or Formula (IIb2) as described herein, and t is 0, 1, 2, 3, or 4.

[0093] In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< ; A 1< is selected from a bond, Cy A1< , -Y-, -C 1-3 alkylene-, -C 1-3 alkylene-Y-, - Y -C 1-3 alkylene-, and -C 1-2 alkylene-Y-C 1-2 alkylene-; wherein said alkylene groups are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, and di(C 1-3 alkyl)amino; A 2< is selected from a bond,Cy A2< , -Y-, -C 1-3 alkylene-, -C 1-3 alkylene-Y-, - Y-C 1-3 alkylene-, and -C 1-2 alkylene-Y-C 1-2 alkylene-; wherein said alkylene groups are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, and di(C 1-3 alkyl)amino; A 3< is selected from a bond, Cy A3< , -Y-, -C 1-3 alkylene-, -C 1-3 alkylene-Y-, - Y-C 1-3 alkylene-, and -C 1-2 alkylene-Y-C 1-2 alkylene-; wherein said alkylene groups are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 haloalkyl, C 1-3 haloalkoxy, amino, C 1-3 alkylamino, and di(C 1-3 alkyl)amino; R A< is H, C 1-6 alkyl, C 1-6 haloalkyl, halo, CN, NO 2 , OR a1< , SR a1< , C(O)R b1< , C(O)NR c1< R d1< , C(O)OR a1< , OC(O)R b1< , OC(O)NR c1< R d1< , NR c1< R d1< , NR c1< OR d1< , NR c1< C(O)R b1< , NR c1< C(O)OR a1< , NR c1< C(O)NR c1< R d1< , C(=NR e1< )R b1< , C(=NR e1< )NR c1< R d1< , NR c1< C(=NR e1< )NR c1< R d1< , NR c1< S(O)R b1< , NRc 1< S(O) 2 R b1< , NR c1< S(O) 2 NR c1< R d1< , S(O)R b1< , S(O)NR c1< R a1< , S(O) 2 R b1< , or S(O)2NR c1< R d1< ; wherein said C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 11< ; Y is O, S, S(O), S(O) 2 , C(O), C(O)NR f< , NR f< C(O), NR f< C(O)NR f< , NR f< S(O) 2 NR f< , S(O) 2 NR f< , NR f< S(O) 2 , or NR f< ; each R f< is independently selected from H and C 1-3 alkyl; Cy A1< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A1< ; each R A1< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; Cy A2< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A2< ; each R A2< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; Cy A3< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A3< ; each R A3< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; each R C< is independently selected from OH, CN, halo, C 1-4 alkyl, C 1-3 haloalkyl, C 1-4 alkoxy, C 1-3 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 alkylsulfinyl, C 1-4 alkylsulfonyl, carbamyl, C 1-4 alkylcarbamyl, di(C 1-4 alkyl)carbamyl, carboxy, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkylcarbonylamino, C 1-4 alkylsulfonylamino, aminosulfonyl, C 1-4 alkylaminosulfonyl, and di(C 1-4 alkyl)aminosulfonyl; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, OR a2< , C(O)R b2< , C(O)NR c2< R d2,< C(O)OR a2< , NR c2< R d2< , NR c2< C(O)R b2< , and NR c2< C(O)OR a2< ; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R 11< is independently selected from CN, NO 2 , OR a3< , SR a3< , C(O)R b3< , C(O)NR c3< R d3< , C(O)OR a3< , OC(O)R b3< , OC(O)NR c3< R d3< , NR c3< R d3< , NR c3< OR d3< , NR c3< C(O)R b3< , NR c3< C(O)OR a3< , NR c3< C(O)NR c3< R d3< , NR c3< S(O)R b3< , NR c3< S(O)2R b3< , NR c3< S(O) 2 NR c3< R d3< , S(O)R b3< , S(O)NR c3< R d3< , S(O) 2 R b3< , and S(O) 2 NR c3< R d3< ; each R 12< is independently selected from halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, OR a4< , SR a4< , C(O)R b4< , C(O)NR c4< R d4< , C(O)OR a4< , OC(O)R b4< , OC(O)NR c4< R d4< , NR c4< R d4< , NR c4< OR d4< , NR c4< C(O)R b4< , NR c4< C(O)OR a4< , NR c4< C(O)NR c4< R d4< , NR c4< S(O)R b4< , NR c4< S(O) 2 R b4< , NR c4< S(O) 2 NR c4< R d4< , S(O)R b4< , S(O)NR c4< R d4< , S(O) 2 R b4< , and S(O) 2 NR c4< R d4< ; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; R a1< , R c1< and R d1< are each independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; or alternatively, R c1< and R d1< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R g< ; R b1< is selected from C 1-6 alkyl and C 1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; R e1< is selected from H, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkylthio, C 1-6 alkylsulfonyl, C 1-6 alkylcarbonyl, C 1-6 alkylaminosulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, aminosulfonyl, C 1-6 alkylaminosulfonyl, and di(C 1-6 alkyl)aminosulfonyl; each R a2< , R c2< , and R d2< is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; or alternatively, any R c2< and R d2< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R 12< ; each R b2< is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R a3< , R c3< and R d3< is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; or alternatively, any R c3< and R d3< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R g< ; each R b3< is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R a4< , R c4< and R d4< , is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; or alternatively, any R c4< and R d4< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R g< ; each R b4< is independently selected from C 1-6 alkyl and C 1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; and each R g< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; provided that: 1) A 1< -A 2< -A 3< is not Y-Y when one of A 1< , A 2< or A 3< is a bond, or Y-Y-Y; and 2) when A 3< is -Y-or-C 1-3 alkylene-Y- then R A< is H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein said C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 11< .

[0094] In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< ; A 1< is selected from a bond, Cy A1< , -Y-, -C 1-3 alkylene-, -C 1-3 alkylene-Y-, and -Y-C 1-3 alkylene-; A 2< is selected from a bond, Cy A2< , -Y-, -C 1-3 alkylene-, -C 1-3 alkylene-Y-, and -Y-C 1-3 alkylene-; A 3< is selected from a bond, Cy A3< , -Y-, -C 1-3 alkylene-, -C 1-3 alkylene-Y-, and -Y-C 1-3 alkylene-; R A< is H, C 1-6 alkyl, C 1-6 haloalkyl, halo, CN, NO 2 , OR a1< , SR a1< , C(O)R b1< , C(O)NR c1< R d1< , C(O)OR a1< , OC(O)R b1< , OC(O)NR c1< R d1< , NR c1< R d1< , NR c1< C(O)R b1< , NR c1< C(O)OR a1< , S(O)R b1< , S(O)NR c1< R d1< , S(O) 2 R b1< , or S(O)2NR c1< R d1< ; wherein said C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 11< ; Y is O, S, S(O), S(O) 2 , or C(O); Cy A1< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A1< ; each R A1< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkylaminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; Cy A2< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A2< ; each R A2< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; Cy A3< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A3< ; each R A3< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; each R C< is independently selected from OH, CN, halo, C 1-4 alkyl, C 1-3 haloalkyl, C 1-4 alkoxy, C 1-3 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-4 alkylsulfinyl, C 1-4 alkylsulfonyl, carbamyl, C 1-4 alkylcarbamyl, di(C 1-4 alkyl)carbamyl, carboxy, C 1-4 alkylcarbonyl, C 1-4 alkoxycarbonyl, C 1-4 alkylcarbonylamino, C 1-4 alkylsulfonylamino, aminosulfonyl, C 1-4 alkylaminosulfonyl, and di(C 1-4 alkyl)aminosulfonyl; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, OR a2< , C(O)R b2< , C(O)NR c2< R d2< , C(O)OR a2< , NR c2< R d2< , NR c2< C(O)R b2< , and NR c2< C(O)OR a2< ; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R 11< is independently selected from CN, NO 2 , OR a3< , SR a3< , C(O)R b3< , C(O)NR c3< R d3< , C(O)OR a3< , OC(O)R b3< , OC(O)NR c3< R d3< , NR c3< R d3< , NR c3< OR d3< , NR c3< C(O)R b3< , NR c3< C(O)OR a3< , NR c3< C(O)NR c3< R d3< , NR c3< S(O)R b3< , NR c3< S(O)2R b3< , NR c3< S(O) 2 NR c3< R d3< , S(O)R b3< , S(O)NR c3< R d3< , S(O)2R b3< , and S(O)2NR c3< R d3< ; each R 12< is independently selected from halo, CN, NO 2 , C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, OR a4< , SR a4< , C(O)R b4< , C(O)NR c4< R d4< , C(O)OR a4< , OC(O)R b4< , OC(O)NR c4< R d4< , NR c4< R d4< , NR c4< OR d4< , NR c4< C(O)R b4< , NR c4< C(O)OR a4< , NR c4< C(O)NR c4< R d4< , NR c4< S(O)R b4< , NR c4< S(O) 2 R b4< , NR c4< S(O) 2 NR c4< R d4< , S(O)R b4< , S(O)NR c4< R d4< , S(O) 2 R b4< , and S(O) 2 NR c4< R d4< ; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; R a1< , R c1< and R d1< are each independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; or alternatively, R c1< and R d1< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R g< ; R b1< is selected from C 1-6 alkyl and C 1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R a2< , R c2< , and R d2< is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; or alternatively, any R c2< and R d2< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R 12< ; each R b2< is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R a3< , R c3< and R d3< is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; or alternatively, any R c3< and R d3< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R g< ; each R b3< is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R a4< , R c4< and R d4< , is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; or alternatively, any R c4< and R d4< attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R g< ; each R b4< is independently selected from C 1-6 alkyl and C 1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; and each R g< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; provided that: 1) A 1< -A 2< -A 3< is not Y-Y when one of A 1< , A 2< or A 3< is a bond, or Y-Y-Y; and 2) when A 3< is -Y-or-C 1-3 alkylene-Y-then R A< is H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein said C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 11< .

[0095] In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< ; A 1< is selected from a bond, -Y-, and -C 1-3 alkylene-; A 2< is selected from a bond, -Y-, and -C 1-3 alkylene-; A 3< is selected from a bond, Cy A3< , -Y-, and -C 1-3 alkylene-; R A< is H, C 1-6 alkyl, C 1-6 haloalkyl, halo, CN, OR a1< , SR a1< , C(O)R b1< , C(O)NR c1< R d1< , C(O)OR a1< , NR c1< R d1< , NR c1< C(O)R b1< , S(O)R b1< , S(O)NR c1< R d1< , S(O) 2 R b1< , or S(O) 2 NR c1< R d1< ; wherein said C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 11< ; Y is O, S, S(O), S(O) 2 , or C(O); Cy A3< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A3< ; each R A3< is independently selected from OH, CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, and C 1-6 alkoxycarbonyl; each R C< is independently selected from OH, CN, halo, C 1-4 alkyl, C 1-3 haloalkyl, C 1-4 alkoxy, C 1-3 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, amino, C 1-4 alkylamino, and di(C 1-4 alkyl)amino; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, OR a2< , C(O)R b2< , C(O)NR c2< R d2< , C(O)OR a2< , NR c2< R d2< , and NR c2< C(O)R b2< ; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R 11< is independently selected from CN, OR a3< , SR a3< , C(O)R b3< , C(O)NR c3< R d3< , C(O)OR a3< , NR c3< R d3< , NR c3< C(O)R b3< , NR c3< C(O)OR a3< , NR c3< S(O)R b3< , NR c3< S(O)2R b3< , NR c3< S(O) 2 NR c3< R d3< , S(O)R b3< , S(O)NR c3< R d3< , S(O) 2 R b3< , and S(O) 2 NR c3< R d3< ; each R 12< is independently selected from halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, OR a4< , SR a4< , C(O)R b4< , C(O)NR c4< R d4< , C(O)OR a4< , NR c4< R d4< , NR c4< C(O)R b4< , NR c4< C(O)OR a4< , NR c4< S(O)R b4< , NR c4< S(O) 2 R b4< , NR c4< S(O) 2 NR c4< R d4< , S(O)R b4< , S(O)NR c4< R d4< , S(O) 2 R b4< , and S(O) 2 NR c4< R d4< ; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; R a1< , R c1< and R d1< are each independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; R b1< is selected from C 1-6 alkyl and C 1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R a2< , R c2< , and R d2< is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R b2< is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R a3< , R c3< and R d3< is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R b3< is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C 3-6 cycloalkyl-C 1-4 alkylene, phenyl-C 1-4 alkylene, 5-6 membered heteroaryl-C 1-4 alkylene, and 4-7 membered heterocycloalkyl-C 1-4 alkylene, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R a4< , R c4< and R d4< , is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R b4< is independently selected from C 1-6 alkyl and C 1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; and each R g< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, thio, C 1-6 alkylthio, C 1-6 alkylsulfinyl, C 1-6 alkylsulfonyl, carbamyl, C 1-6 alkylcarbamyl, di(C 1-6 alkyl)carbamyl, carboxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, C 1-6 alkylcarbonylamino, C 1-6 alkylsulfonylamino, aminosulfonyl, C 1-6 alkylaminosulfonyl, di(C 1-6 alkyl)aminosulfonyl, aminosulfonylamino, C 1-6 alkylaminosulfonylamino, di(C 1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C 1-6 alkylaminocarbonylamino, and di(C 1-6 alkyl)aminocarbonylamino; provided that: 1) A 1< -A 2< -A 3< is not Y-Y when one of A 1< , A 2< or A 3< is a bond, or Y-Y-Y; and 2) when A 3< is -Y-or-C 1-3 alkylene-Y- then R A< is H, C 1-6 alkyl, or C 1-6 haloalkyl, wherein said C 1-6 alkyl or C 1-6 haloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 11< .

[0096] In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< ; A 1< is selected from a bond and -C 1-3 alkylene-; A 2< is selected from a bond and -C 1-3 alkylene-; A 3< is selected from a bond, Cy 3< , and -C 1-3 alkylene-; R A< is H, C 1-6 alkyl, CN, OR a1< , C(O)R b1< , C(0)NR c1< R d1< , C(O)OR a1< , NR c1< R d1< , NR c1< C(O)R b1< , S(O)R b1< , S(O)NR c1< R d1< , S(O) 2 R b1< , or S(O) 2 NR c1< R d1< ; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R 11< ; Cy A3< is C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from R A3< ; each R A3< is independently selected from OH, CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, and C 1-6 alkoxy; each R C< is independently selected from OH, CN, halo, C 1-4 alkyl, C 1-3 haloalkyl, C 1-4 alkoxy, and C 1-3 haloalkoxy; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently selected from halo, C 1-6 alkyl, C 1-6 haloalkyl, phenyl, OR a2< , C(O)R b2< , C(O)NR c2< R d2< , and C(O)OR a2< ; wherein said C 1-6 alkyl and phenyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R 11< is independently selected from CN or OR a3< ; each R 12< is independently selected from halo, CN, C 1-6 alkyl, C 1-6 haloalkyl, phenyl, OR a4< , C(O)R b4< , C(O)NR c4< R d4< , and C(O)OR a4< ; wherein said C 1-6 alkyl, C 3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; R a1< , R c1< and R d1< are each independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; R b1< is selected from C 1-6 alkyl and C 1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R a2< , R c2< , and R d2< is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, and phenyl; wherein said C 1-6 alkyl and phenyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R b2< is independently selected from C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, and phenyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R a3< is independently selected from H, C 1-6 alkyl, C 1-6 haloalkyl, phenyl, phenyl-C 1-4 alkylene; wherein said C 1-6 alkyl, phenyl, and phenyl-C 1-4 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R a4< , R c4< and R d4< , is independently selected from H, C 1-6 alkyl, and C 1-6 haloalkyl; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; each R b4< is independently selected from C 1-6 alkyl and C 1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R g< ; and each R 8< is independently selected from OH, NO 2 , CN, halo, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, cyano-C 1-3 alkyl, HO-C 1-3 alkyl, H 2 N-C 1-3 alkyl, amino, C 1-6 alkylamino, and di(C 1-6 alkyl)amino.

[0097] In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< , (1) wherein said A 1< , A 2< , and A 3< are each a bond, and R A< is C 1-6 alkyl or C(O)NR c1< R d1< , (2) wherein said A 1< is a bond, A 2< is a bond or -C 1-3 alkylene-, A 3< is Cy A3< , and R A< is C 1-6 alkyl, CN, OR a1< , NR c1< R d1< , C(O)R b1< , C(O)NR c1< R d1< , C(O)OR a1< , or S(O) 2 R b1< ; wherein said C 1-6 alkyl of R A< is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 11< , or (3) wherein A 1< is Cy A1< , A 2< is a bond or C(O), A 3< is Cy A3< , and R A< is H; Cy A1< is C 3-7 cycloalkyl or 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; Cy A3< is C 3-7 cycloalkyl, 6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C 3-7 cycloalkyl, 6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 C 1-6 alkyl; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently selected from C 1-6 alkyl, C 2-6 alkynyl, CN, halo, phenyl, 5-6 membered heteroaryl, C 3-6 cycloalkyl, 4-7 membered heterocycloalkyl, OR a2< , C(O)R b2< , and C(O)NR c2< R d2< ; wherein said C 1-6 alkyl, C 2-6 alkynyl, phenyl, 5-6 membered heteroaryl, C 3-6 cycloalkyl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R C< is independently selected from halo and C 1-4 alkyl; each R 11< is independently OR a3< or C(O)NR c3< R d3< ; each R 12< is independently selected from halo, C 1-6 alkyl, CN, phenyl, and OR a4< ; each R a1< , R c1< , and R d1< is independently selected from H and C 1-6 alkyl; each R b1< is independently selected from C 1-6 alkyl; each R a3< , R c3< , R d3< and R a4< is independently selected from H and C 1-6 alkyl; and each R a2< , R b2< , R c2< , and R d2< is independently selected from H, C 1-6 alkyl, and phenyl; wherein said C 1-6 alkyl and phenyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< . In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< , (1) wherein said A 1< , A 2< , and A 3< are each a bond, and R A< is C 1-6 alkyl, or (2) wherein said A 1< is a bond, A 2< is a bond or - C 1-3 alkylene-, A 3< is Cy 3< , and R A< is C 1-6 alkyl, CN, OR a1< , NR c1< R d1< , C(O)R b1< , C(O)NR c1< R d1< , C(O)OR a1< , or S(O) 2 R b1< ; wherein said C 1-6 alkyl of R A< is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 11< ; Cy A3< is C 3-7 cycloalkyl, 6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently selected from C 1-6 alkyl, phenyl, OR a2< , and C(O)NR c2< R d2< ; wherein said C 1-6 alkyl and phenyl optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R C< is independently selected from halo and C 1-4 alkyl; each R 11< is independently OR a3< ; each R 12< is independently selected from halo, phenyl, and OR a4< ; each R a1< , R c1< , and R d1< is independently selected from H and C 1-6 alkyl; each R b1< is independently selected from C 1-6 alkyl; each R a3< and R a4< is independently selected from H and C 1-6 alkyl; and each R a2< , R c2< , and R d2< is independently selected from H, C 1-6 alkyl, and phenyl; wherein said C 1-6 alkyl and phenyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< . In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< , (1) wherein said A 1< , A 2< , and A 3< are each a bond, and R A< is C 1-6 alkyl, or (2) wherein said A 1< and A 2< are each a bond, A 3< is Cy 3< , and R A< is C 1-6 alkyl, CN, OR a1< , C(O)R b1< , C(0)NR c1< R d1< , C(O)OR a1< , or S(O) 2 R b1< ; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 11< ; Cy A3< is C 3-7 cycloalkyl or 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently selected from C 1-6 alkyl and phenyl; wherein said C 1-6 alkyl and phenyl are optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R C< is independently halo; each R 11< is independently OR a3< ; each R 12< is independently selected from halo, phenyl, and OR a4< ; each R a1< , R c1< , and R d1< is independently selected from H and C 1-6 alkyl; each R b1< is independently selected from C 1-6 alkyl; and each R a3< and R a4< is independently selected from H and C 1-6 alkyl.

[0098] In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< , (1) wherein said A 1< , A 2< , and A 3< are each a bond, and R A< is C 1-6 alkyl, or (2) wherein said A 1< and A 2< are each a bond, A 3< is Cy A3< , and R A< is C 1-6 alkyl, CN, OR a1< , C(O)R b1< , C(0)NR c1< R d1< , C(O)OR a1< , or S(O) 2 R b1< ; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 11< ; Cy A3< is C 3-7 cycloalkyl or 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; wherein each R B< is independently selected from C 1-6 alkyl and phenyl; wherein said C 1-6 alkyl and phenyl are optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R C< is independently halo; each R 11< is independently OR a3< ; each R 12< is independently selected from halo, phenyl, and OR a4< ; each R a1< , R c1< , and R d1< is independently selected from H and C 1-6 alkyl; each R b1< is independently selected from C 1-6 alkyl; and each R a3< and R a4< is independently selected from H and C 1-6 alkyl.

[0099] In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< , (1) wherein said A 1< , A 2< , and A 3< are each a bond, and R A< is C 1-6 alkyl, or (2) wherein said A 1< and A 2< are each a bond, A 3< is Cy A3< , and R A< is C 1-6 alkyl, CN, OR a1< , C(O)R b1< , C(0)NR c1< R d1< , C(O)OR a1< , or S(O) 2 R b1< ; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 11< ; Cy A3< is C 3-7 cycloalkyl or 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently selected from C 1-6 alkyl and phenyl; wherein said C 1-6 alkyl and phenyl are optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R C< is independently halo; each R 11< is independently OR a3< ; each R 12< is independently selected from halo, phenyl, and OR a4< ; each R a1< , R c1< , and R d1< is independently selected from H and C 1-6 alkyl; alternatively, R c1< and R d1< attached to the same N atom, together with the N atom to which they are attached, form a 6-membered heterocycloalkyl group; each R b1< is independently selected from C 1-6 alkyl; and each R a3< and R a4< is independently selected from H and C 1-6 alkyl.

[0100] In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< , (1) wherein said A 1< , A 2< , and A 3< are each a bond, and R A< is C 1-6 alkyl, or (2) wherein said A 1< and A 2< are each a bond, A 3< is Cy A3< , and R A< is C 1-6 alkyl, CN, OR a1< , C(O)R b1< , C(0)NR c1< R d1< , C(O)OR a1< , or S(O) 2 R b1< ; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 11< ; Cy A3< is C 3-7 cycloalkyl or 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; wherein each R B< is independently selected from C 1-6 alkyl and phenyl; wherein said C 1-6 alkyl and phenyl are optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R C< is independently halo; each R 11< is independently OR a3< ; each R 12< is independently selected from halo, phenyl, and OR a4< ; each R a1< , R c1< , and R d1< is independently selected from H and C 1-6 alkyl; alternatively, R c1< and R d1< attached to the same N atom, together with the N atom to which they are attached, form a 6-membered heterocycloalkyl group; each R b1< is independently selected from C 1-6 alkyl; and each R a3< and R a4< is independently selected from H and C 1-6 alkyl.

[0101] In some embodiments: R 1< is A 1< -A 2< -A 3< -R A< , (1) wherein said A 1< , A 2< , and A 3< are each a bond, and R A< is C(O)NR c1< R d1< or C 1-6 alkyl; or (2) wherein said A 1< is a bond, A 2< is a bond or-C 1-3 alkylene-, A 3< is Cy 3< , and R A< is H, C 1-6 alkyl, CN, OR a1< , C(O)R b1< , C(O)NR c1< R d1< , NR c1< R d1< , C(O)OR a1< , or S(O) 2 R b1< ; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 11< ; (3) wherein A 1< is Cy A1< , A 2< is Y, Y is C(O), A 3< is Cy 3< , and R A< is H; or (4) wherein A 1< is a bond, A 2< is Cy A2< , A 3< is Cy A3< , wherein R A< is C 1-6 alkyl; Cy A3< is 5-6 membered heteroaryl, C 3-7 cycloalkyl or 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 substituents independently selected from R B< ; each R B< is independently selected from halo, CN, C 1-6 alkyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl, OR a2< , C(O)R b2< , C(O)NR c2< R d2< , wherein said C 1-6 alkyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, and phenyl are optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R C< is independently halo; each R 11< is independently OR a3< or C(O)NR c3< R d3< ; each R 12< is independently selected from halo, CN, C 1-6 alkyl, and OR a4< ; each R a1< , R c1< , and R d1< is independently selected from H and C 1-6 alkyl; alternatively, R c1< and R d1< attached to the same N atom, together with the N atom to which they are attached, form a 6-membered heterocycloalkyl group; each R b1< is independently selected from C 1-6 alkyl; and each R a3< and R a4< is independently selected from H and C 1-6 alkyl.

[0102] In some embodiments, Cy B< is wherein Cy B< -1, Cy B< -2, Cy B< -3, and Cy B< -10 are each optionally substituted with 1, 2 or 3 independently selected R B< groups; R 1< is A 1< -A 2< -A 3< -R A< , (1) wherein said A 1< , A 2< , and A 3< are each a bond, and R A< is C(O)NR c1< R d1< or C 1-6 alkyl; or (2) wherein said A 1< is a bond, A 2< is a bond or -C 1-3 alkylene-, A 3< is Cy 3< , and R A< is H, C 1-6 alkyl, CN, OR a1< , C(O)R b1< , C(O)NR c1< R d1< , NR c1< R d1< , C(O)OR a1< , or S(O) 2 R b1< ; wherein said C 1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 11< ; (3) wherein A 1< is Cy A1< , A 2< is Y, Y is C(O), A 3< is Cy 3< , and R A< is H; or (4) wherein A 1< is a bond, A 2< is Cy A2< , A 3< is Cy 3< , wherein R A< is C 1-6 alkyl; Cy A3< is 5-6 membered heteroaryl, C 3-7 cycloalkyl or 4-7 membered heterocycloalkyl; wherein the 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein a ring-forming carbon atom of C 3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; each R B< is independently selected from halo, CN, C 1-6 alkyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, phenyl, OR a2< , C(O)R b2< , C(O)NR c2< R d2< , wherein said C 1-6 alkyl, C 2-6 alkynyl, C 3-6 cycloalkyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, and phenyl are optionally substituted with 1, 2, 3, or 4 substituents independently selected from R 12< ; each R C< is independently halo; each R 11< is independently OR a3< or C(O)NR c3< R d3< ; each R 12< is independently selected from halo, CN, C 1-6 alkyl, and OR a4< ; each R a1< , R c1< , and R d1< is independently selected from H and C 1-6 alkyl; alternatively, R c1< and R d1< attached to the same N atom, together with the N atom to which they are attached, form a 6-membered heterocycloalkyl group; each R b1< is independently selected from C 1-6 alkyl; and each R a3< and R a4< is independently selected from H and C 1-6 alkyl.

[0103] It is further appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment. Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination.

[0104] At various places in the present specification, substituents of compounds provided herein are disclosed in groups or in ranges. It is specifically intended that the invention include each and every individual subcombination of the members of such groups and ranges. For example, the term "C 1-6 alkyl" is specifically intended to individually disclose methyl, ethyl, C 3 alkyl, C 4 alkyl, C 5 alkyl, and C 6 alkyl.

[0105] At certain places, the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas an azetidin-3-yl ring is attached at the 3-position.

[0106] The term "n-membered" where n is an integer typically describes the number of ring-forming atoms in a moiety where the number of ring-forming atoms is n. For example, piperidinyl is an example of a 6-membered heterocycloalkyl ring, pyrazolyl is an example of a 5-membered heteroaryl ring, pyridyl is an example of a 6-membered heteroaryl ring, and 1,2,3,4-tetrahydro-naphthalene is an example of a 10-membered cycloalkyl group.

[0107] For compounds provided herein in which a variable appears more than once, each variable can be a different moiety independently selected from the group defining the variable. For example, where a structure is described having two R groups that are simultaneously present on the same compound, the two R groups can represent different moieties independently selected from the group defined for R In another example, when an optionally multiple substituent is designated in the form: then it is to be understood that substituent R can occur p number of times on the ring, and R can be a different moiety at each occurrence. It is to be understood that each R group may replace any hydrogen atom attached to a ring atom, including one or both of the (CH 2 ) n hydrogen atoms. Further, in the above example, should the variable Q be defined to include hydrogens, such as when Q is said to be CH 2 , NH, etc., any floating substituent such as R in the above example, can replace a hydrogen of the Q variable as well as a hydrogen in any other non-variable component of the ring.

[0108] As used herein, the phrase "optionally substituted" means unsubstituted or substituted. The substituents are independently selected, and substitution may be at any chemically accessible position. As used herein, the term "substituted" means that a hydrogen atom is removed and replaced by a substituent. A single divalent substituent, e.g., oxo, can replace two hydrogen atoms. It is to be understood that substitution at a given atom is limited by valency.

[0109] Throughout the definitions, the term "C n-m " indicates a range which includes the endpoints, wherein n and m are integers and indicate the number of carbons. Examples include C 1-4 , C 1-6 , and the like.

[0110] As used herein, the term "C n-m alkyl", employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched, having n to m carbons. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, isobutyl, sec-butyl; higher homologs such as 2-methyl-1-butyl, n-pentyl, 3-pentyl, n-hexyl, 1,2,2-trimethylpropyl, and the like. In some embodiments, the alkyl group contains from 1 to 6 carbon atoms, from 1 to 4 carbon atoms, from 1 to 3 carbon atoms, or 1 to 2 carbon atoms.

[0111] As used herein, "C n-m alkenyl" refers to an alkyl group having one or more double carbon-carbon bonds and having n to m carbons. Example alkenyl groups include, but are not limited to, ethenyl, n-propenyl, isopropenyl, n-butenyl, sec-butenyl, and the like. In some embodiments, the alkenyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.

[0112] As used herein, "C n-m alkynyl" refers to an alkyl group having one or more triple carbon-carbon bonds and having n to m carbons. Example alkynyl groups include, but are not limited to, ethynyl, propyn-1-yl, propyn-2-yl, and the like. In some embodiments, the alkynyl moiety contains 2 to 6, 2 to 4, or 2 to 3 carbon atoms.

[0113] As used herein, the term "C n-m alkylene", employed alone or in combination with other terms, refers to a divalent alkyl linking group having n to m carbons. Examples of alkylene groups include, but are not limited to, ethan-1,1-diyl, ethan-1,2-diyl, propan-1,1,-diyl, propan-1,3-diyl, propan-1,2-diyl, butan-1,4-diyl, butan-1,3-diyl, butan-1,2-diyl, 2-methyl-propan-1,3-diyl, and the like. In some embodiments, the alkylene moiety contains 2 to 6, 2 to 4, 2 to 3, 1 to 6, 1 to 4, or 1 to 2 carbon atoms.

[0114] As used herein, the term "C n-m alkoxy", employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group has n to m carbons. Example alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (e.g., n-propoxy and isopropoxy), butoxy (e.g., n-butoxy and tert-butoxy), and the like. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0115] As used herein, the term "C n-m alkylamino" refers to a group of formula -NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkylamino groups include, but are not limited to, N-methylamino, N-ethylamino, N-propylamino (e.g., N-(n-propyl)amino and N-isopropylamino), N-butylamino (e.g., N-(n-butyl)amino and N-(tert-butyl)amino), and the like.

[0116] As used herein, the term "C n-m alkoxycarbonyl" refers to a group of formula -C(O)O-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkoxycarbonyl groups include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl (e.g., n-propoxycarbonyl and isopropoxycarbonyl), butoxycarbonyl (e.g., n-butoxycarbonyl and tert-butoxycarbonyl), and the like.

[0117] As used herein, the term "C n-m alkylcarbonyl" refers to a group of formula -C(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms. Examples of alkylcarbonyl groups include, but are not limited to, methylcarbonyl, ethylcarbonyl, propylcarbonyl (e.g., n-propylcarbonyl and isopropylcarbonyl), butylcarbonyl (e.g., n-butylcarbonyl and tert-butylcarbonyl), and the like.

[0118] As used herein, the term "C n-m alkylcarbonylamino" refers to a group of formula -NHC(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0119] As used herein, the term "C n-m alkylsulfonylamino" refers to a group of formula -NHS(O) 2 -alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0120] As used herein, the term "aminosulfonyl" refers to a group of formula -S(O) 2 NH 2 .

[0121] As used herein, the term "C n-m alkylaminosulfonyl" refers to a group of formula -S(O) 2 NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0122] As used herein, the term "di(C n-m alkyl)aminosulfonyl" refers to a group of formula -S(O) 2 N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0123] As used herein, the term "aminosulfonylamino" refers to a group of formula - NHS(O) 2 NH 2 .

[0124] As used herein, the term "C n-m alkylaminosulfonylamino" refers to a group of formula -NHS(O) 2 NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0125] As used herein, the term "di(C n-m alkyl)aminosulfonylamino" refers to a group of formula -NHS(O) 2 N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0126] As used herein, the term "aminocarbonylamino", employed alone or in combination with other terms, refers to a group of formula -NHC(O)NH 2 .

[0127] As used herein, the term "C n-m alkylaminocarbonylamino" refers to a group of formula -NHC(O)NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0128] As used herein, the term "di(C n-m alkyl)aminocarbonylamino" refers to a group of formula -NHC(O)N(alkyl) 2 , wherein each alkyl group independently has n to m carbon atoms. In some embodiments, each alkyl group has, independently, 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0129] As used herein, the term "C n-m alkylcarbamyl" refers to a group of formula -C(O)-NH(alkyl), wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0130] As used herein, the term "thio" refers to a group of formula -SH.

[0131] As used herein, the term "C n-m alkylthio" refers to a group of formula -S-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0132] As used herein, the term "C n-m alkylsulfinyl" refers to a group of formula -S(O)-alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0133] As used herein, the term "C n-m alkylsulfonyl" refers to a group of formula -S(O) 2 -alkyl, wherein the alkyl group has n to m carbon atoms. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0134] As used herein, the term "amino" refers to a group of formula -NH 2 .

[0135] As used herein, the term "carbamyl" to a group of formula -C(O)NH 2 .

[0136] As used herein, the term "carbonyl", employed alone or in combination with other terms, refers to a -C(=O)- group, which may also be written as C(O).

[0137] As used herein, the term "carboxy" refers to a -C(O)OH group.

[0138] As used herein, the term "cyano-C 1-3 alkyl" refers to a group of formula -(C 1-3 alkylene)-CN.

[0139] As used herein, the term "HO-C 1-3 alkyl" refers to a group of formula -(C 1-3 alkylene)-OH.

[0140] As used herein, the term "HO-C1-3 alkyl" refers to a group of formula -(C1-3 alkylene)-OH.

[0141] As used herein, the term "di(C n-m -alkyl)amino" refers to a group of formula - N(alkyl) 2 , wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0142] As used herein, the term "di(C n-m -alkyl)carbamyl" refers to a group of formula -C(O)N(alkyl) 2 , wherein the two alkyl groups each has, independently, n to m carbon atoms. In some embodiments, each alkyl group independently has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0143] As used herein, "halo" refers to F, Cl, Br, or I. In some embodiments, halo is F, Cl, or Br. In some embodiments, halo is F or Cl.

[0144] As used herein, "C n-m haloalkoxy" refers to a group of formula -O-haloalkyl having n to m carbon atoms. An example haloalkoxy group is OCF 3 . In some embodiments, the haloalkoxy group is fluorinated only. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0145] As used herein, the term "C n-m haloalkyl", employed alone or in combination with other terms, refers to an alkyl group having from one halogen atom to 2s+1 halogen atoms which may be the same or different, where "s" is the number of carbon atoms in the alkyl group, wherein the alkyl group has n to m carbon atoms. In some embodiments, the haloalkyl group is fluorinated only. In some embodiments, the alkyl group has 1 to 6, 1 to 4, or 1 to 3 carbon atoms.

[0146] As used herein, "cycloalkyl" refers to non-aromatic cyclic hydrocarbons including cyclized alkyl and / or alkenyl groups. Cycloalkyl groups can include mono- or polycyclic (e.g., having 2, 3 or 4 fused rings) groups and spirocycles. Ring-forming carbon atoms of a cycloalkyl group can be optionally substituted by oxo or sulfido (e.g., C(O) or C(S)). Also included in the definition of cycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of cyclopentane, cyclohexane, and the like. A cycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. Cycloalkyl groups can have 3, 4, 5, 6, 7, 8, 9, or 10 ring-forming carbons (C 3-10 ). In some embodiments, the cycloalkyl is a C 3-10 monocyclic or bicyclic cycloalkyl. In some embodiments, the cycloalkyl is a C 3-7 monocyclic cycloalkyl. In some embodiments, the cycloalkyl is a C 3-10 monocyclic or bicyclic non-aromatic carbocycle, which optionally has ring members which have oxo (=O) or sulfido (=S) substitution and which optionally has a phenyl or 5-6 membered aromatic heterocycle fused to the non-aromatic portion of the ring structure, wherein the heterocycle has 1-3 ring members independently selected from N, S, or O. In some embodiments, the cycloalkyl is a C 3-7 monocyclic non-aromatic carbocycle, which optionally has ring members which have oxo (=O) or sulfido (=S) substitution and which optionally has a phenyl or 5-6 membered aromatic heterocycle fused to the non-aromatic portion of the ring structure, wherein the heterocycle has 1-3 ring members independently selected from N, S, or O. In some embodiments, the cycloalkyl is a C 3-7 monocyclic cycloalkyl. Example cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cydoheptatrienyl, norbornyl, norpinyl, norcamyl, and the like. In some embodiments, cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

[0147] As used herein, the term "aryl," employed alone or in combination with other terms, refers to an aromatic hydrocarbon group, which may be monocyclic or polycyclic (e.g., having 2, 3 or 4 fused rings). Examples of aryl rings include, but are not limited to, phenyl, 1-naphthyl, 2-naphthyl, and the like. In some embodiments, aryl groups have from 6 to 10 carbon atoms or 6 carbon atoms. In some embodiments, the aryl group is a monocyclic or bicyclic group. In some embodiments, the aryl group is phenyl or naphthyl. In some embodiments, the aryl group is phenyl.

[0148] As used herein, the term "phenylene", refers to a divalent phenyl linking group. In some embodiments, the phenylene is optionally substituted as described herein.

[0149] As used herein, "heteroaryl" refers to a monocyclic or polycyclic aromatic heterocycle having at least one heteroatom ring member selected from sulfur, oxygen, and nitrogen. In some embodiments, the heteroaryl ring has 1, 2, 3, or 4 heteroatom ring members independently selected from nitrogen, sulfur and oxygen. In some embodiments, any ring-forming N in a heteroaryl moiety can be an N-oxide. In one embodiment the heteroaryl group is a 5 to 10 membered heteroaryl group. In another embodiment the heteroaryl group is a 5 to 6 membered heteroaryl group. In certain embodiments, the heteroaryl group is a monocyclic or bicyclic aromatic ring system having 5 to 10 ring-forming atoms, wherein 1 to 4 ring-forming atoms are heteroatoms independently selected from N, O, and S, wherein the N and S as ring members are each optionally oxidized, the carbon ring members may be optionally replaced by carbonyl. In another preferred embodiment, the heteroaryl group is a monocyclic aromatic ring system having 5 to 6 ring-forming atoms, wherein 1 to 4 ring-forming atoms are heteroatoms independently selected from N, O, and S, wherein the N and S as ring members are each optionally oxidized, the carbon ring members may be optionally replaced by carbonyl.

[0150] In some embodiments, the heteroaryl is a five-membered or six-membereted heteroaryl ring. A five-membered heteroaryl ring is a heteroaryl with a ring having five ring atoms wherein one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, and S. Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4-oxadiazolyl. A six-membered heteroaryl ring is a heteroaryl with a ring having six ring atoms wherein one or more (e.g., 1, 2, or 3) ring atoms are independently selected from N, O, and S. Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl, pyridone, uracil and pyridazinyl. In some embodiments, pyridone is substituted e.g., 1-methylpyridin-2(1H)-one and 1-phenylpyridin-2(1H)-one. In some embodiments, uracil is substituted with, e.g., phenyl, isopropyl, and pyridinyl. In some embodiments, uracil is substituted with phenyl and isopropyl, e.g., 1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine. In some embodiments, uracil is substituted with pyridinyl and isopropyl, e.g., 1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine.

[0151] As used herein, the term "heteroarylene", refers to a divalent heteroaryl linking group. In some embodiments, the heteroarylene is optionally substituted as described herein.

[0152] As used herein, "heterocycloalkyl" refers to non-aromatic monocyclic or polycyclic heterocycles having one or more ring-forming heteroatoms selected from O, N, or S. Included in heterocycloalkyl are monocyclic 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl groups. Heterocycloalkyl groups can also include spirocycles. Example heterocycloalkyl groups include pyrrolidin-2-one, 1,3-isoxazolidin-2-one, pyranyl, tetrahydropuran, oxetanyl, azetidinyl, morpholino, thiomorpholino, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, piperidinyl, pyrrolidinyl, isoxazolidinyl, isothiazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, imidazolidinyl, azepanyl, benzazapene, and the like. Ring-forming carbon atoms and heteroatoms of a heterocycloalkyl group can be optionally substituted by oxo or sulfido (e.g., C(O), S(O), C(S), or S(O) 2 , etc.). The heterocycloalkyl group can be attached through a ring-forming carbon atom or a ring-forming heteroatom In some embodiments, the heterocycloalkyl group contains 0 to 3 double bonds. In some embodiments, the heterocycloalkyl group contains 0 to 2 double bonds. Also included in the definition of heterocycloalkyl are moieties that have one or more aromatic rings fused (i.e., having a bond in common with) to the cycloalkyl ring, for example, benzo or thienyl derivatives of piperidine, morpholine, azepine, etc. A heterocycloalkyl group containing a fused aromatic ring can be attached through any ring-forming atom including a ring-forming atom of the fused aromatic ring. In some embodiments, the heterocycloalkyl group is a morpholine ring, pyrrolidine ring, piperazine ring, piperidine ring, dihydropyran ring, tetrahydropyran ring, tetrahyropyridine, azetidine ring, or tetrahydrofuran ring. In certain embodiments, the heterocyloalkyl group is a monocyclic or bicyclic non-aromatic ring or ring system having 4 to 10 ring-forming atoms, wherein 1 to 4 ring-forming atoms are heteroatoms independently selected from N, O, and S, wherein the N and S as ring members are each optionally oxidized, the carbon ring members may be optionally replaced by carbonyl, and the heterocycloalkyl group can be optionally fused to a 5-6 membered heteroaryl or phenyl ring, wherein the 5-6 membered heteroaryl ring may have 1-3 heteroatom ring members independently selected from N, S, and O. In another embodiment, the heterocyloalkyl group is a monocyclic non-aromatic ring or ring system having 4 to 6 ring-forming atoms, wherein 1 to 2 ring-forming atoms are heteroatoms independently selected from N, O, and S, wherein the N and S as ring members are each optionally oxidized, the carbon ring members may be optionally replaced by carbonyl, and the heterocycloalkyl group can be optionally fused to a 5-6 membered heteroaryl or phenyl ring, wherein the 5-6 membered heteroaryl ring may have 1-3 heteroatom ring members independently selected from N, S, and O. In some embodiments, a 10-membered heterocycloalkyl group is 7,8-dihydroquinoline-2,5(1H,6H)-dione. In some embodiments, a 6-membered heterocycloalkyl group is piperidinyl, piperazinyl, or tetrahydropyranyl.

[0153] In some embodiments, the aryl group (e.g., phenyl), heteroaryl group, heterocycloalkyl group, or cycloalkyl group as used herein (e.g., in variables Cy A1< , Cy A2< , Cy A3< etc.) can be a terminal group or an internal group (e.g., a divalent linker). In some embodiments, the terms aryl, heteroaryl, heterocycloalkyl, and cycloalkyl and their corresponding arylene, heteroarylene, hetercycloalkylene and cycloalkylene terms are used interchangeably. A skilled artisan would readily recognize whether such a group is a terminal substituent or a linker based on the structure, the substituents described herein, and the context in which such a term appears. For example, even though the disclosure may list phenyl in the definition of varibles such as Cy A2< , depending on the substitution pattern, the disclosure also covers phenylene groups.

[0154] As used herein, "C n-m cycloalkyl-C o-p alkylene" refers to a group of formula - alkylene-cycloalkyl, wherein the cycloalkyl group has n to m ring members and the alkylene group has o to p carbon atoms.

[0155] As used herein, "C n-m heterocycloalkyl-C o-p alkylene" refers to a group of formula -alkylene-heterocycloalkyl, wherein the heterocycloalkyl group has n to m ring members and the alkylene group has o to p carbon atoms.

[0156] As used herein, "phenyl-C o-p alkylene" refers to a group of formula -alkylene-phenyl, wherein the alkylene group has o to p carbon atoms.

[0157] As used herein, "C n-m aryl-C o-p alkylene" refers to a group of formula - alkylene-aryl, wherein the aryl group has n to m ring members and the alkylene group has o to p carbon atoms.

[0158] As used herein, "C n-m heteroaryl-C o-p alkylene" refers to a group of formula - alkylene-heteroaryl, wherein the heteroaryl group has n to m ring members and the alkylene group has o to p carbon atoms.

[0159] As used herein, the term "oxo" refers to an oxygen atom as a divalent substituent, forming a carbonyl group when attached to a carbon (e.g., C=O), or attached to a heteroatom forming a sulfoxide or sulfone group.

[0160] At certain places, the definitions or embodiments refer to specific rings (e.g., an azetidine ring, a pyridine ring, etc.). Unless otherwise indicated, these rings can be attached to any ring member provided that the valency of the atom is not exceeded. For example, an azetidine ring may be attached at any position of the ring, whereas a pyridin-3-yl ring is attached at the 3-position.

[0161] The compounds described herein can be asymmetric (e.g., having one or more stereocenters). All stereoisomers, such as enantiomers and diastereomers, are intended unless otherwise indicated. Compounds of the present disclosure that contain asymmetrically substituted carbon atoms can be isolated in optically active or racemic forms. Methods on how to prepare optically active forms from optically inactive starting materials are known in the art, such as by resolution of racemic mixtures or by stereoselective synthesis. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present disclosure. Cis and trans geometric isomers of the compounds of the present disclosure are described and may be isolated as a mixture of isomers or as separated isomeric forms. In some embodiments, the compound has the (R)-configuration. In some embodiments, the compound has the (S)-configuration.

[0162] Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallizaion using a chiral resolving acid which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids such as □-camphorsulfonic acid. Other resolving agents suitable for fractional crystallization methods include stereoisomerically pure forms of α-methylbenzylamine (e.g., S and R forms, or diastereomerically pure forms), 2-phenylglycinol, norephedrine, ephedrine, N-methylephedrine, cyclohexylethylamine, 1,2-diaminocyclohexane, and the like.

[0163] Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art.

[0164] Compounds provided herein also include tautomeric forms. Tautomeric forms result from the swapping of a single bond with an adjacent double bond together with the concomitant migration of a proton. Tautomeric forms include prototropic tautomers which are isomeric protonation states having the same empirical formula and total charge. Example prototropic tautomers include ketone - enol pairs, amide - imidic acid pairs, lactam - lactim pairs, enamine - imine pairs, and annular forms where a proton can occupy two or more positions of a heterocyclic system, for example, 1H- and 3H-imidazole, 1H-, 2H- and 4H- 1,2,4-triazole, 1H- and 2H-isoindole, and 1H- and 2H-pyrazole. Tautomeric forms can be in equilibrium or sterically locked into one form by appropriate substitution.

[0165] All compounds, and pharmaceutically acceptable salts thereof, can be found together with other substances such as water and solvents (e.g. hydrates and solvates) or can be isolated.

[0166] In some embodiments, preparation of compounds can involve the addition of acids or bases to affect, for example, catalysis of a desired reaction or formation of salt forms such as acid addition salts.

[0167] Example acids can be inorganic or organic acids and include, but are not limited to, strong and weak acids. Some example acids include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, p-toluenesulfonic acid, 4-nitrobenzoic acid, methanesulfonic acid, benzenesulfonic acid, trifluoroacetic acid, and nitric acid. Some weak acids include, but are not limited to acetic acid, propionic acid, butanoic acid, benzoic acid, tartaric acid, pentanoic acid, hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, and decanoic acid.

[0168] Example bases include lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, and sodium bicarbonate. Some example strong bases include, but are not limited to, hydroxide, alkoxides, metal amides, metal hydrides, metal dialkylamides and arylamines, wherein; alkoxides include lithium, sodium and potassium salts of methyl, ethyl and t-butyl oxides; metal amides include sodium amide, potassium amide and lithium amide; metal hydrides include sodium hydride, potassium hydride and lithium hydride; and metal dialkylamides include lithium, sodium, and potassium salts of methyl, ethyl, n-propyl, iso-propyl, n-butyl, tert-butyl, trimethylsilyl and cyclohexyl substituted amides.

[0169] In some embodiments, the compounds provided herein, or salts thereof, are substantially isolated. By "substantially isolated" is meant that the compound is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the compounds provided herein. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the compounds provided herein, or salt thereof. Methods for isolating compounds and their salts are routine in the art.

[0170] Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom For example, one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 deuterium atoms. Synthetic methods for including isotopes into organic compounds are known in the art.

[0171] Substitution with heavier isotopes such as deuterium, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances. (A. Kerekes et.al. J. Med. Chem. 2011, 54, 201-210; R Xu et.al. J. Label Compd. Radiopharm. 2015, 58, 308-312).

[0172] The term "compound" as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified.

[0173] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0174] The present application also includes pharmaceutically acceptable salts of the compounds described herein. The present disclosure also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, "pharmaceutically acceptable salts" refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, alcohols (e.g., methanol, ethanol, iso-propanol, or butanol) or acetonitrile (ACN) are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science, 66, 2 (1977).

[0175] The following abbreviations may be used herein: AcOH (acetic acid); Ac 2 O (acetic anhydride); aq. (aqueous); atm. (atmosphere(s)); Boc (t-butoxycarbonyl); br (broad); Cbz (carboxybenzyl); calc. (calculated); d (doublet); dd (doublet of doublets); DCM (dichloromethane); DEAD (diethyl azodicarboxylate); DIAD (N,N'-diisopropyl azidodicarboxylate); DIPEA (N,N-diisopropylethylamine); DMF (N,N-dimethylformamide); Et (ethyl); EtOAc (ethyl acetate); g (gram(s)); h (hour(s)); HATU (N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate); HCl (hydrochloric acid); HPLC (high performance liquid chromatography); Hz (hertz); J (coupling constant); LCMS (liquid chromatography - mass spectrometry); m (multiplet); M (molar); mCPBA (3-chloroperoxybenzoic acid); MgSO 4 (magnesium sulfate); MS (Mass spectrometry); Me (methyl); MeCN (acetonitrile); MeOH (methanol); mg (milligram(s)); min. (minutes(s)); mL (milliliter(s)); mmol (millimole(s)); N (normal); NaHCO 3 (sodium bicarbonate); NaOH (sodium hydroxide); Na 2 SO 4 (sodium sulfate); NH 4 Cl (ammonium chloride); NH 4 OH (ammonium hydroxide); nM (nanomolar); NMR (nuclear magnetic resonance spectroscopy); OTf (trifluoromethanesulfonate); Pd (palladium); Ph (phenyl); pM (picomolar); PMB (para-methoxybenzyl), POCl 3 (phosphoryl chloride); RP-HPLC (reverse phase high performance liquid chromatography); s (singlet); t (triplet or tertiary); TBS (tert-butyldimethylsilyl); tert (tertiary); tt (triplet of triplets); t-Bu (tert-butyl); TFA (trifluoroacetic acid); THF (tetrahydrofuran); µg (microgram(s)); µL (microliter(s)); µM (micromolar); wt% (weight percent).

[0176] As used herein, the term "cell" is meant to refer to a cell that is in vitro, ex vivo or in vivo. In some embodiments, an ex vivo cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism such as a mammal.

[0177] As used herein, the term "contacting" refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, "contacting" the TAM kinases with a compound of the disclosure includes the administration of a compound of the present disclosure to an individual or patient, such as a human, having TAM, as well as, for example, introducing a compound of the disclosure into a sample containing a cellular or purified preparation containing the TAM kinases.

[0178] As used herein, the term "individual" or "patient," used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans.

[0179] As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal, individual or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.

[0180] As used herein the term "treating" or "treatment" refers to 1) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and / or symptomatology), or 2) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and / or symptomatology).

[0181] As used herein the term "preventing" or "prevention" refers to preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease.Synthesis

[0182] Compounds provided herein, including salts thereof, can be prepared using known organic synthesis techniques and according to various possible synthetic routes.

[0183] The reactions for preparing compounds provided herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.

[0184] Preparation of compounds provided herein can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999).

[0185] Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1< H or 13< C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.

[0186] The expressions, "ambient temperature", "room temperature", and "r.t.", as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.

[0187] Compounds as disclosed herein can be prepared by one skilled in the art according to preparatory routes known in the literature and according to various possible synthetic routes. Example synthetic methods for preparing compounds of the present application are provided in Scheme 1 below.

[0188] The reactions for preparing compounds provided herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially nonreactive with the starting materials (reactants), the intermediates, or products at the temperatures at which the reactions are carried out, e.g., temperatures which can range from the solvent's freezing temperature to the solvent's boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the particular reaction step, suitable solvents for a particular reaction step can be selected by the skilled artisan.

[0189] Preparation of compounds provided herein can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups, can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., Wiley & Sons, Inc., New York (1999).

[0190] Reactions can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1< H or 13< C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry, or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography.

[0191] The expressions, "ambient temperature", "room temperature", and "r.t.", as used herein, are understood in the art, and refer generally to a temperature, e.g. a reaction temperature, that is about the temperature of the room in which the reaction is carried out, for example, a temperature from about 20 °C to about 30 °C.

[0192] Compounds as disclosed herein can be prepared by one skilled in the art according to preparatory routes known in the literature. A compound of Formula I can be prepared according to Scheme 1. Compounds (i) can be prepared by standard Suzuki coupling of bromides (i-a) with boronic esters or acids (i-b), wherein R 1< contains the alkenylene functionality. Catalytic hydrogenation of the R 1< functional group using Pd on carbon or another suitable catalyst can then provide compounds (ii) wherein R 1< contains the alkylene functionality. Selective bromination of compound (ii) using, e.g., NBS, yields bromides (iii) which are then directly treated with boronic esters or acids (iv) under, e.g., standard Suzuki coupling conditions, to afford compounds of Formula I. Alternatively, compounds of Formula I can be prepared through Suzuki coupling of bromides (iii) with boronic esters or acids (v) followed by reaction of the resultant amines (vi) with carboxylic acids (vii), and a suitable coupling reagent such as HATU or BOP.

[0193] The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of TAM kinases as described below.

[0194] Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g. "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity check under the following conditions: Instrument; Agilent 1100 series, LC / MSD, Column: Waters Sunfire ™< C 18 5 µm particle size, 2.1 x 5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient 2% to 80% of B in 3 minutes with flow rate 2.0 mL / minute.

[0195] Some of the compounds prepared were also separated on a preparative scale by reverse-phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse-phase high performance liquid chromatography (RP-HPLC) column conditions are as follows: pH = 2 purifications: Waters Sunfire ™< C 18 5 µm particle size, 19 x 100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 30 mL / minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 mL / minute.

[0196] pH = 10 purifications: Waters XBridge C 18 5 µm particle size, 19 x 100 mm column, eluting with mobile phase A: 0.15% NH 4 OH in water and mobile phase B: acetonitrile; the flow rate was 30 mL / minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with 30 x 100 mm column was 60 mL / minute.TAM kinases

[0197] Receptor tyrosine kinases (RTKs) are cell surface proteins that transmit signals from the extracellular environment to the cell cytoplasm and nucleus to regulate cellular events such as survival, growth, proliferation, differentiation, adhesion and migration. All RTKs contain an extracellular ligand binding domain and a cytoplasmic protein tyrosine kinase domain. Ligand binding leads to the dimerization of RTKs, which triggers the activation of the cytoplasmic kinase and initiates downstream signal transduction pathways. RTKs can be classified into distinct subfamilies based on their sequence similarity. The TAM subfamily consists of three RTKs including TYRO3, AXL and MER (Graham et al., 2014, Nature reviews Cancer 14, 769-785; and Linger et al., 2008, Oncogene 32, 3420-3431). TAM kinases are characterized by an extracellular ligand binding domain consisting of two immunoglobulin-like domains and two fibronectin type III domains. Two ligands, growth arrest specific 6 (GAS6) and protein S (ProS), have been identified for TAM kinases. GAS6 can bind to and activate all three TAM kinases, while ProS is a ligand for MER and TYRO3 (Graham et al., 2014, Nature reviews Cancer 14, 769-785).

[0198] TAM kinases are over-expressed in many cancers and play important roles in tumor initiation and maintenance; therefore, TAM inhibition represents an attractive approach for targeting another class of oncogenic RTKs (Graham et al., 2014, Nature reviews Cancer 14, 769-785; and Linger et al., 2008, Oncogene 32, 3420-3431).

[0199] Axl was originally identified as a transforming gene from DNA of patients with chronic myelogenous leukemia (O'Bryan et al., 1991, Molecular and cellular biology 11, 5016-5031). GAS6 binds to Axl and induces subsequent auto-phosphorylation and activation of Axl tyrosine kinase. Axl activates several downstream signaling pathways including PI3K-Akt, Raf-MAPK, PLC-PKC (Feneyrolles et al., 2014, Molecular cancer therapeutics 13, 2141-2148; Linger et al., 2008, Oncogene 32, 3420-3431). AXL is over-expressed or amplified in a variety of malignancies including lung cancer, prostate cancer, colon cancer, breast cancer, melanoma, and renal cell carcinoma (Linger et al., 2008, Oncogene 32, 3420-3431). Over-expression of AXL is correlated with poor prognosis (Linger et al., 2008, Oncogene 32, 3420-3431). As a result, AXL activation promotes cancer cell survival, proliferation, angiogenesis, metastasis, and resistance to chemotherapy and targeted therapies. AXL knockdown or AXL antibody can inhibit the migration of breast cancer and NSCLC cancer in vitro, and blocked tumor growth in xenograft tumor models (Li et al., 2009, Oncogene 28, 3442-3455). In pancreatic cancer cells, inhibition of AXL decreased cell proliferation and survival (Koorstra et al., 2009, Cancer biology & therapy 8, 618-626). In prostate cancer, AXL inhibition decreased cell migration, invasion, and proliferation (Tai et al., 2008, Oncogene 27, 4044-4055). In addition, AXL over-expression or amplification is a major mechanism for resistance to EGFR inhibitors by lung cancer cells, and AXL inhibition can reverse the resistance (Zhang et al., 2012, Nature genetics 44, 852-860).

[0200] Mer was originally identified as a phospho-protein from a lymphoblastoid expression library (Graham et al., 1995, Oncogene 10, 2349-2359). Both GAS6 and ProS can bind to Mer and induce the phosphorylation and activation of Mer kinase (Lew et al., 2014. eLife, 3:e03385). Like Axl, Mer activation also conveys downstream signaling pathways including PI3K-Akt and Raf-MAPK (Linger et al., 2008, Oncogene 32, 3420-3431). MER is over-expressed in many cancers including multiple myeloma, gastric, prostate, breast, melanoma and rhabdomyosarcoma (Linger et al., 2008, Oncogene 32, 3420-3431). MER knockdown inhibits multiple myeloma cell growth in vitro and in xenograft models (Waizenegger et al., 2014, Leukemia, 1-9). In acute myeloid leukemia, MER knockdown induced apoptosis, decreased colony formation, and increased survival in a mouse model (Lee-Sherick et al., 2013, Oncogene 32, 5359-5368). MER inhibition increased apoptosis, decreased colony formation, increased chemo-sensitivity, and decreased tumor growth in NSCLC (Linger et al., 2013, Oncogene 32, 3420-3431). Similar effects are observed for MER knockdown in melanoma (Schlegel et al., 2013) and glioblastoma (Wang et al., 2013, Oncogene 32, 872-882).

[0201] Tyro3 was originally identified through a PCR-based cloning study (Lai and Lemke, 1991, Neuron 6, 691-704). Both ligands, GAS6 and ProS, can bind to and activate Tyro3. TYRO3 also plays a role in cancer growth and proliferation. TYRO3 is over-expressed in melanoma cells, and knockdown of TYRO3 induces apoptosis in these cells (Demarest et al., 2013, Biochemistry 52, 3102-3118).

[0202] In addition to their role as transforming oncogenes, TAM kinases have emerged as potential immune-oncology targets. The durable clinical responses to immune checkpoint blockade observed in cancer patients clearly indicate that the immune system plays a critical role in tumor initiation and maintenance. Genetic mutations from cancer cells can provide a diverse set of antigens that the immune cells can use to distinguish tumor cells from their normal counterpart. However, cancer cells have evolved multiple mechanisms to evade host immune surveillance. In fact, one hallmark of human cancer is its ability to avoid immune destruction. Cancer cells can induce an immune-suppressive microenvironment by promoting the formation of M2 tumor associated macrophages, myeloid derived suppressor cells (MDSC), and regulatory T cells. Cancer cells can also produce high levels of immune checkpoint proteins such as PD-L1 to induce T cell anergy or exhaustion. It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance (Pardoll, 2012, Cancer 12, 252-264). Antagonizing these negative regulators of T-cell function with antibodies has shown striking efficacy in clinical trials of a number of malignancies including advanced melanoma, non-small cell lung and bladder cancer. While these therapies have shown encouraging results, not all patients mount an anti-tumor response suggesting that other immune-suppressive pathways may also be important.

[0203] TAM kinases have been shown to function as checkpoints for immune activation in the tumor milieu. All TAM kinases are expressed in NK cells, and TAM kinases inhibit the anti-tumor activity of NK cells. LDC1267, a small molecule TAM inhibitor, activates NK cells, and blocks metastasis in tumor models with different histologies (Paolino et al., 2014, Nature 507, 508-512). In addition, MER kinase promotes the activity of tumor associated macrophages through the increased secretion of immune suppressive cytokines such as IL10 and IL4, and decreased production of immune activating cytokines such as IL12(Cook et al., 2013, The Journal of clinical investigation 123, 3231-3242). MER inhibition has been shown to reverse this effect. As a result, MER knockout mice are resistant to PyVmT tumor formation (Cook et al., 2013, The Journal of clinical investigation 123, 3231-3242). The role of TAM kinases in the immune response is also supported by knockout mouse studies. TAM triple knockout mice (TKO) are viable. However, these mice displayed signs of autoimmune disease including enlarged spleen and lymph nodes, autoantibody production, swollen footpad and joints, skin lesions, and systemic lupus erythematosus (Lu and Lemke, 2001, Science 293, 306-311). This is consistent with the knockout phenotype for approved immune-oncology targets such as CTLA4 and PD-1. Both CTLA-4 and PD-1 knockout mice showed signs of autoimmune disease, and these mice die within a few weeks after birth (Chambers et al., 1997, Immunity 7, 885-895; and Nishimura et al., 2001, Science 291, 319-322).

[0204] TAM inhibition will have not only direct activity against neoplastic cells, but also activate the anti-cancer immune response. Thus TAM inhibitors represent an attractive approach for the treatment of cancer as single agents. In addition, TAM inhibitors may be combined with other targeted therapies, chemotherapies, radiation, or immunotherapeutic agents to achieve maximal efficacy in the clinic.Methods of Use

[0205] Compounds of the present disclosure can modulate or inhibit the activity of TAM kinases. For example, the compounds of the disclosure can be used to inhibit activity of a TAM kinase in a cell or in an individual or patient in need of inhibition of the kinases by administering an inhibiting amount of a compound of the disclosure to the cell, individual, or patient.

[0206] In some embodiments, the compounds of the disclosure are selective for the TAM kinases over one or more of other kinases. In some embodiments, the compounds of the disclosure are selective for the TAM kinases over other kinases. In some embodiments, the selectivity is 2-fold or more, 3-fold or more, 5-fold or more, 10-fold or more, 25-fold or more, 50-fold or more, or 100-fold or more.

[0207] The compounds of the invention can inhibit one or more of AXL, MER and TYRO3. In some embodiments the compounds are selective for one TAM kinase over another. "Selective" means that the compound binds to or inhibits a TAM kinase with greater affinity or potency, respectively, compared to a reference enzyme, such as another TAM kinase. For example, the compounds can be selective for AXL over MER and TYRO3, selective for MER over AXL and TYRO3, or selective for AXL and MER over TYRO3. In some embodiments, the compounds inhibit all of the TAM family members (e.g., AXL, MER and TYRO3). In some embodiments, the compounds can be selective for AXL and MER over TYRO3 and other kinases. In some embodiments, provided herein is a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in inhibiting AXL and MER kinase.

[0208] As TAM kinases inhibitors, the compounds of the disclosure are useful in the treatment of various diseases associated with abnormal expression or activity of the TAM kinases. Compounds which inhibit TAM kinases will be useful in providing a means of preventing the growth or inducing apoptosis in tumors, particularly by inhibiting angiogenesis. It is therefore anticipated that the compounds will prove useful in treating or preventing proliferative disorders such as cancers. In particular, tumours with activating mutants of receptor tyrosine kinases or upregulation of receptor tyrosine kinases may be particularly sensitive to the inhibitors.

[0209] In certain embodiments, the disclosure provides a compound of the invention, or a pharmaceutically acceptable composition thereof, for use in treating a disease or disorder mediated by TAM kinases in a patient in need thereof.

[0210] For example, the compounds of the disclosure are useful in the treatment of cancer. Example cancers include bladder cancer, breast cancer, cervical cancer, colorectal cancer, cancer of the small intestine, colon cancer, rectal cancer, cancer of the anus, endometrial cancer, gastric cancer, head and neck cancer (e.g., cancers of the larynx, hypopharynx, nasopharynx, oropharynx, lips, and mouth), kidney cancer, liver cancer (e.g., hepatocellular carcinoma, cholangiocellular carcinoma), lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, parvicellular and non-parvicellular carcinoma, bronchial carcinoma, bronchial adenoma, pleuropulmonary blastoma), ovarian cancer, prostate cancer, testicular cancer, uterine cancer, esophageal cancer, gall bladder cancer, pancreatic cancer (e.g. exocrine pancreatic carcinoma), stomach cancer, thyroid cancer, parathyroid cancer, skin cancer (e.g., squamous cell carcinoma, Kaposi sarcoma, Merkel cell skin cancer), and brain cancer (e.g., astrocytoma, medulloblastoma, ependymoma, neuro-ectodermal tumors, pineal tumors).

[0211] Other cancers treatable with the compounds of the disclosure include bone cancer, intraocular cancers, gynecological cancers, cancer of the endocrine system, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, pituitary cancer, triple-negative breast cancer (TNBC) and environmentally induced cancers including those induced by asbestos.

[0212] Further example cancers include hematopoietic malignancies such as leukemia or lymphoma, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, cutaneous T-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia, and primary myelofibrosis), Waldenstrom's Macroglubulinemia, hairy cell lymphoma, chronic myelogenic lymphoma, acute lymphoblastic lymphoma, AIDS-related lymphomas, and Burkitt's lymphoma.

[0213] Other cancers treatable with the compounds of the disclosure include tumors of the eye, glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, and osteosarcoma.

[0214] Compounds of the disclosure can also be useful in the inhibition of tumor metastisis.

[0215] In some embodiments, diseases and indications that are treatable using the compounds of the present disclosure include, but are not limited to hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers.

[0216] Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), Non-Hodgkin lymphoma (including relapsed or refractory NHL), follicular lymphoma (FL), Hodgkin lymphoma, lymphoblastic lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET)), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, chronic myelogenic lymphoma and Burkitt's lymphoma.

[0217] Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, and teratoma.

[0218] Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, and mesothelioma.

[0219] Exemplary gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colorectal cancer and bile duct cancer.

[0220] Exemplary genitourinary tract cancers include cancers of the kidney (adenocarcinoma, Wilm's tumor [nephroblastoma], renal cell carcinoma), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, urothelial carcinoma), prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma).

[0221] Exemplary liver cancers include hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.

[0222] Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors

[0223] Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), as well as neuroblastoma, Lhermitte-Duclos disease, neoplasm of the central nervous system (CNS), primary CNS lymphoma and spinal axis tumor.

[0224] Exemplary gynecological cancers include cancers of the uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma).

[0225] Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell skin cancer, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids.

[0226] Exemplary head and neck cancers include glioblastoma, melanoma, rhabdosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinomas, adenocarcinomas, oral cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancers, thyroid and parathyroid cancers.

[0227] In some embodiments, the present disclosure provides a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of the invention, for use in treating hepatocellular carcinoma in a patient in need thereof.

[0228] In some embodiments, the present disclosure provides a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of the invention, for use in treating Rhabdomyosarcoma, esophageal cancer, breast cancer, or cancer of a head or neck, in a patient in need thereof.

[0229] In some embodiments, the present disclosure provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in treating cancer, wherein the cancer is selected from hepatocellular cancer, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer, and rhabdosarcoma.

[0230] Targeting TAM receptor tyrosine kinases can provide a therapeutic approach to treat viral diseases (T Shibata, et.al. The Journal of Immunology, 2014, 192, 3569-3581). The present disclosure provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in treating infections such as viral infections. Examples of viruses causing infections treatable by compounds of the invention include, but are not limit to, human immunodeficiency virus, human papillomavirus, influenza, hepatitis A, B, C or D viruses, adenovirus, poxvirus, herpes simplex viruses, human cytomegalovirus, severe acute respiratory syndrome virus, ebola virus, Marburg virus and measles virus. In some embodiments, viruses causing infections treatable by compounds of the invention include, but are not limit to, hepatitis (A, B, or C), herpes virus (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, flaviviruses (for example: West Nile, dengue, tick-borne encephalitis, yellow fever, Zika), echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumpsvirus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus.

[0231] In some embodiments, the present disclosure provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in treating thrombus formation (J.M.E.M. Cosemans et.al. J. of Thrombosis and Haemostasis 2010, 8, 1797-1808 and A. Angelillo-Scherrer et.al. J. Clin. Invest. 2008, 118, 583-596).Combination Therapy

[0232] One or more additional pharmaceutical agents or treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (e.g., IL2, GM-CSF, etc.), and / or tyrosine kinase inhibitors can be used in combination with the compounds of Formula (IIb1) or Formula (IIb2) or a compound as described herein for treatment of TAM-associated diseases, disorders or conditions. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.

[0233] Suitable antiviral agents contemplated for use in combination with the compounds of the present disclosure can comprise nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.

[0234] Example suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; beta-L-FD4 (also called beta-L-D4C and named beta-L-2', 3'-dicleoxy-5-fluoro-cytidene); DAPD, ((-)-beta-D-2,6,-diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinedione); and (+)-calanolide A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK-639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1 549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.11607.

[0235] Suitable agents for use in combination with the compounds of the present application for the treatment of cancer include chemotherapeutic agents, targeted cancer therapies, immunotherapies or radiation therapy. Compounds of this application may be effective in combination with anti-hormonal agents for treatment of breast cancer and other tumors. Suitable examples are anti-estrogen agents including but not limited to tamoxifen and toremifene, aromatase inhibitors including but not limited to letrozole, anastrozole, and exemestane, adrenocorticosteroids (e.g. prednisone), progestins (e.g. megastrol acetate), and estrogen receptor antagonists (e.g. fulvestrant). Suitable anti-hormone agents used for treatment of prostate and other cancers may also be combined with compounds of the present disclosure. These include anti-androgens including but not limited to flutamide, bicalutamide, and nilutamide, luteinizing hormone-releasing hormone (LHRH) analogs including leuprolide, oserelin, triptorelin, and histrelin, LHRH antagonists (e.g. degarelix), androgen receptor blockers (e.g. enzalutamide) and agents that inhibit androgen production (e.g. abiraterone).

[0236] Compounds of the present disclosure may be combined with or in sequence with other agents against membrane receptor kinases especially for patients who have developed primary or acquired resistance to the targeted therapy. These therapeutic agents include inhibitors or antibodies against EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, PDGFR, FGFR1, FGFR2, FGFR3, FGFR4, TrkA, TrkB, TrkC, ROS, c-Kit, or Flt-3 and against cancer-associated fusion protein kinases such as Bcr-Abl and EML4-Alk. Inhibitors against EGFR include gefitinib and erlotinib, and inhibitors against EGFR / Her2 include but are not limited to dacomitinib, afatinib, lapitinib and neratinib. Antibodies against the EGFR include but are not limited to cetuximab, panitumumab and necitumumab. Inhibitors of c-Met may be used in combination with TAM inhibitors. These include onartumzumab, tivantnib, and INC-280. Agents against FGFRs include but not limited to AZD4547, BAY1187982, ARQ087, BGJ398, BIBF1120, TKI258, lucitanib, dovitinib, TAS-120, JNJ-42756493, and Debio1347. Agents against Trks include but not limited to LOXO-101 and RXDX-101. Agents against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and ponatinib and those against Alk (or EML4-ALK) include crizotinib.

[0237] Angiogenesis inhibitors may be efficacious in some tumors in combination with TAM inhibitors. These include antibodies against VEGF or VEGFR or kinase inhibitors of VEGFR. Antibodies or other therapeutic proteins against VEGF include bevacizumab and aflibercept. Inhibitors of VEGFR kinases and other anti-angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib, and vandetanib

[0238] Activation of intracellular signaling pathways is frequent in cancer, and agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance. Examples of agents that may be combined with compounds of the present disclosure include inhibitors of the PI3K-AKT-mTOR pathway, inhibitors of the Raf-MAPK pathway, inhibitors of JAK-STAT pathway, inhibitors of Pim kinases, and inhibitors of protein chaperones and cell cycle progression.

[0239] Agents against the PI3 kinase include but are not limited to pilaralisib, idelalisib, buparlisib, and IPI-549. In some embodiments, the PI3K inhibitor is selective for PI3K alpha, PI3K beta, PI3K gamma or PI3K delta. Inhibitors of mTOR such as rapamycin, sirolimus, temsirolimus, and everolimus may be combined with TAM kinases inhibitors. Other suitable examples include but are not limited to vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib and GDC-0973 (MEK. inhibitors). Inhibitors of one or more JAKs (e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 (e.g., tanespimycin), cyclin dependent kinases (e.g., palbociclib), PARP (e.g., olaparib), and proteasomes (e.g., bortezomib, carfilzomib) can also be combined with compounds of the present disclosure. In some embodiments, the JAK inhibitor is selective for JAK1 over JAK2 and JAK3. Agents against Pim kinases include but not limited to LGH447, INCB053914, and SGI-1776.

[0240] Other suitable agents for use in combination with the compounds of the present disclosure include chemotherapy combinations such as platinum-based doublets used in lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed) or gemcitabine plus paclitaxel bound particles (Abraxane ®< ).

[0241] Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazenes) such as uracil mustard, chlormethine, cyclophosphamide (Cytoxan ™< ), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.

[0242] Other suitable agents for use in combination with the compounds of the present disclosure include: dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen," which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine, and DTIC; or temozolomide. Compounds provided herein may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) inhibitors.

[0243] Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.

[0244] Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (TAXOL ™< ), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (especially IFN-a), etoposide, and teniposide.

[0245] Other cytotoxic agents include navelbene, CPT-11, anastrazole, letrazole, capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine.

[0246] Also suitable are cytotoxic agents such as epidophyllotoxin; an antineoplastic enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination complexes such as cis-platin and carboplatin; biological response modifiers; growth inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic growth factors.

[0247] Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab (Herceptin), antibodies to costimulatory molecules such as CTLA-4, 4-1BB and PD-1, or antibodies to cytokines (IL-10, TGF-β, etc.).

[0248] Other anti-cancer agents include CSF1R inhibitors (PLX3397, LY3022855, etc.) and CSF1R antibodies (IMC-CS4, RG7155, etc.).

[0249] Other anti-cancer agents include BET inhibitors (INCB054329, OTX015, CPI-0610, etc.), LSD1 inhibitors (GSK2979552, INCB059872, etc), HDAC inhibitors (panobinostat, vorinostat, etc), DNA methyl transferase inhibitors (azacitidine and decitabine), and other epigenetic modulators.

[0250] Other anti-cancer agents include Bcl2 inhibitor ABT-199, and other Bcl-2 family protein inhibitors.

[0251] Other anti-acner agents include TGF beta receptor kinase inhibitor such as LY2157299.

[0252] Other anti-cancer agents include BTK inhibitor such as ibnitinib.

[0253] Other anti-cancer agents include beta catenin pathway inhibitors, notch pathway inhibitors and hedgehog pathway inhibitors.

[0254] Other anti-cancer agents include inhibitors of kinases associated cell proliferative disorder. These kinases include but not limited to Aurora-A, CDK1, CDK2, CDK3, CDK5, CDK7, CDK8, CDK9, ephrin receptor kinases, CHK1, CHK2, SRC, Yes, Fyn, Lck, Fer, Fes, Syk, Itk, Bmx, GSK3, JNK, PAK1, PAK2, PAK3, PAK4, PDK1, PKA, PKC, Rsk and SGK.

[0255] Other anti-cancer agents also include those that block immune cell migration such as antagonists to chemokine receptors, including CCR2 and CCR4.

[0256] Other anti-cancer agents also include those that augment the immune system such as adjuvants or adoptive T cell transfer.

[0257] Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines and recombinant viruses.

[0258] One or more additional immune checkpoint inhibitors can be used in combination with a compound as described herein for treatment of TAM-associated diseases, disorders or conditions. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, CD96, TIGIT, and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors.

[0259] In some embodiments, the inhibitor of an immune checkpoint molecule is anti-PD1 antibody, anti-PD-L1 antibody, or anti-CTLA-4 antibody.

[0260] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab, or PDR001. In some embodiments, the anti-PD1 antibody is pembrolizumab.

[0261] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab).

[0262] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or tremelimumab.

[0263] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525.

[0264] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, MK-4166, INCAGN01876 or MK-1248.

[0265] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of OX40, e.g., an anti-OX40 antibody or OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, INCAGN01949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600 or LAG525. In some embodiments, the OX40L fusion protein is MEDI6383.

[0266] In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CD20, e.g., an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.

[0267] The compounds of the present disclosure can be used in combination with bispecific antibodies. In some embodiments, one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3 or TGFβ receptor.

[0268] Compounds of the present disclosure can be used in combination with one or more agents for the treatment of diseases such as cancer. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatory agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM).

[0269] The compounds of the present disclosure can be combined with another immunogenic agent, such as cancerous cells, purified tumor antigens (including recombinant proteins, peptides, and carbohydrate molecules), cells, and cells transfected with genes encoding immune stimulating cytokines. Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as peptides of gp100, MAGE antigens, Trp-2, MARTI and / or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.

[0270] The compounds of the present disclosure can be used in combination with a vaccination protocol for the treatment of cancer. In some embodiments, the tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include the proteins from viruses implicated in human cancers such as Human Papilloma Viruses (HPV), Hepatitis Viruses (HBV and HCV) and Kaposi's Herpes Sarcoma Virus (KHSV). In some embodiments, the compounds of the present disclosure can be used in combination with tumor specific antigen such as heat shock proteins isolated from tumor tissue itself. In some embodiments, the compounds of the present disclosure can be combined with dendritic cells immunization to activate potent anti-tumor responses.

[0271] The compounds of the present disclosure can be used in combination with bispecific macrocyclic peptides that target Fc alpha or Fc gamma receptor-expressing effectors cells to tumor cells. The compounds of the present disclosure can also be combined with macrocyclic peptides that activate host immune responsiveness.

[0272] The compounds of the present disclosure can be used in combination with arginase inhibitors, for example CB-1158.

[0273] The compounds of the present disclosure can be used in combination with bone marrow transplant for the treatment of a variety of tumors of hematopoietic origin.

[0274] The compounds of the present disclosure can be used as anticoagulant as single agent or in combination with other anticoagulants including but not limited to apixaban, dabigatran, edoxaban, fondaparinex, heparin, rivaroxaban, and warfarin.

[0275] Methods for the safe and effective administration of most of these chemotherapeutic agents are known to those skilled in the art. In addition, their administration is described in the standard literature. For example, the administration of many of the chemotherapeutic agents is described in the "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ).Pharmaceutical Formulations and Dosage Forms

[0276] When employed as pharmaceuticals, the compounds provided herein can be administered in the form of pharmaceutical compositions which refers to a combination of a compound provided herein, or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

[0277] This application also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds provided herein in combination with one or more pharmaceutically acceptable carriers. In making the compositions of the present disclosure, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10 % by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

[0278] In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.

[0279] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the present disclosure can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

[0280] The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

[0281] The active compound can be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[0282] For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present disclosure. When referring to these pre-formulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.1 to about 500 mg of the active ingredient of the present disclosure.

[0283] The tablets or pills of the present disclosure can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

[0284] The liquid forms in which the compounds and compositions of the present disclosure can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

[0285] The compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner.

[0286] The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient, and the like.

[0287] The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

[0288] The therapeutic dosage of the compounds of the present disclosure can vary according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound provided herein in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds provided herein can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w / v of the compound for parenteral administration. Some typical dose ranges are from about 1 µg / kg to about 1 g / kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg / kg to about 100 mg / kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.

[0289] The compounds provided herein can also be formulated in combination with one or more additional active ingredients which can include any pharmaceutical agent such as anti-viral agents, vaccines, antibodies, immune enhancers, immune suppressants, anti-inflammatory agents and the like.Labeled Compounds and Assay Methods

[0290] Another aspect of the present disclosure relates to fluorescent dye, spin label, heavy metal or radio-labeled compounds provided herein that would be useful not only in imaging but also in assays, both in vitro and in vivo, for localizing and quantitating the TAM kinases in tissue samples, including human, and for identifying TAM kinases ligands by inhibition binding of a labeled compound. Accordingly, the present disclosure includes TAM kinases assays that contain such labeled compounds.

[0291] The present disclosure further includes isotopically-labeled compounds of the invention. An "isotopically" or "radio-labeled" compound is a compound provided herein where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring). Suitable radionuclides that may be incorporated in compounds of the present disclosure include but are not limited to 2< H (also written as D for deuterium), 3< H (also written as T for tritium), 11< C, 13< C, 14< C, 13< N, 15< N, 15< O, 17< O, 18< O, 18< F, 35< S, 36< Cl, 82< Br, 75< Br, 76< Br, 77< Br, 123< I, 124< I, 125< I and 131< I. The radionuclide that is incorporated in the instant radio-labeled compounds will depend on the specific application of that radio-labeled compound. For example, for in vitro TAM kinases labeling and competition assays, compounds that incorporate 3< H, 14< C, 82< Br, 125< I, 131< I, or 35< S will generally be most useful. For radio-imaging applications 11< C, 18< F, 125< I, 123< I, 124< I, 131< I, 75< Br, 76< Br or 77< Br will generally be most useful.

[0292] It is understood that a "radio-labeled" or "labeled compound" is a compound that has incorporated at least one radionuclide. In some embodiments the radionuclide is selected from the group consisting of 3< H, 14< C, 125< I, 35< S and 82< Br.

[0293] Synthetic methods for incorporating radio-isotopes into organic compounds are applicable to compounds provided herein and are well known in the art.

[0294] A radio-labeled compound provided herein can be used in a screening assay to identify / evaluate compounds. In general terms, a newly synthesized or identified compound (i.e., test compound) can be evaluated for its ability to reduce binding of the radio-labeled compound of the application to the TAM kinases. Accordingly, the ability of a test compound to compete with the radio-labeled compound for binding to the TAM kinases directly correlates to its binding affinity.

[0295] Compounds of the invention can also include all isotopes of atoms occurring in the intermediates or final compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium One or more constituent atoms of the compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound includes at least one deuterium atom For example, one or more hydrogen atoms in a compound of the present disclosure can be replaced or substituted by deuterium In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1, 2, 3, 4, 5, 6, 7 or 8 deuterium atoms. Synthetic methods for including isotopes into organic compounds are known in the art.Kits

[0296] The present disclosure also includes pharmaceutical kits useful, for example, in the treatment or prevention of TAM-associated diseases or disorders, obesity, diabetes and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound provided herein. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and / or guidelines for mixing the components, can also be included in the kit.

[0297] The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of non-critical parameters which can be changed or modified to yield essentially the same results. The compounds of the Examples were found to be inhibitors of TAM kinases as described below.

[0298] Preparatory LC-MS purifications of some of the compounds prepared were performed on Waters mass directed fractionation systems. The basic equipment setup, protocols, and control software for the operation of these systems have been described in detail in the literature. See e.g. "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002) ; "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and "Preparative LC-MS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). The compounds separated were typically subjected to analytical liquid chromatography mass spectrometry (LCMS) for purity check under the following conditions: Instrument; Agilent 1100 series, LC / MSD, Column: Waters Sunfire ™< C 18 5 µm particle size, 2.1 x 5.0 mm, Buffers: mobile phase A: 0.025% TFA in water and mobile phase B: acetonitrile; gradient 2% to 80% of B in 3 minutes with flow rate 2.0 mL / minute.

[0299] Some of the compounds prepared were also separated on a preparative scale by reverse-phase high performance liquid chromatography (RP-HPLC) with MS detector or flash chromatography (silica gel) as indicated in the Examples. Typical preparative reverse-phase high performance liquid chromatography (RP-HPLC) column conditions are as follows: pH = 2 purifications: Waters Sunfire ™< C 18 5 µm particle size, 19 x 100 mm column, eluting with mobile phase A: 0.1% TFA (trifluoroacetic acid) in water and mobile phase B: acetonitrile; the flow rate was 30 mL / minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with the 30 x 100 mm column was 60 mL / minute.

[0300] pH = 10 purifications: Waters XBridge C 18 5 µm particle size, 19 x 100 mm column, eluting with mobile phase A: 0.15% NH 4 OH in water and mobile phase B: acetonitrile; the flow rate was 30 mL / minute, the separating gradient was optimized for each compound using the Compound Specific Method Optimization protocol as described in the literature [See "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate used with 30 x 100 mm column was 60 mL / minute.EXAMPLES Example 1. N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide

[0301] Step 1: N-[(2,6-Dioxocyclohexylidene)methyl]urea

[0302]

[0303] To a mixture of 1,3-cyclohexanedione (from Aldrich, 500 mg, 4.46 mmol) and urea (268 mg, 4.46 mmol) dissolved in N,N-dimethylformamide (1.73 mL at 50 °C), was added ethyl orthoformate (1.11 mL, 6.69 mmol) and acetic acid (8.9 mL). The reaction mixture was heated in a sealed tube at 90 °C for 3 h. The reaction mixture was cooled, concentrated under vacuum, and left at rt for crystallization. The resulting precipitate was filtered by vacuum and the cake was washed with cold sec-BuOH to give the desired product as off-white powders (536 mg, 66%). LCMS calcd for C 8 H 11 N 2 O 3 (M+H) +< : m / z = 183.1. Found: 183.1.Step 2: Methyl 2,5-dioxo-5, 6, 7,8-tetrahydro-2H-chromene-3-carboxylate

[0304]

[0305] N-[(2,6-Dioxocyclohexylidene)methyl]urea (50 mg, 0.27 mmol) was dissolved in dry N,N-dimethylformamide (0.54 mL), followed by the addition of acetic acid, cyanomethyl ester (35.4 mg, 0.36 mmol) and potassium tert-butoxide (61.6 mg, 0.55 mmol) with stirring. The reaction mixture was heated at 100 °C for 1 h. After filtration and removal of the solvent, an oily residue was obtained as the desired product (70 mg). The crude product was used directly in the next step without further purification. LCMS calcd for C 11 H 11 O 5 (M+H) +< : m / z = 223.1. Found: 223.1.Step 3: Methyl 1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate

[0306]

[0307] To a solution of methyl 2,5-dioxo-5,6,7,8-tetrahydro-2H-chromene-3-carboxylate (30 mg, 0.14 mmol) in tetrahydrofuran (0.4 mL) and N,N-dimethylformamide (0.1 mL) at rt was added p-fluoroaniline (15 mg, 0.14 mmol). The reaction mixture was stirred at rt for 3 h, followed by the addition of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (34 mg, 0.18 mmol) and 4-dimethylaminopyridine (4.1 mg, 0.034 mmol) at rt. The reaction mixture was stirred at rt for additional 20 h. After filtration, the crude was purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product (12 mg, 28%). LCMS calcd for C 17 H 15 FNO 4 (M+H) +< : m / z = 316.1. Found: 316.1.Step 4: 1-(4-Fluorophenyl)-2,5-dioxo-1, 2, 5,6, 7, 8-hexahydroquinoline-3-carboxylic acid

[0308]

[0309] To a solution of methyl 1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylate (5.0 mg, 0.016 mmol) in methanol (0.10 mL) was added 1.0 M sodium hydroxide in water (0.15 mL). The reaction mixture was stirred at rt for 30 min, and the crude was neutralized with HCl (1N), diluted with EtOAc. The EtOAc layer was separated, and the aqueous layer was washed with EtOAc twice. The combined organic layers were dried, concentrated under vacuum to give the desired acid product as off-white powders. LCMS calcd for C 16 H 13 FNO 4 (M+H) +< : m / z = 302.1. Found: 302.2.Step 5: 7-Vinylpyrrolo[2,1-f][1,2,4]triazin-4-amine

[0310]

[0311] In a sealed flask a mixture of 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (from Aldrich, 1.52 g, 9.86 mmol), 7-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (from J & W Pharm Lab, 1.50 g, 7.04 mmol) and N,N-diisopropylethylamine (3.7 mL, 21 mmol) in 1,4-dioxane (20 mL) and water (0.97 mL) was stirred and flushed with N 2 for 5 min before bis(tri-Z-butylphosphine)palladium (540 mg, 1.0 mmol) was added. The reaction mixture was sealed and heated at 110 °C in an oil bath for 60 min, filtered through a pad of celite and concentrated. The crude was purified by Biotage silica gel column chromatography (40 g column, 0 to 100% EtOAc in hexanes) to give the desired product as white powders (541 mg, 48%). LCMS calcd for C 8 H 9 N 4 (M+H) +< : m / z = 161.1. Found: 161.1.Step 6: 7-Ethylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0312]

[0313] To a solution of 7-vinylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (1.00 g, 6.24 mmol) in methanol (30 mL) was added a mixture of palladium (1.33 g) (5% Pd on carbon). The reaction mixture was placed on hydrogen Parr shaker at 25 psi for 2 h. After filtration through a celite pad, the filtrate was concentrated under vacuum to give the desired product as off-white powders. LCMS calcd for C 8 H 11 N 4 (M+H) +< : m / z = 163.1. Found: 163.1.Step 7: 5-Bromo-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0314]

[0315] To a solution of 7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (600 mg, 3.7 mmol) in N,N-dimethylformamide (16 mL) was added N-bromosuccinimide (395 mg, 2.22 mmol). The resulting mixture was stirred at rt for 30 min, diluted with EtOAc and filtered. The filtrate was washed with saturated NaHCO 3 , water, dried over Na 2 SO 4 , filtered and concentrated under vacuum to give the desired product as tan solid. LCMS calcd for C 8 H 10 BrN 4 (M+H) +< : m / z = 241.0, 243.0. Found: 241.0,243.0.Step 8: 5-(4-Aminophenyl)-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0316]

[0317] In a sealed tube a mixture of 5-bromo-7-ethylpyrrolo[2,1-J] [1,2,4]triazin-4-amine (200 mg, 0.83 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (from Aldrich, 236 mg, 1.08 mmol) and N,N-diisopropylethylamine (0.43 mL, 2.5 mmol) in 1,4-dioxane (3.24 mL) and water (0.30 mL) was stirred and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (130 mg, 0.25 mmol) was added. The reaction mixture was sealed and heated at 110°C in an oil bath for 1 h. After filtration, the crude was diluted with MeOH and purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product as light brown powders (88 mg, 42%). LCMS calcd for C 14 H 16 N 5 (M+H) +< : m / z = 254.1. Found: 254.1.Step 9: N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2,5-dioxo-1,2, 5, 6, 7, 8-hexahydroquinoline-3-carboxamide

[0318] 5-(4-Aminophenyl)-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (3.2 mg, 0.013 mmol), 1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxylic acid (4.6 mg, 0.015 mmol) (prepared in Example 1, step 4), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (12 mg, 0.032 mmol) in N,N-dimethylformamide (0.10 mL) and N,N-diisopropylethylamine (5.0 mg, 0.04 mmol) were mixed together and stirred at rt for 20 min. The mixture was filtered, concentrated and purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC 18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product as white powders (1.6 mg, 20%). LCMS calcd for C 30 H 26 FN 6 O 3 (M+H) +< : m / z = 537.2. Found: 537.2.Example 2. N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ] [1,2,4]triazin-5-yl)phenyl]-1-[(1R)-2-hydroxy-1-phenylethyl]-2-oxo-1,2-dihydropyridine-3-carboxamide

[0319] Step 1: 1-[(1R)-2-Hydroxy-1-phenylethyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid

[0320]

[0321] Dimethyl [(2E)-3-methoxyprop-2-en-1-ylidene]malonate (from Acros Organics, 0.20 g, 1.00 mmol) was taken up in methanol (1.8 mL), combined with (2R)-2-amino-2-phenylethanol (0.14 g, 1.00 mmol) and N,N-diisopropylethylamine (0.55 mL, 3.2 mmol). The reaction mixture was sealed and stirred for 2 h at 130 °C. Then the reaction mixture was combined with 2.0 M sodium hydroxide in methanol (5.0 mL) and 2.0 M sodium hydroxide in water (5.0 mL) and continuously stirred at rt for 2 h. The crude was neutralized with HCl (3N), extracted with EtOAcx3. The combined organic layers were dried, filtered and concentrated under vacuum to give the desired product as light brown gum LCMS calcd for C 14 H 14 NO 4 (M+H) +< : m / z = 260.1. Found: 260.1.Step 2: N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-[(1R)-2-hydroxy-1-phenylethyl]-2-oxo-1,2-dihydropyridine-3-carboxamide

[0322] 5-(4-aminophenyl)-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (3.0 mg, 0.012 mmol) (prepared in Example HF1, step 8), 1-[(1R)-2-hydroxy-1-phenylethyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid (3.6 mg, 0.014 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (11.2 mg, 0.03 mmol) in N,N-dimethylformamide (0.10 mL) and N,N-diisopropylethylamine (4.6 mg, 0.035 mmol) were mixed together and stirred at rt for 60 min. The reaction mixture was filtered, concentrated and purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product as white powders (2.0 mg, 34%). LCMS calcd for C 28 H 27 N 6 O 3 (M+H) +< : m / z = 495.2. Found: 495.2.Example 3. N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-[(1R)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydropyridine-3-carboxamide

[0323] Step 1: 1-[(1R)-2-Hydroxy-1-methylethyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid

[0324]

[0325] Dimethyl [(2E)-3-methoxyprop-2-en-1-ylidene]malonate (from Acros Organics, 200 mg, 1.00 mmol) was taken up in methanol (1.82 mL), combined with (R)-(-)-2-amino-1-propanol (from Aldrich, 75.0 mg, 1.00 mmol) and N,N-diisopropylethylamine (0.55 mL, 3.2 mmol). The reaction mixture was sealed and stirred for 2 h at 130 °C. Then the reaction mixture was combined with 2.0 M sodium hydroxide in methanol (5.0 mL) and 2.0 M sodium hydroxide in water (5.0 mL) and continuously stirred at rt for 2 h. The reaction mixture was acidified with 5.0 mL of HCl (3 N), concentrated under vacuum to remove solvents. The residue was washed with THF and EtOAc, dried, filtered and concentrated under vacuum to give the desired product as off-white powders. LCMS calcd for C 9 H 12 NO 4 (M+H) +< : m / z = 198.1. Found: 198.1.Step 2: N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-[(1R)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydropyridine-3-carboxamide

[0326] 5-(4-Aminophenyl)-7-ethylpyrrolo[2,1-f][1,2,4]triazin-4-amine (5.0 mg, 0.020 mmol) (prepared in Example HF1, step 8), 1-[(1R)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid (4.7 mg, 0.024 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (18.8 mg, 0.05 mmol) in N,N-dimethylformamide (0.1 mL) and N,N-diisopropylethylamine (7.7 mg, 0.06 mmol) were mixed together and stirred at rt for 30 min. The mixture was filtered, concentrated and purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC 18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product as white powders (2.0 mg, 23%). LCMS calcd for C 23 H 25 N 6 O 3 (M+H) +< : m / z = 433.2. Found: 433.2.Example 4. N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-[(1R)-1-(hydroxymethyl)propyl]-2-oxo-1,2-dihydropyridine-3-carboxamide

[0327] Step 1: 1-[(1R)-1-(Hydroxymethyl)propyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid

[0328]

[0329] Dimethyl [(2E)-3-methoxyprop-2-en-1-ylidene]malonate (from Acros Organics, 200 mg, 1.00 mmol) was taken up in methanol (1.82 mL), combined with (2R)-2-aminobutan-1-ol (89.0 mg, 1.00 mmol) and N,N-diisopropylethylamine (0.55 mL, 3.2 mmol). The reaction mixture was sealed and stirred for 2 h at 130 °C. Then the reaction mixture was combined with 2.0 M sodium hydroxide in methanol (5.0 mL) and 2.0 M sodium hydroxide in water (5.0 mL) and continuously stirred at rt for 1 h. The reaction mixture was acidified with 5.0 mL of HCl (3 N), concentrated under vacuum to remove solvents. The residue was washed with THF and EtOAc, dried, filtered and concentrated under vacuum to give the desired product as off-white powders. LCMS calcd for C 10 H 14 NO 4 (M+H) +< : m / z = 212.1. Found: 212.1.Step 2: N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-[(1R)-1-(hydroxymethyl)propyl]-2-oxo-1, 2-dihydropyridine-3-carboxamide

[0330] 5-(4-Aminophenyl)-7-ethylpyrrolo[2,1-f][1,2,4]triazin-4-amine (5.0 mg, 0.020 mmol) (prepared in Example HF1, step 8), 1-[(1R)-1-(hydroxymethyl)propyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid (5.0 mg, 0.024 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (18.8 mg, 0.049 mmol) in N,N-dimethylformamide (0.1 mL) and N,N-diisopropylethylamine (7.7 mg, 0.06 mmol) were mixed together and stirred at rt for 30 min. The reaction mixture was filtered, concentrated and purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product as white powders (1.7 mg, 19%). LCMS calcd for C 24 H 27 N 6 O 3 (M+H) +< : m / z = 447.2. Found: 447.2.Example 5. N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-benzyl-2-oxo-1,2-dihydropyridine-3-carboxamide

[0331]

[0332] 5-(4-Aminophenyl)-7-ethylpyrrolo[2,1-f][1,2,4]triazin-4-amine (4.6 mg, 0.02 mmol) (prepared in Example 1, step 8), 1-benzyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (from Aurum Pharmatech, 5 mg, 0.02 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (17.3 mg, 0.05 mmol) in N,N-dimethylformamide (0.1 mL) and N,N-diisopropylethylamine (7 mg, 0.05 mmol) were mixed together and stirred at rt for 30 min. The reaction mixture was filtered, concentrated and purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product as white powders (2.4 mg, 28%). LCMS calcd for C 27 H 25 N 6 O 2 (M+H) +< : m / z = 465.2. Found: 465.2.Example 6. N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide

[0333]

[0334] 5-(4-Aminophenyl)-7-ethylpyrrolo[2,1-f][1,2,4]triazin-4-amine (4 mg, 0.02 mmol) (prepared in Example 1, step 8), 1-methyl-2-oxo-1,2-dihydropyridine-3-carboxylic acid (from Synthonix, 2.9 mg, 0.02 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (12 mg, 0.03 mmol) in N,N-dimethylformamide (0.1 mL) and triethylamine (4.8 mg, 0.05 mmol) were mixed together and stirred at rt for 30 min. The reaction mixture was filtered, concentrated and purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product as white powders (1.6 mg, 26%). LCMS calcd for C 21 H 21 N 6 O 2 (M+H) +< : m / z = 389.2. Found: 389.2.Example 7a. N-{4-[4-Amino-7-(cis-4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide Example 7b. N-{4-[4-Amino-7-(trans-4-hydroxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0335] Step 1: Methyl 2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylate

[0336]

[0337] A mixture of methyl 2-oxo-1,2-dihydropyridine-3-carboxylate (from Aldrich, 1.50 g, 9.80 mmol), phenylboronic acid (3.6 g, 29 mmol), activated 4Å molecular sieves (2.8 g, 12 mmol) and cupric acetate (3.6 g, 20.0 mmol) in methylene chloride (60 mL) was treated with pyridine (2.4 mL, 29 mmol). The reaction mixture was stirred at rt for 60 h, filtered through a celite pad. The filtrate was concentrated under vacuum The crude product was purified by Biotage silica gel chromatography (0 to 100% ethyl acetate in hexanes) to afford the desired product as white powders (1.26 g, 56%). LCMS calcd for C 13 H 12 NO 3 (M+H) +< : m / z = 230.1. Found: 230.1.Step 2: 2-Oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid

[0338]

[0339] Methyl 2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylate (800 mg, 3.49 mmol) was dissolved in tetrahydrofuran (7.4 mL) and methanol (3.7 mL). The mixture was then treated with 1.0 M sodium hydroxide in water (14.0 mL), and stirred at rt for 30 min. The reaction mixture was neutralized with HCl (12 M) to pH = 6-7. The solvents were removed under vacuum and the product precipitated out. The solid was collected by vacuum filtration, and the cake was washed with water and dried overnight to give the desired acid product as white powders (636 mg, 85%). LCMS calcd for C 12 H 10 NO 3 (M+H) +< : m / z = 216.1. Found: 216.1.Step 3: 2-Oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide

[0340]

[0341] To a mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (from Aldrich, 214 mg, 0.98 mmol) and 2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid (200 mg, 0.93 mmol) in N,N-dimethylformamide (4.5 mL) was added triethylamine (194 µL, 1.4 mmol) followed by N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (424 mg, 1.12 mmol). The resulting reaction mixture, which became a mixture of solids quickly, was stirred at rt for 1 h. The solids were filtered and washed with water. Drying by vacuum suction gave the desired product as a white solid (306 mg, 79%). LCMS calcd for C 24 H 26 BN 2 O 4 (M+H) +< : m / z = 417.2. Found: 417.2.Step 4: 7-(4-{[tert-Butyl(dimethyl)silyl]oxy}cyclohex-1-en-1-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0342]

[0343] A mixture of tert-bulyl(dimethyl){[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl]oxy}silane (450 mg, 1.33 mmol), 7-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (283 mg, 1.33 mmol), sodium carbonate (470 mg, 4.4 mmol), and [1,1'-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium (II) (101 mg, 0.133 mmol) in tert-butyl alcohol (4.0 mL) and water (1.5 mL) was degassed with nitrogen, then stirred and heated at 110 °C for 2 h, then 95 °C overnight. The mixture was diluted with ethyl acetate, washed with saturated NaHCO 3 , water, dried over Na 2 SO 4 , filtered and concentrated. The product was purified by Biotage silica gel chromatography (0 to 50% EtOAc in hexanes) to give the desired product as off-white powders (242.3 mg, 53%). LCMS calcd for C 18 H 29 N 4 OSi (M+H) +< : m / z = 345.2. Found: 345.2.Step 5: 7-(4-{[tert-Butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1-ƒ][1,2, 4]triazin-4-amine

[0344]

[0345] To a solution of 7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohex-1-en-1-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (230 mg, 0.67 mmol) in methanol (2.8 mL) and tetrahydrofuran (1.4 mL) was added a mixture of palladium (4.6 mg) (10% Pd on carbon). The reaction mixture was vacuumed and placed under a hydrogen balloon for 1 h. After filtration through a celite pad, the filtrate was concentrated under vacuum to give the desired product (161.9 mg, 70%). LCMS calcd for C 18 H 31 N 4 OSi (M+H) +< : m / z = 347.2. Found: 347.2.Step 6: 5-Bromo-7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1-ƒ][1,2, 4]triazin-4-amine

[0346]

[0347] To a solution of 7-(4-{[tert-butyl(dimethyl)silyl]oxy }cyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (80.0 mg, 0.23 mmol) in N,N-dimethylformamide (1.0 mL) was added N-bromosuccinimide (39.0 mg, 0.22 mmol). The resulting mixture was stirred at rt for 10 min. The reaction mixture was diluted with EtOAc, filtered. The filtrate was washed with saturated NaHCO 3 , water, dried, filtered again and concentrated under vacuum to give the desired product as tan solid. LCMS calcd for C 18 H 30 BrN 4 OSi (M+H) +< : m / z = 425.1,427.1. Found: 425.1,427.1.Step 7: N-{4-[4-Amino-7-(4-([tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0348]

[0349] A mixture of 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (48.9 mg, 0.12 mmol) (prepared in Example 7, step 3), 5-bromo-7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (50 mg, 0.12 mmol), sodium carbonate (42 mg, 0.39 mmol), and [1,1'-bis(dicyclohexylphosphino)ferrocene]dichloropalladium (II) (13.4 mg, 0.018 mmol) in tert-butyl alcohol (0.35 mL) and water (0.13 mL) was degassed with nitrogen, then stirred and heated at 110 °C for 1 h. The mixture was diluted with ethyl acetate, washed with saturated NaHCO 3 , water, dried over Na 2 SO 4 , filtered and concentrated. The crude product was purified by Biotage silica gel chromatography (0 to 100% EtOAc in hexanes) to give the desired product as white powders (34 mg, 46%). LCMS calcd for C 36 H 43 N 6 O 3 Si (M+H) +< : m / z = 635.3. Found: 635.3.Step 8: N-{4-[4-Amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0350] A solution of N-{4-[4-amino-7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (34 mg, 0.05 mmol) in tetrahydrofuran (0.2 mL) was treated with 4.0 M hydrogen chloride in dioxane (0.9 mL, 3.6 mmol). The reaction mixture was stirred at rt for 30 min. The crude (trans and cis isomers with a ratio of 1:4) was concentrated under vacuum and purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired cis isomer (9.2 mg, 33%). The minor trans isomer (3.5 mg, 12%) was also isolated. Retention time (RT) = RT = 1.189 min for minor trans isomer, first peak off the column; RT = 1.216 min for major cis isomer, second peak off the column. LCMS calcd for C 30 H 29 N 6 O 3 (M+H) +< : m / z = 521.2. Found: 521.2. 1< H NMR (500 MHz, dmso) δ 12.06 (s, 1H), 8.62 (dd, J = 7.3, 2.2 Hz, 1H), 8.14 (dd, J = 6.6, 2.2 Hz, 1H), 7.90 (s, 1H), 7.82 (d, J = 8.6 Hz, 2H), 7.66 - 7.52 (m, 6H), 7.47 (d, J = 8.5 Hz, 2H), 6.78 - 6.72 (m, 2H), 6.55 (s, 1H), 4.38 (d, J = 2.9 Hz, 1H), 3.92 (s, 1H), 3.62 (d, J = 6.5 Hz, 1H), 3.16 (t, J = 11.4 Hz, 1H), 1.99 - 1.84 (m, 2H), 1.84 - 1.70 (m, 4H), 1.62 (t, J = 12.2 Hz, 1H).Example 8. N-[4-(4-Amino-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyiidine-3-carboxamide

[0351] Step 1: 7-Methylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0352]

[0353] To a solution of 7-bromopyrrolo[2,1ƒ][1,2,4]triazin-4-amine (from J & W Pharm Lab, 150 mg, 0.70 mmol) in tetrahydrofuran (2.86 mL) under N 2 at rt was added tetrakis(triphenylphosphine)palladium(0) (163 mg, 0.14 mmol). The mixture in a sealed flask was evacuated and refilled with N 2 several times, followed by the addition of 2.0 M dimethylzinc in toluene (5.3 mL, 10 mmol) at rt. The reaction mixture was heated at 90 °C for 4 h. The reaction mixture was quenched with ice-water, extracted with EtOAc. The combined organic layers were dried over Na 2 SO 4 , filtered, concentrated under vacuum to give the crude, which was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to afford the desired product as white powders (29.2 mg, 28%). LCMS calcd for C 7 H 9 N 4 (M+H) +< : m / z = 149.1. Found: 149.1.Step 2: 5-Bromo-7-methylpyrrolo(2,1-ƒ][1,2, 4]triazin-4-amine

[0354]

[0355] To a solution of 7-methylpyrrolo[2,1:f][1,2,4]triazin-4-amine (29.2 mg, 0.20 mmol) in N,N-dimethylformamide (0.85 mL) was added N-bromosuccinimide (33.3 mg, 0.19 mmol). The resulting mixture was stirred at rt for 15 min and the reaction mixture was diluted with EtOAc, filtered, then washed with saturated NaHCO 3 , water, dried, filtered and concentrated under vacuum to give the desired product as off-white powders. LCMS calcd for C 7 H 8 BrN 4 (M+H) +< : m / z = 227.0, 229.0. Found: 227.0, 229.0.Step 3: N (4-(4-Amino--7-methylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0356] In a sealed tube a mixture of 5-bromo-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (5.6 mg, 0.02 mmol), 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (8.0 mg, 0.02 mmol) (prepared in Example 7, step 3) and N,N-diisopropylethylamine (0.01 mL, 0.06 mmol) in 1,4-dioxane (0.14 mL) and water (20 µL) was stirred together and flushed with N 2 bubble for 5 min before bis(tri-t-butylphosphine)palladium (4.7 mg, 0.01 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (2.8 mg, 36%). LCMS calcd for C 25 H 21 N 6 O 2 (M+H) +< : m / z = 437.2. Found: 437.2.Example 9. N-[4-(4-Amino-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0357] Step 1: Methyl 1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate

[0358]

[0359] A mixture of methyl 2-oxo-1,2-dihydropyridine-3-carboxylate (from Aldrich, 1.50 g, 9.8 mmol), 4-fluorophenylboronic acid (from Aldrich, 4.1 g, 29 mmol), activated 4Å molecular sieves (2.8 g, 12 mmol) and cupric acetate (3.6 g, 20 mmol) in methylene chloride (60 mL) was treated with pyridine (2.4 mL) and then stirred at rt for 18 h. The mixture was filtered through celite and the filtrate was concentrated under vacuum The crude was purified by Biotage silica gel column chromatography (0 to 100% ethyl acetate in hexanes) to afford the desired product as offwhite gum (1.33 g, 55%). LCMS calcd for C 13 H 11 FNO 3 (M+H) +< : m / z = 248.1. Found: 248.1.Step 2: 1-(4-Fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid

[0360]

[0361] Methyl 1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate (800 mg, 3.24 mmol) was dissolved in tetrahydrofuran (6.82 mL) and methanol (3.41 mL). The mixture was then treated with 1.0 M sodium hydroxide in water (12.9 mL), and the reaction mixture was stirred at rt for 30 min. The reaction mixture was neutralized with HCl (12 M) to pH = 6-7. The solvents were removed under vacuum and the product precipitated out. The solid was collected by vacuum filtration, and the cake was washed with water and dried overnight to give the desired acid product as white powders (540 mg, 72%). LCMS calcd for C 12 H 9 FNO 3 (M+H) +< : m / z = 234.1. Found: 234.1.Step 3: 1-(4-Fluorophenyl)-2-oxo-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide

[0362]

[0363] To a mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (from Aldrich, 197.3 mg, 0.90 mmol) and 1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (from Aldrich, 200 mg, 0.86 mmol) in N,N dimethylformamide (4.0 mL) was added triethylamine (180 µL, 1.3 mmol) followed by N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (391 mg, 1.03 mmol). The resulting mixture, which became a mixture of solids quickly, was stirred at rt for 1 h. The solids were filtered and washed with water. Drying by vacuum suction gave the desired product as a white solid (343 mg, 92%). LCMS calcd for C 24 H 25 BFN 2 O 4 (M+H) +< : m / z = 435.2. Found: 435.2.Step 4: N-[3-Fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0364]

[0365] To a mixture of 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (from Aldrich, 289.2 mg, 1.22 mmol) and 2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxylic acid (250 mg, 1.16 mmol) (prepared in Example 7, step 2) in N,N-dimethylformamide (5.0 mL) was added triethylamine (243 µL, 1.74 mmol) followed by N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (530 mg, 1.39 mmol). The resulting mixture, which became a mixture of solids quickly, was stirred at rt for 1 h. The solids were filtered and washed with water. Drying by vacuum suction gave the desired product as a white solid (335 mg, 66%). LCMS calcd for C 24 H 25 BFN 2 O 4 (M+H) +< : m / z = 435.2. Found: 435.2.Step 5: 1-(4 Fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide

[0366]

[0367] To a mixture of 3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (from Aldrich, 213.5 mg, 0.90 mmol) and 1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxylic acid (200 mg, 0.86 mmol) (prepared in Example 9, step 2) in N,N-dimethylformamide (4.7 mL) was added triethylamine (179 µL, 1.29 mmol) followed by N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (391 mg, 1.03 mmol). The resulting mixture, which became a mixture of solids quickly, was stirred at rt for 1 h. The solids were filtered and washed with water. Drying by vacuum suction gave the desired product as a white solid (305 mg, 79%). LCMS calcd for C 24 H 24 BF 2 N 2 O 4 (M+H) +< : m / z = 453.2. Found: 453.2.Step 6: N-[4-(4-Amino-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0368] In a sealed tube a mixture of 5-bromo-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (5 mg, 0.02 mmol) (prepared in Example 8, step 2), 1-(4-fluorophenyl)-2-oxoN-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (8 mg, 0.02 mmol) (prepared in Example 9, step 3) and N,N-diisopropylethylamine (0.01 mL, 0.05 mmol) in 1,4-dioxane (0.13 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (4.2 mg, 0.01 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (2.4 mg, 32%). LCMS calcd for C 25 H 20 FN 6 O 2 (M+H) +< : m / z = 455.2. Found: 455.2.Example 10. N-[4-(4-Amino-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0369]

[0370] In a sealed tube a mixture of 5-bromo-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (5 mg, 0.016 mmol) (prepared in Example 8, step 2), N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl] -2-oxo-1 -phenyl-1,2-dihy dropyridine-3-carboxamide (7.5 mg, 0.017 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.01 mL, 0.049 mmol) in 1,4-dioxane (0.128 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (4.2 mg, 0.01 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (1.7 mg, 23%). LCMS calcd for C 25 H 20 FN 6 O 2 (M+H) +< : m / z = 455.2. Found: 455.2.Example 11. N-[4-(4-Amino-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0371]

[0372] In a sealed tube a mixture of 5-bromo-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (3.2 mg, 0.01 mmol) (prepared in Example 8, step 2), 1-(4-fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide (5 mg, 0.01 mmol) (prepared in Example 9, step 5) and N,N-diisopropylethylamine (0.01 mL, 0.04 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (2.7 mg, 0.005 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (2.0 mg, 40%). LCMS calcd for C 25 H 19 F 2 N 6 O 2 (M+H) +< : m / z = 473.2. Found: 473.2.Example 12. N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0373]

[0374] In a sealed tube a mixture of 5-bromo-7-ethylpyrrolo[2,1-J] [1,2,4]triazin-4-amine (6 mg, 0.018 mmol) (prepared in Example 1, step 7), N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (8.3 mg, 0.02 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.02 mL, 0.11 mmol) in 1,4-dioxane (0.14 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (4.6 mg, 0.01 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (2.4 mg, 28%). LCMS calcd for C 26 H 22 FN 6 O 2 (M+H) +< : m / z = 469.2. Found: 469.2.Example 13. N-14-[4-Amino-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0375] Step 1: 7-(3,6-Dihydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0376]

[0377] In a sealed flask a mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyran (from Aldrich, 0.64 g, 3.01 mmol), 7-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (from J & W Pharm Lab, 0.500 g, 2.35 mmol) and N,N-diisopropylethylamine (1.2 mL, 7.0 mmol) in 1,4-dioxane (6 mL) and water (0.32 mL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (100 mg, 0.24 mmol) was added. The reaction mixture was then sealed and heated at 120 °C for 4 h, filtered through a pad of celite and concentrated. The crude was purified by Biotage silica gel column chromatography (40 g column, 0 to 100% EtOAc in hexanes) to give the desired product as white powders (168.5 mg, 33%). LCMS calcd for C 11 H 13 N 4 O (M+H) +< : m / z = 217.1. Found: 217.1.Step 2: 7-(Tetrahydro-2Hpyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine

[0378]

[0379] To a solution of 7-(3,6-dihydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (120 mg, 0.55 mmol) in methanol (2.67 mL) and THF (1.3 mL) was added a mixture of palladium (120 mg) (10% Pd on carbon). The reaction mixture was placed under a hydrogen balloon for 2 hours. After filtration through a celite pad, the filtrate was concentrated under vacuum to give the desired product as white powders (90.2 mg, 75%). LCMS calcd for C 11 H 15 N 4 O (M+H) +< : m / z = 219.1. Found: 219.1.Step 3: 5-Bromo-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0380]

[0381] To a solution of 7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (50 mg, 0.23 mmol) in N,N-dimethylformamide (0.99 mL) was added N-bromosuccinimide (41 mg, 0.23 mmol). The resulting mixture was stirred at rt for 15 min. The reaction mixture was diluted with EtOAc, filtered. The filtrate was washed with saturated NaHCO 3 , water, dried, filtered again and concentrated under vacuum to give the desired product as tan solid. LCMS calcd for C 11 H 14 BrN 4 O (M+H) +< : m / z = 297.0, 299.0. Found: 297.0,299.0.Step 4: N-{4-[4-Amino-7-(tetrahydro-2Hpyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0382] In a sealed tube a mixture of 5-bromo-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (6 mg, 0.02 mmol), 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2 -yl)phenyl]-1,2-dihydropyridine-3-carboxamide (8.8 mg, 0.02 mmol) (prepared in Example 7, step 3) and N,N-diisopropylethylamine (0.01 mL, 0.06 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 or 5 min before bis(tri-t-butylphosphine)palladium (5.2 mg, 0.01 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (3.2 mg, 31%). LCMS calcd for C 29 H 27 N 6 O 3 (M+H) +< : m / z = 507.2. Found: 507.2.Example 14. N-{4-[4-Amino-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0383]

[0384] In a sealed tube a mixture of 5-bromo-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (6 mg, 0.02 mmol) (prepared in Example 13, step 3), 1-(4-fluorophenyl)-2-oxo-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (9.2 mg, 0.02 mmol) (prepared in Example 9, step 3) and N,N-diisopropylethylamine (0.01 mL, 0.06 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (5.2 mg, 0.01 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (4.8 mg, 45%). LCMS calcd for C 29 H 26 FN 6 O 3 (M+H) +< : m / z = 525.2. Found: 525.2.Example 15. N-{4-[4-Amino-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-ftuorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0385]

[0386] In a sealed tube a mixture of 5-bromo-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (5 mg, 0.02 mmol) (prepared in Example 13, step 3), N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (7.3 mg, 0.017 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.01 mL, 0.06 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (4.3 mg, 0.01 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 2 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (6.4 mg, 72%). LCMS calcd for C 29 H 26 FN 6 O 3 (M+H) +< : m / z = 525.2. Found: 525.2.Example 16. N-{4-[4-Amino-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ] [1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0387]

[0388] In a sealed tube a mixture of 5-bromo-7-(tetrahydro-2H pyran-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (6 mg, 0.02 mmol) (prepared in Example 13, step 3), 1-(4-fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide (9.6 mg, 0.02 mmol) (prepared in Example 9, step 5) and N,N-diisopropylethylamine (0.01 mL, 0.06 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (5.2 mg, 0.01 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (4.4 mg, 40%). LCMS calcd for C 29 H 25 F 2 N 6 O 3 (M+H) +< : m / z = 543.2. Found: 543.2.Example 17a. N-{4-[4-Amino-7-(cis-4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Example 17b. N-{4-[4-Amino-7-(trans-4-hydrnxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0389] Step 1: N-(4-[4-Amino-7-(4-{[tert-butyl(dimethyl)silyl]oxy)cyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0390]

[0391] In a sealed tube a mixture of 5-bromo-7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1ƒ][1,2,4]triazin-4-amine (5 mg, 0.012 mmol) (prepared in Example 7, step 6), 1-(4-fluorophenyl)-2-oxo-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (5.4 mg, 0.012 mmol) (prepared in Example 9, step 3) and N,N-diisopropylethylamine (0.012 mL, 0.07 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3 mg, 0.006 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was used directly in the next step. LCMS calcd for C 36 H 42 FN 6 O 3 Si (M+H) +< : m / z = 653.3. Found: 653.3.Step 2: N-{4-[4-Amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0392] A solution of N-{4-[4-amino-7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (7.7 mg, 0.012 mmol) in methanol (0.05 mL) was treated with 4.0 M hydrogen chloride in dioxane (0.20 mL). The reaction mixture was stirred at rt for 20 min. The crude was concentrated under vacuum and purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (cis isomer) as white powders (2.8 mg, 44%). RT = 2.047 min for the major cis isomer, second peak off the column. The trans isomer is the minor product and is the first peak off the column. The trans isomer was not isolated. LCMS calcd for C 30 H 28 FN 6 O 3 (M+H) +< : m / z = 539.2. Found: 539.2.Example 18a. N-{4-[4-Amino-7-(cis-4-hydroxycydohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide Example 18b. N-{4-[4-Amino-7-(trans-4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0393] Step 1: N-{4-[4-Amino-7-(4-([tert-butyl(dimethyl)silyl]oxy)cyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0394]

[0395] In a sealed tube a mixture of 5-bromo-7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1ƒ][1,2,4]triazin-4-amine (6 mg, 0.014 mmol) (prepared in Example 7, step 6), N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (6.1 mg, 0.014 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.014 mL, 0.08 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.6 mg, 0.007 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 40 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was directly used in the next step. LCMS calcd for C 36 H 42 FN 6 O 3 Si (M+H) +< : m / z = 653.3. Found: 653.3.Step 2: N-{4-[4-Amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0396] A solution of N-{4-[4-amino-7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (9.2 mg, 0.014 mmol) in mthanol (0.06 mL) was treated with 4.0 M hydrogen chloride in dioxane (0.24 mL). The reaction mixture was stirred at rt for 30 min. The crude was concentrated under vacuum and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product (cis isomer) as white powders. RT = 1.208 min for the cis isomer, second peak off the column. LCMS calcd for C 30 H 28 FN 6 O 3 (M+H) +< : m / z = 539.2. Found: 539.2.Example 19a. N-{4-[4-Amino-7-(cis-4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Example 19b. N-{4-[4-Amino-7-(trans-4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0397] Step 1: N-{4-[4-Amino-7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0398]

[0399] In a sealed tube a mixture of 5-bromo-7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1ƒ][1,2,4]triazin-4-amine (5 mg, 0.012 mmol) (prepared in Example 7, step 6), 1-(4-fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide (5.6 mg, 0.012 mmol) (prepared in Example 9, step 5) and N,N-diisopropylethylamine (0.012 mL, 0.07 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3 mg, 0.006 mmol) was added. The reaction mixture was sealed and then heated at 100 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was used directly in the next step. LCMS calcd for C 36 H 41 F 2 N 6 O 3 Si (M+H) +< : m / z = 671.3. Found: 671.3.Step 2: N-{4-[4-Amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0400] A solution of N-{4-[4-amino-7-(4-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (7.9 mg, 0.012 mmol) in methanol (0.05 mL) was treated with 4.0 M hydrogen chloride in dioxane (0.2 mL) . The reaction mixture was stirred at rt for 30 min. The crude was concentrated under vacuum and purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (cis isomer) as white powders (1.8 mg, 27%). RT = 2.114 min for the major cis isomer, second peak off the column. The trans isomer was not isolated, which is the first peak off the column. LCMS calcd for C 30 H 27 F 2 N 6 O 3 (M+H) +< : m / z = 557.2. Found: 557.2.Example 20. N-{4-[4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0401] Step 1: 7-(1Methyl-1,2,3,6-tetrahydropyridin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine

[0402]

[0403] The mixture of 7-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (from J & W Pharm Lab, 208 mg, 0.97 mmol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine (from Aldrich, 250 mg, 1.12 mmol), potassium phosphate (0.61 g, 2.9 mmol) in 1,4-dioxane (3.4 mL) and water (1.1 mL) was degassed, refilled with nitrogen, followed by addition of dicyclohexyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine - (2'-aminobiphenyl-2-yl)(chloro)palladium (1:1) (110 mg, 0.14 mmol). The reaction mixture was degassed again, refilled with nitrogen and was then sealed and heated at 80 °C for 1 h. The reaction mixture was allowed to cool to rt, diluted with ethyl acetate, washed with brine, dried over sodium sulfate, filtered, and concentrated under vacuum to give the crude product, which was used directly in the next step. LCMS calcd for C 12 H 16 N 5 (M+H) +< : m / z = 230.1. Found: 230.1.Step 2: 7-(1-Methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0404]

[0405] To a solution of 7-(1-methyl-1,2,3,6-tetrahydropyridin-4 yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (134 mg, 0.26 mmol) in methanol (1.26 mL) and THF (0.5 mL) was added a mixture of palladium (150 mg, 0.14 mmol) (10% Pd on carbon). The reaction mixture was placed under a hydrogen balloon for 4 hours. After filtration through a celite pad, the filtrate was concentrated under vacuum to give the crude. The crude was further purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product as white powders (22 mg, 36%). LCMS calcd for C 12 H 18 N 5 (M+H) +< : m / z = 232.2. Found: 232.2.Step 3: 5-Bromo-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0406]

[0407] To a solution of 7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (16.5 mg, 0.07 mmol) in N,N-dimethylformamide (0.31 mL) and tetrahydrofuran (0.20 mL) was added N-bromosuccinimide (10.2 mg, 0.06 mmol). The resulting mixture was stirred at rt for 10 min. The reaction mixture was diluted with EtOAc, filtered. The filtrate was washed with saturated NaHCO 3 , water, dried, filtered and concentrated under vacuum to give the desired product as tan solid. LCMS calcd for C 12 H 17 BrN 5 (M+H) +< : m / z = 310.1,312.1. Found: 310.1, 312.1.Step 4: N-{4-[4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2, 4]triazin-5-yl]phenyl}-2-oxo-l-phenyl-1,2-dihydropyridine-3-carboxamide

[0408] In a sealed tube a mixture of 5-bromo-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (4 mg, 0.013 mmol), 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (5.6 mg, 0.014 mmol) (prepared in Example 7, step 3) and N,N-diisopropylethylamine (0.012 mL, 0.078 mmol) in 1,4-dioxane (0.15 m) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.3 mg, 0.006 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 40 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (4.0 mg, 60%). LCMS calcd for C 30 H 30 N 7 O 2 (M+H) +< : m / z = 520.2. Found: 520.2.Example 21. N-{4-[4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0409]

[0410] In a sealed tube a mixture of 5-bromo-7-(1-methylpiperidin-4 yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (4 mg, 0.013 mmol) (prepared in Example 20, step 3), 1-(4-fluorophenyl)-2-oxo-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)phenyl]-1,2-dihydropyridine-3-carboxamide (5.9 mg, 0.014 mmol) (prepared in Example 9, step 3) and N,N-diisopropylethylamine (0.014 mL, 0.04 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.3 mg, 0.006 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (2.1 mg, 30%). LCMS calcd for C 30 H 29 FN 7 O 2 (M+H) +< : m / z = 538.2. Found: 538.2.Example 22. N-{4-[4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0411]

[0412] In a sealed tube a mixture of 5-bromo-7-(1-methylpiperidin-4 yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (3 mg, 0.01 mmol) (prepared in Example 20, step 3), N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (4.2 mg, 0.01 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.01 mL, 0.03 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (2.5 mg, 0.005 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 40 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product. LCMS calcd for C 30 H 29 FN 7 O 2 (M+H) +< : m / z = 538.2. Found: 538.2.Example 23. N-{4-[4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0413]

[0414] In a sealed tube a mixture of 5-bromo-7-(1-methylpiperidin-4 yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (4 mg, 0.013 mmol) (prepared in Example 20, step 3), 1-(4-fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide (5.8 mg, 0.013 mmol) (prepared in Example 9, step 5) and N,N-diisopropylethylamine (0.014 mL, 0.08 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.3 mg, 0.006 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 40 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (2.5 mg, 35%). LCMS calcd for C 30 H 28 F 2 N 7 O 2 (M+H) +< : m / z = 556.3. Found: 556.3.Example 24. N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-l-phenyl-1,2-dihydropyridine-3-carboxamide

[0415] Step 1: 7-(1-Acetyl-1, 2, 3, 6-tetrahydropyridin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0416]

[0417] A mixture of 1-acetyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridine (from Combi-Blocks, 500 mg, 1.99 mmol), 7-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (from J & W Pharm Lab, 424 mg, 1.99 mmol), sodium carbonate (700 mg, 6.6 mmol), and [1,1'-bis(dicyclohexylphosphino)ferrocene]dichloropalladium (II) (199 mg, 0.26 mmol) in tert-butyl alcohol (6.0 mL) and water (2.2 mL) was degassed with nitrogen, then stirred and heated at 110 °C for 2 h. The mixture was diluted with ethyl acetate, washed with saturated NaHCO 3 , water, dried over Na 2 SO 4 , filtered and concentrated. The product was purified by Biotage silica gel chromatography (20 g column, 0 to 30% MeOH in EtOAc) to give the desired product as brown solid (317 mg, 62%). LCMS calcd for C 13 H 16 N 5 O (M+H) +< : m / z = 258.1. Found: 258.1.Step 2: 7-(1-Acetylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine

[0418]

[0419] To a cloudy solution of 7-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (305 mg, 1.19 mmol) in methanol (4.9 mL) and tetrahydrofuran (2.4 mL) was added a mixture of palladium (610 mg) (10% Pd on carbon). The reaction mixture was placed under a hydrogen balloon for 18 h, and filtered through a celite pad. The filtrate was concentrated under vacuum to give the desired product as light brown powders (187 mg, 61%). LCMS calcd for C 13 H 18 N 5 O (M+H) +< : m / z = 260.1. Found: 260.1.Step 3: 7-(1-Acetylpiperidin-4-yl)-5-bromopyrrolo[2,1-f][1,2,4]triazin-4-amine

[0420]

[0421] To a solution of 7-(1-acetylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (178 mg, 0.69 mmol) in N,N-dimethylformamide (3.0 mL) was added N-bromosuccinimide (116 mg, 0.65 mmol). The resulting mixture was stirred at rt for 15 min. The reaction mixture was diluted with EtOAc, and filtered. The filtrate was washed with saturated NaHCO 3 , water, dried, filtered and concentrated under vacuum to give the desired product as tan solid. LCMS calcd for C 13 H 17 BrN 5 O (M+H) +< : m / z = 338.1, 340.1. Found: 338.1, 340.1.Step 4: N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4}triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0422] In a sealed tube a mixture of 7-(1-acetylpiperidin-4-yl)-5-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (6 mg, 0.02 mmol), 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (7.8 mg, 0.019 mmol) (prepared in Example 7, step 3) and N,N-diisopropylethylamine (0.018 mL, 0.11 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (4.5 mg, 0.009 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (3.0 mg, 31 %) as. LCMS calcd for C 31 H 30 N 7 O 3 (M+H) +< : m / z = 548.2. Found: 548.2.Example 25. N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-ftuorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0423]

[0424] In a sealed tube a mixture of 7-(1-aceiylpiperidin-4-yl)-5-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (6 mg, 0.02 mmol) (prepared in Example 24, step 3), 1-(4-fluorophenyl)-2-oxo-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (8.1 mg, 0.019 mmol) (prepared in Example 9, step 3) and N,N-diisopropylethylamine (0.018 mL, 0.11 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (4.5 mg, 0.009 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (2.9 mg, 29%) as. LCMS calcd for C 31 H 29 FN 7 O 3 (M+H) +< : m / z = 566.2. Found: 566.2.Example 26. N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0425]

[0426] In a sealed tube a mixture of 7-(1-aceiylpiperidin-4-yl)-5-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (6 mg, 0.02 mmol) (prepared in Example 24, step 3), N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (8.1 mg, 0.02 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.18 mL, 0.11 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (4.5 mg, 0.01 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product (2.4 mg, 24%) as. LCMS calcd for C 31 H 29 FN 7 O 3 (M+H) +< : m / z = 566.2. Found: 566.2.Example 27. N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0427]

[0428] In a sealed tube a mixture of 7-(1-aceiylpiperidin-4-yl)-5-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (6 mg, 0.02 mmol) (prepared in Example 24, step 3), 1-(4-fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide (8.4 mg, 0.02 mmol) (prepared in Example 9, step 5) and N,N-diisopropylethylamine (0.018 mL, 0.11 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (4.5 mg, 0.009 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired product as off-white powders (2.3 mg, 22%). LCMS calcd for C 31 H 28 F 2 N 7 O 3 (M+H) +< : m / z = 584.2. Found: 584.2.Example 28a. N-{4-[4-Amino-7-(cis-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide Example 28b. N-{4-[4-Amino-7-(trans-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0429] Step 1: 4-(4-Aminopyrrolo[2,1-ƒ][1,2,4]triazin-7-yl)cyclohex-3-ene-1-carbonitrile

[0430]

[0431] A mixture of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-ene-1-carbonitrile (from Pharma Block, 500 mg, 2.15 mmol), 7-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (from J & W Pharm Lab, 457 mg, 2.14 mmol), sodium carbonate (760 mg, 7.1 mmol), and [1,1'-bis(di-cyclohexylphosphino)ferrocene]dichloropalladium (II) (211 mg, 0.279 mmol) in tert-butyl alcohol (6.4 mL) and water (2.4 mL) was degassed with nitrogen, then stirred and heated at 110 °C for 2 h. The mixture was diluted with ethyl acetate, washed with saturated NaHCO 3 , water, dried over Na 2 SO 4 , filtered and concentrated. The product was purified by Biotage silica gel chromatography (20 g column, 0 to 100% EtOAc in hexanes) to give the desired product as off-white powders (238 mg, 46%). LCMS calcd for C 13 H 14 N 5 (M+H) +< : m / z = 240.1. Found: 240.1.Step 2: 4-(4-Aminopyrrolo[2,1ƒ][1,2,4]triazin-7-yl)cyclohexanecarbonitrile

[0432]

[0433] To a solution of 4-(4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-7-yl)cyclohex-3-ene-1-carbonitrile (238 mg, 0.99 mmol) in methanol (4.1 mL) and tetrahydrofuran (2.0 mL) was added a mixture of palladium (512 mg) (10% Pd on carbon). The reaction mixture was placed under a hydrogen balloon for 18 h. After filtration through a celite pad, the filtrate was concentrated under vacuum to give the desired product as clear gum (147.2 mg, 61%). LCMS calcd for C 13 H 16 N 5 (M+H) +< : m / z = 242.1. Found: 242.1.Step 3: 4-(4-Amino-5-bromopyrrolo[2,1-ƒ][1,2,4]triazin-7-yl)cyclohexanecarbonitrile

[0434]

[0435] To a solution of 4-(4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-7-yl)cyclohexanecarbonitrile (137 mg, 0.57 mmol) in N,N-dimethylformamide (2.4 mL) was added N-bromosuccinimide (96 mg, 0.54 mmol). The resulting mixture was stirred at rt for 15 min. The reaction mixture was diluted with EtOAc, and filtered. The filtrate was washed with saturated NaHCO 3 , water, dried, filtered and concentrated under vacuum to give the desired product as off-white powders (182 mg, 100%). LCMS calcd for C 13 H 15 BrN 5 (M+H) +< : m / z = 320.0, 322.0. Found: 320.0, 322.0.Step 4: N-{4-[4-Amino-7-(4-cyanocyclohexyl)pyrrolo[2,1-f][1,2, 4]triazin-5-yl]phenyl}-2-oxo-l-phenyl-1,2-dihydropyridine-3-carboxamide

[0436] In a sealed tube a mixture of 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)cyclohexanecarbonitrile (9 mg, 0.03 mmol), 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (11.7 mg, 0.028 mmol) (prepared in Example 7, step 3) and N,N-diisopropylethylamine (0.015 mL, 0.084 mmol) in 1,4-dioxane (0.11 mL) and water (20 µL) was stirred together and flushed with N 2 or 5 min before bis(tri-t-butylphosphine)palladium (7.2 mg, 0.014 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired cis isomer as off-white powders. RT= 1.341 min for the cis isomer, first peak off the column. LCMS calcd for C 31 H 28 N 7 O 2 (M+H) +< : m / z = 530.2. Found: 530.2.Example 29a. N-{4-[4-Amino-7-(cis-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Example 29b. N-{4-[4-Amino-7-(trans-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0437]

[0438] In a sealed tube a mixture of 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)cyclohexanecarbonitrile (9 mg, 0.028 mmol) (prepared in Example 28, step 3), 1-(4-fluorophenyl)-2-oxo-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (13 mg, 0.03 mmol) (prepared in Example 9, step 3) and N,N-diisopropylethylamine (0.015 mL, 0.08 mmol) in 1,4-dioxane (0.11 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (7.2 mg, 0.014 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired cis isomer. RT = 1.352 min for the cis isomer, first peak off the column. LCMS (M+H)+: found m / z = 548.3. LCMS calcd for C 31 H 27 FN 7 O 2 (M+H) +< : m / z = 548.2. Found: 548.2.Example 30a. N-{4-[4-Amino-7-(cis-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide Example 30b. N-{4-[4-Amino-7-(trans-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0439]

[0440] In a sealed tube a mixture of 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7yl)cyclohexanecarbonitrile (9 mg, 0.028 mmol) (prepared in Example 28, step 3), N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (13 mg, 0.03 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.015 mL, 0.084 mmol) in 1,4-dioxane (0.11 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (7.2 mg, 0.014 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired cis isomer as white powders. RT = 1.332 min for the cis isomer, first peak off the column. LCMS calcd for C 31 H 27 FN 7 O 2 (M+H) +< : m / z = 548.2. Found: 548.2.Example 31a. N-{4-[4-Amino-7-(cis-4-cyanocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide Example 31b. N-{4-[4-Amino-7-(trans-4-cyanocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0441]

[0442] In a sealed tube a mixture of 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)cyclohexanecarbonitrile (9 mg, 0.03 mmol) (prepared in Example 28, step 3), 1-(4-fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide (13 mg, 0.03 mmol) (prepared in Example 9, step 5) and N,N-diisopropylethylamine (0.015 mL, 0.084 mmol) in 1,4-dioxane (0.11 mL) and water (20 µL) was stirred together and flushed with N 2 bubble for 5 min before bis(tri-t-butylphosphine)palladium (7.2 mg, 0.014 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 1 h. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 10 method; XBridge ™< PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.15% NH 4 OH) to give the desired cis isomer as white powders. RT = 2.666 min for the cis isomer, first peak off the column. LCMS (M+H)+: found m / z = 566.3. LCMS calcd for C 31 H 26 F 2 N 7 O 2 (M+H) +< : m / z = 566.2. Found: 566.2.Example 32. N-[4-(4-Amino-7-piperidin-4-ylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0443] Step 1: tert-Butyl 4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,6-dihydropyridine-1 (2H)-carboxylate

[0444]

[0445] A mixture of tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2H)-carboxylate (from Aldrich, 0.885 g, 2.86 mmol), 7-bromopyrrolo[2,1-ƒ][1,2,4]triazin-4-amine (from J & W Pharm Lab, 610 mg, 2.86 mmol), sodium carbonate (1.0 g, 9.5 mmol), and [1,1'-bis(dicyclohexylphosphino)ferrocene]dichloropalladium (II) (217 mg, 0.286 mmol) in tert-butyl alcohol (8.6 mL) and water (3.2 mL) was degassed with nitrogen, then stirred and heated at 110 °C for 2 h. The mixture was diluted with ethyl acetate, washed with saturated NaHCO 3 , water, dried over Na 2 SO 4 , filtered and concentrated. The crude was purified by Biotage silica gel chromatography (40 g column, 0 to 100% EtOAc in hexanes) to give the desired product as off-white powders (705 mg, 78%). LCMS calcd for C 16 H 22 N 5 O 2 (M+H) +< : m / z = 316.2. Found: 316.2.Step 2: tert-Butyl 4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate

[0446]

[0447] To a slightly cloudy solution of tert-butyl 4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate (700 mg, 2.22 mmol) in methanol (9.2 mL) and tetrahydrofuran (4.6 mL) was added a mixture of palladium (2.20 g) (10% Pd on carbon). The reaction mixture was placed under a hydrogen balloon for 20 h, and filtered through a celite pad. The filtrate was concentrated under vacuum to give the desired product as light brown powders (455 mg, 65%). LCMS calcd for C 16 H 24 N 5 O 2 (M+H) +< : m / z = 318.2. Found: 318.2.Step 3: tert-Butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate

[0448]

[0449] To a solution of tert-butyl 4-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (450 mg, 1.42 mmol) in N,N-dimethylformamide (6.1 mL) was added N-bromosuccinimide (240 mg, 1.35 mmol). The resulting mixture was stirred at rt for 10 min. The reaction mixture was diluted with EtOAc, filtered. The filtrate was washed with saturated NaHCO 3 , water, dried, filtered and concentrated under vacuum to give the desired product as tan solid. LCMS calcd for C 16 H 23 BrN 5 O 2 (M+H) +< : m / z = 396.1, 398.1. Found: 396.1,398.1.Step 4: 5-Bromo-7-piperidin-4-ylpyrrolo[2,1f][1,2,4]triazin-4-amine dihydrochloride

[0450]

[0451] tert-Butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidino-1-carboxylate (562 mg, 1.42 mmol) was mixed with methanol (3.5 mL) and 4.0 M hydrogen chloride in dioxane (7.1 mL). The mixture was stirred at rt for 1 h. After concentration, the crude product was directly used in the next step as off-white powders. LCMS calcd for C 11 H 15 BrN 5 (M+H) +< : m / z = 296.0, 298.0. Found: 296.0, 298.0.Step 5: N-(4-(4-Amino-7-piperidin-4-ylpyrrolo(2,1-f][1,2,4]triazin-5yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0452] In a sealed tube a mixture of 5-bromo-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine dihydrochloride (6.7 mg, 0.013 mmol), 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (5.4 mg, 0.013 mmol) (prepared in Example 7, step 3) and N,N-diisopropylethylamine (0.013 mL, 0.077 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.3 mg, 0.0064 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 60 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as off-white powders (4 mg, 61%). LCMS calcd for C 29 H 28 N 7 O 2 (M+H) +< : m / z = 506.2. Found: 506.2.Example 33. N-[4-(4-Amino-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0453]

[0454] In a sealed tube a mixture of 5-bromo-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine dihydrochloride (6.7 mg, 0.013 mmol) (prepared in Example 32, step 4), 1-(4-fluorophenyl)-2-oxo-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (5.6 mg, 0.013 mmol) (prepared in Example 9, step 3) and N,N-diisopropylethylamine (0.013 mL, 0.08 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.3 mg, 0.006 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 60 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (4 mg, 59%). LCMS calcd for C 29 H 27 FN 7 O 2 (M+H) +< : m / z = 524.2. Found: 524.2.Example 34. N-[4-(4-Amino-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0455]

[0456] In a sealed tube a mixture of 5-bromo-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine dihydrochloride (6.7 mg, 0.013 mmol) (prepared in Example 32, step 4), N-[3-fluoro-4-(4,4,5,5-tebramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridino-3-carboxamide (5.6 mg, 0.013 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.0067 mL, 0.039 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.3 mg, 0.006 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 60 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as off-white powders (3.2 mg, 47%). LCMS calcd for C 29 H 27 FN 7 O 2 (M+H) +< : m / z = 524.2. Found: 524.2.Example 35. N-[4-(4-Amino-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0457]

[0458] In a sealed tube a mixture of 5-bromo-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine dihydrochloride (6.7 mg, 0.013 mmol) (prepared in Example 32, step 4), 1-(4-fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide (5.8 mg, 0.013 mmol) (prepared in Example 9, step 5) and N,N-diisopropylethylamine (0.014 mL, 0.077 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.3 mg, 0.006 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 60 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum. The crude was purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (3.6 mg, 52%). LCMS calcd for C 29 H 26 F 2 N 7 O 2 (M+H) +< : m / z = 542.2. Found: 542.2.Example 36. Methyl 4-[4-amino-5-(4-{[(2-oxo-1-phenyl-1,2-dihydropyridin-3-yl)carbonyl]amino}phenyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]piperidine-1- carboxylate

[0459] Step 1: Methyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate

[0460]

[0461] To a mixture of 5-bromo-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine dihydrochloride (56 mg, 0.11 mmol) (prepared in Example 32, step 4) in tetrahydrofuran (0.6 mL) was added 1.0 M sodium bicarbonate in water (0.65 mL, 0.65 mmol), followed by the slow addition of methyl chloroformate (42 µL, 0.54 mmol) at 0 °C. After stirred at rt for 10 min, the resultant mixture was filtered, extracted with EtOAc, dried, filtered and concentrated to dryness under reduced pressure. The resulting crude was used directly in the next step as light yellow powders (52.6 mg). LCMS calcd for C 13 H 17 BrN 5 O 2 (M+H) +< : m / z = 354.0, 356.0. Found: 354.0, 356.0.Step 2: Methyl 4-[4-amino-5-(4-{[(2-oxo-1-phenyl-1,2-dihydropyridin-3-yl)carbonyl}amino}phenyl)pyrrolo[2,1-f][1,2,4}triazin-7-yl}piperidine-1-carborylate

[0462] In a sealed tube a mixture of methyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (6.8 mg, 0.014 mmol), 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (6.2 mg, 0.015 mmol) (prepared in Example 7, step 3) and N,N-diisopropylethylamine (0.0074 mL, 0.042 mmol) in 1,4-dioxane (0.11 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.6 mg, 0.007 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 30 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as off-white powders (6.5 mg, 82%). LCMS calcd for C 31 H 30 N 7 O 4 (M+H) +< : m / z = 564.2. Found: 564.2.Example 37. Methyl 4-14-amino-5-[4-(1[1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridin-3-yl]carbonyl}amino)phenyl]pyrrolo[2,1-f][1,2,4]triazin-7-yl}piperidine-1-carboxylate

[0463]

[0464] In a sealed tube a mixture of methyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (6.8 mg, 0.014 mmol) (prepared in Example 36, step 1), 1-(4-fluorophenyl)-2-oxo-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (6.4 mg, 0.015 mmol) (prepared in Example 9, step 3) and N,N-diisopropylethylamine (0.0074 mL, 0.042 mmol) in 1,4-dioxane (0.11 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.6 mg, 0.007 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 30 min. The crude was diluted with MeOH, filtered and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as off-white powders (5.0 mg, 61%). LC-MS found m / z = 582.3. LCMS calcd for C 31 H 29 FN 7 O 4 (M+H) +< : m / z = 582.2. Found: 582.2.Example 38. Methyl 4-[4-amino-5-(2-fluoro-4-{[(2-oxo-1-phenyl-1,2-dihydropyridin-3-yl)carbonyl]amino}phenyl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]piperidine-1-carboxylate

[0465]

[0466] In a sealed tube a mixture of methyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (6.8 mg, 0.014 mmol) (prepared in Example 36, step 1), N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (6.4 mg, 0.015 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.0074 mL, 0.04 mmol) in 1,4-dioxane (0.11 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.6 mg, 0.007 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 30 min. The crude was diluted with MeOH, filtered and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (6.4 mg, 78%). LCMS calcd for C 31 H 29 FN 7 O 4 (M+H) +< : m / z = 582.2. Found: 582.2.Example 39. Methyl 4-{4-amino-5-[2-fluoro-4-({[1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridin-3-yl]carbonyl}amino)phenyl]pyrrolo[2,1-f][1,2,4]triazin-7-yl}piperidine-1-carboxylate

[0467]

[0468] In a sealed tube a mixture of methyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (6.8 mg, 0.014 mmol) (prepared in Example 36, step 1), 1-(4-fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide (6.7 mg, 0.015 mmol) (prepared in Example 9, step 5) and N,N-diisopropylethylamine (0.0074 mL, 0.042 mmol) in 1,4-dioxane (0.11 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.6 mg, 0.007 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 30 min. The crude was diluted with MeOH, filtered and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (4.9 mg, 58%). LCMS calcd for C 31 H 28 F 2 N 7 O 4 (M+H) +< : m / z = 600.2. Found: 600.2.Example 40. N-(4-{4-Amino-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]tiriazin-5-yl)phenyl)-2-oxo-1-phenyl-1,2-dihydropyiidine-3-carboxamide

[0469] Step 1: 5-Bromo-7-[1-(methylsidfonyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-4-amine

[0470]

[0471] To a mixture of 5-bromo-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine dihydrochloride (56 mg, 0.11 mmol) (prepared in Example 32, step 4) in tetrahydrofuran (0.6 mL) was added 1.0 M sodium bicarbonate in water (0.65 mL), followed by the slow addition of methanesulfonyl chloride (13 µL, 0.16 mmol) at 0 °C. After stirred at rt for 10 min, the resultant mixture was filtered, extracted with EtOAc, dried, filtered and concentrated to dryness under reduced pressure. The resulting crude was used directly in the next step as light yellow powders (36.5 mg, 90%). LCMS calcd for C 12 H 17 BrN 5 O 2 S (M+H) +< : m / z = 374.0, 376.0. Found: 374.0, 376.0.Step 2: N-(4-{4-Amino-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-2-oxo-1-phenyl-1, 2-dihydropyridine-3-carboxamide

[0472] In a sealed tube a mixture of 5-bromo-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-4-amine (5 mg, 0.01 mmol), 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (5.8 mg, 0.014 mmol) (prepared in Example 7, step 3) and N,N-diisopropylethylamine (0.01 mL, 0.06 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.4 mg, 0.0067 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 30 min. The crude was diluted with MeOH, filtered and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (5.4 mg, 69%). LCMS calcd for C 30 H 30 N 7 O 4 S (M+H) +< : m / z = 584.2. Found: 584.2.Example 41. N-(4-{4-Amino-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine,3-carboxamide

[0473]

[0474] In a sealed tube a mixture of 5-bromo-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-4-amine (5 mg, 0.013 mmol) (prepared in Example 40, step 1), 1-(4-fluorophenyl)-2-oxo-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (6.1 mg, 0.014 mmol) (prepared in Example 9, step 3) and N,N-diisopropylethylamine (0.01 mL, 0.06 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.4 mg, 0.0067 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 30 min. The crude was diluted with MeOH, filtered and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (6.2 mg, 77%). LCMS calcd for C 30 H 29 FN 7 O 4 S (M+H) +< : m / z = 602.2. Found: 602.2.Example 42. N-(4-{4-Amino-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl}-3-ftuorophenyl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0475]

[0476] In a sealed tube a mixture of 5-bromo-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-4-amine (5 mg, 0.013 mmol) (prepared in Example 40, step 1), N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (6.1 mg, 0.014 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.01 mL, 0.06 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.4 mg, 0.0067 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 30 min. The crude was diluted with MeOH, filtered and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (3.8 mg, 47%). LCMS calcd for C 30 H 29 FN 7 O 4 S (M+H) +< : m / z = 602.2. Found: 602.2.Example 43. N-(4-{4-Amino-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl}-3-fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0477]

[0478] In a sealed tube a mixture of 5-bromo-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-4-amine (5.3 mg, 0.014 mmol) (prepared in Example 40, step 1), 1-(4-fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide (6.7 mg, 0.015 mmol) (prepared in Example 9, step 5) and N,N-diisopropylethylamine (0.01 mL, 0.05 mmol) in 1,4-dioxane (0.15 mL) and water (20 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (3.6 mg, 0.007 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 30 min. The crude was diluted with MeOH, filtered and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30x100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (3.2 mg, 36%). LCMS calcd for C 30 H 28 F 2 N 7 O 4 S (M+H) +< : m / z = 620.2. Found: 620.2.Example 44. N-[4-(4-Amino-7-{1-[(dimethylamino)carbonyl]piperidin-4-yl}pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0479] Step 1: 4-(4-Amino-5-bromopyrrolo{2,1-f][1,2,4}triazin-7-yl)-N,N-dimethylpiperidine-1-carboxamide

[0480]

[0481] To a mixture of 5-bromo-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine dihydrochloride (56 mg, 0.11 mmol) (prepared in Example 32, step 4) in tetrahydrofuran (0.6 mL) was added 1.0 M sodium bicarbonate in water (0.65 mL, 0.65 mmol), followed by the slow addition of N,N-dimethylcarbamoyl chloride (140 mg, 1.3 mmol) at 0 °C. After stirred at rt for 80 min, the resultant mixture was filtered, extracted with EtOAc, dried, filtered and concentrated to dryness under reduced pressure. The resulting crude was used directly in the next step as light yellow powders (59.8 mg). LCMS calcd for C 14 H 20 BrN 6 O (M+H) +< : m / z = 367.1, 369.1. Found: 367.1, 369.1.Step 2: N-[4-(4-Amino-7-{1-[(dimethylamino)carbonyl]piperidin-4-yl}pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0482] In a sealed tube a mixture of 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)-N,N-dimethylpiperidine-1-carboxamide (3.8 mg, 0.007 mmol), 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3- carboxamide (3.1 mg, 0.0074 mmol) (prepared in Example 7, step 3) and N,N-diisopropylethylamine (0.004 mL, 0.02 mmol) in 1,4-dioxane (0.1 mL) and water (15 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (1.8 mg, 0.004 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 50 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (2 mg, 49%). LCMS calcd for C 32 H 33 N 8 O 3 (M+H) +< : m / z = 577.3. Found: 577.3.Example 45. N-[4-(4-Amino-7-{1-[(dhnethylamino)carbonyl]piperidin-4-yl}pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0483]

[0484] In a sealed tube a mixture of 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)-N,N-dimethylpiperidine-1-carboxamide (3.8 mg, 0.007 mmol) (prepared in Example 44, step 1), 1-(4-fluorophenyl)-2-oxo-N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (3.2 mg, 0.0074 mmol) (prepared in Example 9, step 3) and N,N-diisopropylethylamine (0.006 mL, 0.03 mmol) in 1,4-dioxane (0.11 mL) and water (10 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (1.8 mg, 0.004 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 50 min. The crude was diluted with MeOH, filtered and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (2.3 mg, 55%). LCMS calcd for C 32 H 32 FN 8 O 3 (M+H) +< : m / z = 595.3. Found: 595.3.Example 46. N-[4-(4-Amino-7-{1-[(dimethylamino)carbonyl]piperidin-4-yl}pyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0485]

[0486] In a sealed tube a mixture of 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)-N,N-dimethylpiperidine-1-carboxamide (3.8 mg, 0.007 mmol) (prepared in Example 44, step 1), N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide (3.2 mg, 0.0074 mmol) (prepared in Example 9, step 4) and N,N-diisopropylethylamine (0.006 mL, 0.03 mmol) in 1,4-dioxane (0.11 mL) and water (10 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (1.8 mg, 0.004 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 50 min. The crude was diluted with MeOH, filtered and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (3.8 mg, 91%). LCMS calcd for C 32 H 32 FN 8 O 3 (M+H) +< : m / z = 595.3. Found: 595.3.Example 47. N-[4-(4-Amino-7-{1-[(dhnethylamino)carbonyllpiperidin-4-yl}pyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-ftuorophenyl]-1-(4-ftuorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide

[0487]

[0488] In a sealed tube a mixture of 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)-N,N-dimethylpiperidine-1-carboxamide (3.8 mg, 0.007 mmol) (prepared in Example 44, step 1), 1-(4-fluorophenyl)-N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide (3.3 mg, 0.0074 mmol) (prepared in Example 9, step 5) and N,N-diisopropylethylamine (0.006 mL, 0.03 mmol) in 1,4-dioxane (0.11 mL) and water (15 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (1.8 mg, 0.004 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 50 min. The crude was diluted with MeOH, filtered and purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (2.4 mg, 56%). LCMS calcd for C 32 H 31 F 2 N 8 O 3 (M+H) +< : m / z = 613.2. Found: 613.2.Example 48. N-(4-{4-Amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl}phenyl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide

[0489] Step 1: 5-Bromo-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-4-amine

[0490]

[0491] To a mixture of 5-bromo-7-piperidin-4-ylpyrrolo[2,1-f][1,2,4]triazin-4-amine dihydrochloride (56 mg, 0.11 mmol) (prepared in Example 32, step 4) in ethanol (0.5 mL) was added potassium carbonate (90 mg, 0.65 mmol), triethylamine (91 µL, 0.65 mmol) and potassium iodide (27 mg, 0.16 mmol), followed by ethane, 1-bromo-2-methoxy (75.4 mg, 0.54 mmol). The reaction mixture was sealed and refluxed in an oil bath at 110 °C for 1 h. After cooling, the mixture was filtered, and the cake was washed with EtOH. The filtrate was concentrated under reduced pressure to give the desired product as off-white powders. LCMS calcd for C 14 H 21 BrN 5 O (M+H) +< : m / z = 354.1, 356.1. Found: 354.1,356.1.Step 2: N-(4-{4-Amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-2-oxo-1-phenyl-1, 2-dihydropyridine-3-carboxamide

[0492] In a sealed tube a mixture of 5-bromo-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-4-amine (7.6 mg, 0.01 mmol), 2-oxo-1-phenyl-N-[4-(4,4,5,5-tetrainothyl-1,3,2-dioxaborolan-2-yl)phenyl]-1,2-dihydropyridine-3-carboxamide (3.7 mg, 0.01 mmol) (prepared in Example 7, step 3) and N,N-diisopropylethylamine (0.006 mL, 0.03 mmol) in 1,4-dioxane (0.1 mL) and water (10 µL) was stirred together and flushed with N 2 for 5 min before bis(tri-t-butylphosphine)palladium (2.2 mg, 0.004 mmol) was added. The reaction mixture was sealed and then heated at 110 °C for 40 min. After separation and the aqueous layer extracted with EtOAc, the organic layer was dried, filtered and concentrated under vacuum The crude was purified by prep LC-MS (pH = 2 method; Waters SunFire PrepC18 5µm OBD ™< column, 30×100 mm, 60 mL / min, eluting with a gradient of MeCN and water with 0.1% TFA) to give the desired product as white powders (4 mg, 84%). LCMS calcd for C 32 H 34 N 7 O 3 (M+H) +< : m / z = 564.3. Found: 564.3.Example 49. N-(4-{4-Amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyiidine,3-carboxamide

[0493]

[0494] In a sealed tube a mixture of 5-bromo-7-[1-(2-...

Claims

1. A compound of Formula (IIb1) or Formula (IIb2): or a pharmaceutically acceptable salt thereof, wherein: R1 is A1-A2-A3-RA; A1 is selected from a bond, CyA1, -Y-, -C1-3 alkylene-, -C1-3 alkylene-Y-, - Y-C1-3 alkylene-, and -C1-2 alkylene-Y-C1-2 alkylene-; wherein said alkylene groups are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, amino, C1-3 alkylamino, and di(C1-3 alkyl)amino; A2 is selected from a bond, CyA2, -Y-, -C1-3 alkylene-, -C1-3 alkylene-Y-, - Y-C1-3 alkylene-, and -C1-2 alkylene-Y-C1-2 alkylene-; wherein said alkylene groups are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, amino, C1-3 alkylamino, and di(C1-3 alkyl)amino; A3 is selected from a bond, CyA3, -Y-, -C1-3 alkylene-, -C1-3 alkylene-Y-, - Y-C1-3 alkylene-, and -C1-2 alkylene-Y-C1-2 alkylene-; wherein said alkylene groups are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy, amino, C1-3 alkylamino, and di(C1-3 alkyl)amino; RA is H, C1-6 alkyl, C1-6 haloalkyl, halo, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1ORd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(=NRe1)Rb1, C(=NRe1)NRc1Rd1, NRc1C(=NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, or S(O)2NRc1Rd1; wherein said C1-6 alkyl or C1-6 haloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R11; Y is O, S, S(O), S(O)2, C(O), C(O)NRf, NRfC(O), NRfC(O)NRf, NRfS(O)2NRf, S(O)2NRf, NRfS(O)2, or NRf; each Rf is independently selected from H and C1-3 alkyl; CyA1 is C3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from RA1; each RA1 is independently selected from OH, NO2, CN, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano-C1-3 alkyl, HO-C1-3 alkyl, H2N-C1-3 alkyl, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, thio, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, carboxy, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl, C1-6 alkylaminosulfonyl, di(C1-6 alkyl)aminosulfonyl, aminosulfonylamino, C1-6 alkylaminosulfonylamino, di(C1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C1-6 alkylaminocarbonylamino, and di(C1-6 alkyl)aminocarbonylamino; CyA2 is C3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from RA2; each RA2 is independently selected from OH, NO2, CN, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano-C1-3 alkyl, HO-C1-3 alkyl, H2N-C1-3 alkyl, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, thio, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, carboxy, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl, C1-6 alkylaminosulfonyl, di(C1-6 alkyl)aminosulfonyl, aminosulfonylamino, C1-6 alkylaminosulfonylamino, di(C1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C1-6 alkylaminocarbonylamino, and di(C1-6 alkyl)aminocarbonylamino; CyA3 is C3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; wherein each 5-6 membered heteroaryl and 4-7 membered heterocycloalkyl has at least one ring-forming carbon atom and 1, 2, 3, or 4 ring-forming heteroatoms independently selected from N, O, and S; wherein the N and S are optionally oxidized; wherein a ring-forming carbon atom of C3-7 cycloalkyl and 4-7 membered heterocycloalkyl is optionally substituted by oxo to form a carbonyl group; and wherein the C3-7 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3 or 4 substituents independently selected from RA3; each RA3 is independently selected from OH, NO2, CN, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano-C1-3 alkyl, HO-C1-3 alkyl, H2N-C1-3 alkyl, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, thio, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, carboxy, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl, C1-6 alkylaminosulfonyl, di(C1-6 alkyl)aminosulfonyl, aminosulfonylamino, C1-6 alkylaminosulfonylamino, di(C1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C1-6 alkylaminocarbonylamino, and di(C1-6 alkyl)aminocarbonylamino; each RC is independently selected from OH, CN, halo, C1-4 alkyl, C1-3 haloalkyl, C1-4 alkoxy, C1-3 haloalkoxy, cyano-C1-3 alkyl, HO-C1-3 alkyl, amino, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-4 alkylsulfinyl, C1-4 alkylsulfonyl, carbamyl, C1-4 alkylcarbamyl, di(C1-4alkyl)carbamyl, carboxy, C1-4 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-4 alkylcarbonylamino, C1-4 alkylsulfonylamino, aminosulfonyl, C1-4 alkylaminosulfonyl, and di(C1-4 alkyl)aminosulfonyl; CyB is wherein CyB-1, CyB-2, CyB-3, and CyB-10 are each optionally substituted with 1, 2 or 3 substituents independently selected from RB; each RB is independently selected from halo, C1-6 alkyl, C2-6 alkynyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, CN, ORa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, NRc2Rd2, NRc2C(O)Rb2, and NRc2C(O)ORa2; wherein said C1-6 alkyl, C2-6 alkynyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R12; each R11 is independently selected from CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3ORd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; each R12 is independently selected from halo, CN, NO2, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4ORd4, NRc4C(O)Rb4, NRc4C(O)ORa4, NRc4C(O)NRc4Rd4, NRc4S(O)Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, and S(O)2NRc4Rd4; wherein said C1-6 alkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; Ra1, Rc1 and Rd1 are each independently selected from H, C1-6 alkyl, and C1-6 haloalkyl; wherein said C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or alternatively, Rc1 and Rd1 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; Rb1 is selected from C1-6 alkyl and C1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; Re1 is selected from H, CN, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkylthio, C1-6 alkylsulfonyl, C1-6 alkylcarbonyl, C1-6 alkylaminosulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, aminosulfonyl, C1-6 alkylaminosulfonyl, and di(C1-6 alkyl)aminosulfonyl; each Ra2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl; wherein said C1-6 alkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from R12; or alternatively, any Rc2 and Rd2 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from R12; each Rb2 is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, and 4-7 membered heterocycloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from R12; each Ra3, Rc3 and Rd3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-C1-4 alkylene, phenyl-C1-4 alkylene, 5-6 membered heteroaryl-C1-4 alkylene, and 4-7 membered heterocycloalkyl-C1-4 alkylene; wherein said C1-6 alkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-C1-4 alkylene, phenyl-C1-4 alkylene, 5-6 membered heteroaryl-C1-4 alkylene, and 4-7 membered heterocycloalkyl-C1-4 alkylene are each optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or alternatively, any Rc3 and Rd3 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; each Rb3 is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-6 cycloalkyl, phenyl, 5-6 membered heteroaryl, 4-7 membered heterocycloalkyl, C3-6 cycloalkyl-C1-4 alkylene, phenyl-C1-4 alkylene, 5-6 membered heteroaryl-C1-4 alkylene, and 4-7 membered heterocycloalkyl-C1-4 alkylene, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Ra4, Rc4 and Rd4, is independently selected from H, C1-6 alkyl, and C1-6 haloalkyl; wherein said C1-6 alkyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; or alternatively, any Rc4 and Rd4 attached to the same N atom, together with the N atom to which they are attached, form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2 or 3 substituents independently selected from Rg; each Rb4 is independently selected from C1-6 alkyl and C1-6 haloalkyl, each of which is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rg; each Rg is independently selected from OH, NO2, CN, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, cyano-C1-3 alkyl, HO-C1-3 alkyl, H2N-C1-3 alkyl, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, thio, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, carbamyl, C1-6 alkylcarbamyl, di(C1-6 alkyl)carbamyl, carboxy, C1-6 alkylcarbonyl, C1-6 alkoxycarbonyl, C1-6 alkylcarbonylamino, C1-6 alkylsulfonylamino, aminosulfonyl, C1-6 alkylaminosulfonyl, di(C1-6 alkyl)aminosulfonyl, aminosulfonylamino, C1-6 alkylaminosulfonylamino, di(C1-6 alkyl)aminosulfonylamino, aminocarbonylamino, C1-6 alkylaminocarbonylamino, and di(C1-6 alkyl)aminocarbonylamino; and wherein "cycloalkyl" refers to non-aromatic cyclic hydrocarbons including cyclized alkyl and / or alkenyl groups, including moieties that have one or more aromatic rings fused to the cycloalkyl ring; provided that: 1) A1-A2-A3 is not Y-Y when one of A1, A2 or A3 is a bond, or Y-Y-Y; and 2) when A3 is -Y- or -C1-3 alkylene-Y- then RA is H, C1-6 alkyl, or C1-6 haloalkyl, wherein said C1-6 alkyl or C1-6 haloalkyl is optionally substituted with 1, 2, 3 or 4 substituents independently selected from R11.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: (a) R1 is H, halo, C1-6 alkyl or C1-6 haloalkyl; or (b) R1 is C1-6 alkyl; or (c) R1 is A2-A3-RA; or (d) R1 is CyA3-RA.

3. The compound of any one of claims 1, 2(c), and 2(d), or a pharmaceutically acceptable salt thereof, wherein: (a) CyA3 is C3-7 cycloalkyl, 5-6 membered heteroaryl, or 4-7 membered heterocycloalkyl; each optionally substituted with 1, 2, 3 or 4 substituents independently selected from RA3; or (b) CyA3 is C3-6 cycloalkyl or 4-6 membered heterocycloalkyl, each optionally substituted with 1 or 2 substituents independently selected from RA3; or (c) CyA3 is piperidinyl, cyclohexyl, tetrahydropyranyl, pyrazolyl, pyridinyl, azetidinyl, cyclopropyl, or morpholinyl; each optionally substituted with 1 or 2 substituents independently selected from RA3; or (d) CyA3 is piperidinyl, cyclohexyl, or tetrahydropyranyl; each optionally substituted with 1 or 2 substituents independently selected from RA3; or (e) CyA3 is wherein CyA3-1, CyA3-2 and CyA3-3 are each optionally substituted with 1, 2 or 3 substituents independently selected from RA3.

4. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: (a) R1 is selected from methyl, ethyl, or (b) R1 is or (c) R1 is 5. The compound of any one of claims 1, 2(c), and 2(d), or a pharmaceutically acceptable salt thereof, wherein: (a) RA is C1-6 alkyl, CN, ORa1, NRc1Rd1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1 or S(O)2NRc1Rd1; wherein said C1-6 alkyl is optionally substituted with 1 or 2 substituents independently selected from R11, provided that if RA is attached to a nitrogen atom, then RA is not CN, ORa1, or NRc1Rd1; or (b) RA is C1-6 alkyl, CN, ORa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, and S(O)2Rb1; wherein said C1-6 alkyl is optionally substituted with 1 substituent selected from R11, provided that if RA is attached to a nitrogen atom, then RA is not CN or ORa1.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein: (a) each R11 is independently ORa3; or (b) each R11 is independently OH or OCH3.

7. The compound of any one of claims 1, 2(c), 2(d), 5, and 6, or a pharmaceutically acceptable salt thereof, wherein: (a) CyA3 is piperidinyl, cyclohexyl, tetrahydropyranyl, pyrazolyl, pyridinyl, azetidinyl, cyclopropyl, or morpholinyl; each optionally substituted with RA independently selected from CH3, CN, OH, CH2CH2OH, CH2CH2OCH3, C(O)CH3, C(O)CH2CH3, C(O)CH(CH3)2, C(O)CH2OH, C(O)CH(CH3)OH, S(O)2CH3, C(O)OCH3, C(O)N(CH3)2, C(O)NH(CH3), C(O)N(CH2CH3)2, C(O)NH(CH2CH3), C(O)N(CH3)(CH2CH3), CH2C(O)N(CH3)2, 1-methyl-2-oxopyrrolidin-3-yl, C(O)(cyclopropyl), N(CH3)2, and C(O)(morpholin-4-yl); or (b) CyA3 is piperidinyl, cyclohexyl, or tetrahydropyranyl; each optionally substituted with RA independently selected from CH3, CN, OH, CH2CH2OH, CH2CH2OCH3, C(O)CH3, C(O)CH2CH3, C(O)CH(CH3)2, C(O)CH2OH, C(O)CH(CH3)OH, S(O)2CH3, C(O)OCH3, C(O)N(CH3)2, C(O)NH(CH3), C(O)N(CH2CH3)2, C(O)NH(CH2CH3), C(O)N(CH3)(CH2CH3), and C(O)(morpholin-4-yl).

8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein: (a) each RB is independently unsubstituted phenyl, 4-fluoro-phenyl, 3-fluorophenyl, 2-fluorophenyl, CH2(phenyl), CH(CH2OH)phenyl, Br, Cl, CN, CH3, CHF2, CH2CH3, CH2OCH3, CH2OCH2CH3, CH(CH3)2, CH(CH2OH)CH2CH3, CH(CH2OH)CH3, CH2CH2OH, CH2CH(OH)(CH3), OCH3, OCH2CH3, C(O)NH2, C(O)CH3, 2,5-difluorophenyl, 3-pyridinyl, 2-pyridinyl, 1-methyl-1H-pyrazol-4-yl, 1-methyl-1H-pyrazol-3-yl, 1-methyl-1H-pyrazol-5-yl, 1,4-dimethyl-1H-pyrazol-3-yl, 1,5-dimethyl-1H-pyrazol-3-yl, 2-methylthiazol-5-yl, cyclohexyl, 3-cyanophenyl, 5-methylisoxazol-3-yl, 5-fluoropyridin-3-yl, 5-fluoropyridin-2-yl, 3-cyanophenyl, CH2CN, thiazol-4-yl, 6-methylpyridin-3-yl, 2-methylpyridin-3-yl, 6-methylpyridin-2-yl, pyrimidin-2-yl, morpholin-4-yl, cyclopropyl, oxazol-2-yl, CCCH(OH)(CH3), or C(O)NH(4-fluoro-phenyl); or (b) each RB is independently unsubstituted phenyl, 4-fluoro-phenyl, 3-fluorophenyl, 2-fluorophenyl, 2-pyridinyl, CH2(phenyl), CH(CH2OH)phenyl, CH3, CH2CH3, CH(CH3)2, CH(CH2OH)CH2CH3, CH(CH2OH)CH3, CH2CH2OH, OCH3, OCH2CH3, or C(O)NH(4-fluoro-phenyl).

9. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein: (a) CyB is wherein CyB-1, CyB-2, CyB-3, and CyB-10 are each optionally substituted with 1, 2 or 3 substituents independently selected from RB; each RB is independently methyl, ethyl, isopropyl, sec-butyl, 2-pyridinyl, or phenyl, each of which is optionally substituted by 1 or 2 substituents independently selected from R12; each R12 is independently selected from C1-6 alkyl, halo, phenyl, and ORa4; wherein said C1-6 alkyl and phenyl are each optionally substituted by 1 or 2 substituents independently selected from Rg group; each Ra4 is H or C1-3 alkyl; and each Rg is independently selected from halo; or (b) CyB is wherein CyB-1, CyB-2, and CyB-3 are each optionally substituted with 1, 2 or 3 groups independently selected from unsubstituted phenyl, 4-fluoro-phenyl, 3-fluorophenyl, 2-fluorophenyl, 2-pyridinyl, CH2(phenyl), CH(CH2OH)phenyl, CH3, CH2CH3, CH(CH3)2, CH(CH2OH)CH2CH3, CH(CH2OH)CH3, CH2CH2OH, OCH2CH3 and OCH3; or (c) CyB is wherein CyB-2 and CyB-3 are each optionally substituted 1, 2 or 3 groups independently selected from unsubstituted phenyl, CH(CH3)2, and 2-pyridinyl.

10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein: (a) each RC is independently F, Cl, or methyl; or (b) each RC is F.

11. The compound of claim 1 having Formula (IIg1) or Formula (IIg2): or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1, wherein: (a) the compound is selected from: N-[4-(4-Amino-7-ethylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-[(1R)-2-hydroxy-1-phenylethyl]-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-[(1R)-2-hydroxy-1-methylethyl]-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-[(1R)-1-(hydroxymethyl)propyl]-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-ethylpyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl]-1-benzyl-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-ethylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Aamino-7-(cis-4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(trans-4-hydroxycyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3 -carboxamide; N-[4-(4-Amino-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-methylpyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-methylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide; N-[4-(4-Amino-7-ethylpyrrolo[2,1-f][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N-{4-[4-Amino-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(tetrahydro-2H-pyran-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N-{4-[4-Amino-7-(cis-4-hydroxycyclohexyl)pyrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(trans-4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N-4-[4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3 -fluorophenyl} -1 -(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl }-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Aamino-7-(cis-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Aamino-7-(trans-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(cis-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N-{4-[4-Amino-7-(trans-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N{4-[4-Amino-7-(cis-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(trans-4-cyanocyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(cis-4-cyanocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3 -fluorophenyl} -1 -(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N-{4-[4-Amino-7-(trans-4-cyanocyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-piperidin-4-ylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-piperidin-4-ylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N-[4-(4-Amino-7-piperidin-4-ylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3 -carboxamide; N-[4-(4-Amino-7-piperidin-4-ylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)-3-fluorophenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; Methyl 4-[4-amino-5-(4-{[(2-oxo-1-phenyl-1,2-dihydropyridin-3-yl)carbonyl]amino}phenyl)pyrrolo[2,1-ƒ][1,2,4]triazin-7-yl]piperidine-1-carboxylate; Methyl 4-{4-amino-5-[4-({[1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridin-3-yl]carbonyl} amino)phenyl]pyrrolo[2,1-ƒ]1,2,4]triazin-7-yl}piperidine-1-carboxylate; Methyl 4-[4-amino-5-(2-fluoro-4-{[(2-oxo-1-phenyl-1,2-dihydropyridin-3-yl)carbonyl]amino}phenyl)pyrrolo[2,1-ƒ][1,2,4]triazin-7-yl]piperidine-1-carboxylate; Methyl 4-{4-amino-5-[2-fluoro-4-({[1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridin-3-yl]carbonyl}amino)phenyl]pyrrolo[2,1-ƒ][1,2,4]triazin-7-yl}piperidine-1-carboxylate; N-(4-{4-Amino-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}phenyl)-2-oxo-1 -phenyl-1,2-dihydropyridine-3 -carboxamide; N-(4-{4-Amino-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}phenyl)-1 -(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 - carboxamide; N-(4-{4-Amino-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}-3-fluorophenyl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-(4-{4-Amino-7-[1-(methylsulfonyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}-3-fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-{1-[(dimethylamino)carbonyl]piperidin-4-yl}pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-{1-[(dimethylamino)carbonyl]piperidin-4-yl}pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-{1-[(dimethylamino)carbonyl]piperidin-4-yl}pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)-3-fluorophenyl]-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-[4-(4-Amino-7-{1-[(dimethylamino)carbonyl]piperidin-4-yl}pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)-3 -fluorophenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-{4-Amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}phenyl)-2-oxo-1-phenyl-1,2-dihydropyridine-3 -carboxamide; N-(4-{4-Amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}phenyl)-1 -(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 - carboxamide; N-(4-{4-Amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}-3-fluorophenyl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-(4-{4-Amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl} -3 -fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-{4-Amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}phenyl)-2-oxo-1-phenyl-1,2-dihydropyridine-3 -carboxamide; N-(4-{4-Amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrolo[2,1-ƒ][1,2,4]triazin-5-yl}phenyl)-1 -(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 - carboxamide; N-(4-{4-Amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrolo[2,1-ƒ][1,2,4]triazin-5-yl}-3-fluorophenyl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-(4-{4-Amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrolo[2,1-ƒ][1,2,4]triazin-5-yl} -3 -fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(1-{[ethyl(methyl)amino]carbonyl}piperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(1-{[ethyl(methyl)amino]carbonyl}piperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-{4-[4-Amino-7-(1-{[ethyl(methyl)amino]carbonyl}piperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-(4-{4-Amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}phenyl)-1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; and N-(4-{4-Amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}-3-fluorophenyl)-1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; or a pharmaceutically acceptable salt thereof; or (b) the compound is selected from: N-{4-[4-Amino-7-(cis-4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(trans-4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(4-hydroxycyclohexyl)pyrrolo[2,1,ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[7-(1-Acetylpiperidin-4-yl)-4-aminopyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3 -fluorophenyl} -1 -(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N-[4-(4-Amino-7-piperidin-4-ylpyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)-3 - fluorophenyl]-1 -(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3 -carboxamide; N-[4-(4-Amino-7-{1-[(dimethylamino)carbonyl]piperidin-4-yl}pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)-3 -fluorophenyl]-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-{4-Amino-7-[1-(2-methoxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl} -3 -fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-{4-Amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl} -3 -fluorophenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(1-{[ethyl(methyl)amino]carbonyl}piperidin-4-yl)pyrrolo[2,1 -ƒ][1,2,4]triazin-5-yl]phenyl}-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(1-{[ethyl(methyl)amino]carbonyl}piperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]phenyl} -1 -(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-{4-[4-Amino-7-(1-{[ethyl(methyl)amino]carbonyl}piperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl]-3-fluorophenyl}-1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-(4-{4-Amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}phenyl)-1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; and N-(4-{4-Amino-7-[1-(2-hydroxyethyl)piperidin-4-yl]pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl}-3-fluorophenyl)-1-(4-fluorophenyl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; or a pharmaceutically acceptable salt thereof; or (c) the compound is selected from: N-(4-(4-Amino-7-(1-(dimethylcarbamoyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N (4-(4-Amino-7-(1-(ethyl(methyl)carbamoyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(dimethylcarbamoyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(ethyl(methyl)carbamoyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-3-(4-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(dimethylcarbamoyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-ethyl-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(morpholine-4-carbonyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-ethyl-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(ethyl(methyl)carbamoyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-3-(2-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(dimethylcarbamoyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-3-(3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-3-(3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(dimethylcarbamoyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-ethyl-3-(3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-ethyl-3-(3-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; or a pharmaceutically acceptable salt thereof; or (d) the compound is selected from: N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)-3-fluorophenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-3-(2,5-difluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)-3-methylphenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide; (R)-N-(4-(4-Amino-7-(1-(2-hydroxypropanoyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-ethyl-3-(4-fluorophenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(cyclopropanecarbonyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-(2-hydroxypropyl)-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(2-(dimethylamino)-2-oxoethyl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(1-methyl-2-oxopyrrolidin-3-yl)piperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3 -(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-3-(3-fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-amino-7-(6-(dimethylcarbamoyl)-4-methylpyridin-3-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; 4-Amino-5-(4-(3 -(3 -fluorophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenyl)-N,N-dimethylpyrrolo[2,1-f][1,2,4]triazine-7-carboxamide; N (4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-3-(1-methyl-1H-pyrazol-4-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-3-(1-methyl-1H-pyrazol-3-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-3-(2-methylthiazol-5-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl)-3-cyclohexyl-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl)-3-(3-cyanophenyl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-ƒ][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-3-(5-methylisoxazol-3-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(4-(dimethylamino)cyclohexyl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1 -isopropyl-2,4-dioxo-3 -phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-(cyclopropanecarbonyl)azetidin-3-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(morpholinomethyl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-4-oxo-1,4-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5'-fluoro-1-isopropyl-2-methyl-4-oxo-1,4-dihydro-[3,3'-bipyridine]-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5-(3-cyanophenyl)-1-isopropyl-6-methyl-4-oxo-1,4-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-5-bromo-1-(5-fluoropyridin-3-yl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5-(cyanomethyl)-5'-fluoro-6-methyl-2-oxo-2H-[1,3'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5'-fluoro-6-methyl-2-oxo-5-(thiazol-4-yl)-2H-[1,3'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-6-oxo-1-phenyl-1,6-dihydro-[2,2'-bipyridine]-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-6'-methyl-6-oxo-1-phenyl-1,6-dihydro-[2,3'-bipyridine]-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-3-methyl-6-oxo-1-phenyl-1,6-dihydro-[2,3'-bipyridine]-5-carboxamide; N-{4-[4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl}-6-methyl-5-(1-methyl-1H-pyrazol-4-yl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl}-6-methyl-2-oxo-1-phenyl-5-pyrimidin-2-yl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(1-methylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl}-6-methyl-2-oxo-1-phenyl-5-pyrimidin-2-yl-1,2-dihydropyridine-3-carboxamide; N-{4-[4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl]phenyl}-6-methyl-5-morpholin-4-yl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5-cyano-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N3-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3,5-dicarboxamide; 5-Acetyl-N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-6-methyl-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-(5-fluoropyridin-3-yl)-2,5-dioxo-1,2,5,6,7,8-hexahydroquinoline-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-7,7-dimethyl-2,5-dioxo-1-(pyridin-3-yl)-1,2, 5,6, 7, 8-hexahydroquinoline-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-(5-fluoropyridin-3-yl)-6,6-dimethyl-2,5-dioxo-1,2, 5,6, 7, 8-hexahydroquinoline-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5-bromo-6-methyl-2-oxo-2H-[1,2'-bipyridine]-3-carboxamide; and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-cyclopropyl-6-methyl-5-(oxazol-2-yl)-4-oxo-1,4-dihydropyridine-3-carboxamide; or a pharmacuetically acceptable salt thereof; or (e) the compound is selected from: N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5'-fluoro-5,6-dimethyl-2-oxo-2H-[1,3'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-5-(cyanomethyl)-6-methyl-2-oxo-1-(pyridin-2-yl)-1,2-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-2H-[1,2'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5-chloro-6-methyl-2-oxo-2H-[1,2'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-6-methyl-5-(1-methyl-1H-pyrazol-3-yl)-2-oxo-2H-[1,2'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-6-methyl-5-(oxazol-2-yl)-2-oxo-2H-[1,2'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5-(difluoromethyl)-6-methyl-2-oxo-2H-[1,2'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-4-oxo-5-(pyridin-3-yl)-1,4-dihydropyridine-3-carboxamide; N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-5-(5-fluoropyridin-3-yl)-1-isopropyl-4-oxo-1,4-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5-bromo-6-methyl-2-oxo-2H-[1,3'-bipyridine]-3-carboxamide; N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5-chloro-6-methyl-2-oxo-2H-[1,3'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5,6-dimethyl-2-oxo-2H-[1,3'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-6-methyl-5-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2H-[1,3'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-2H-[1,3'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-6-methyl-5-(1-methyl-1H-pyrazol-3-yl)-2-oxo-2H-[1,3'-bipyridine]-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5-bromo-6-(methoxymethyl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-5-cyano-6-(ethoxymethyl)-2-oxo-1-phenyl-1,2-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-3 -(1,4-dimethyl-1H-pyrazol-3-yl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-cyclopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-cyclopropyl-2,4-dioxo-3-(pyridin-3-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1'-cyclopropyl-2'-methyl-4'-oxo-1',4'-dihydro-[2,3'-bipyridine]-5'-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[2,1-f][1,2,4]triazin-5-yl)phenyl)-1-cyclopropyl-2,2'-dimethyl-4-oxo-1,4-dihydro-[3,3'-bipyridine]-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyrimidin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-cyclopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-3-(5-fluoropyridin-2-yl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-4-oxo-5-(pyridin-2-yl)-1,4-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-cyclopropyl-6-methyl-4-oxo-5-(pyridin-3-yl)-1,4-dihydropyridine-3-carboxamide; N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-3-(1,5-dimethyl-1H-pyrazol-3-yl)-1-isopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-3-(6-methylpyridin-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide; or a pharmacuetically acceptable salt thereof.

13. The compound of claim 1, which is N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1, which is N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

15. The compound of claim 1, which is N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3 -phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof.

16. The compound of claim 1, which is N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide.

17. A pharmaceutical composition comprising a compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition comprising N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide, and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition comprising N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, and a pharmaceutically acceptable carrier.

22. A compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 17-21, for use in inhibiting a TAM kinase.

23. A compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 17-21, for use in inhibiting AXL and MER kinase.

24. A compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 17-21, for use in treating a cancer in a patient.

25. The compound or pharmaceutical composition for use according to claim 24, wherein: (a) the cancer is selected from hepatocellular cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdomyosarcoma; (b) the cancer is lung cancer, prostate cancer, colon cancer, breast cancer, melanoma, renal cell carcinoma, multiple myeloma, gastric cancer, or rhabdomyosarcoma; or (c) the cancer is head and neck cancer.

26. A compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 17-21, for use in treating sarcoma, wherein the sarcoma is selected from chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, and teratoma.

27. A compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of any one of claims 17-21, for use in medicine.